

Appendix G. Aim 3 Full Sample Analyses

## **Appendix G: Aim 3 Full Sample Analyses**

**For all subsequent model tables:**

**Model 1: Adjusted for sociodemographics**

**Model 2: Adjusted for above plus comorbidities**

**Model 3: Adjusted for above plus prescribing facility factors**

**Model 4: Adjusted for above plus service utilization factors**

**Model 5: Propensity weighted**

**Changes in PTSD Checklist Score by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	63.0217	62.2819	-0.73985	(-0.741,-0.725)	<.0001	-1.17%
Mirtazapine	61.9497	61.2383	-0.71142	(-0.712,-0.696)	<.0001	-1.15%
Prazosin	62.6848	61.5977	-1.08712	(-1.088,-1.072)	<.0001	-1.73%
Tricyclics	61.8691	61.1413	-0.72781	(-0.729,-0.713)	0.0079	-1.18%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	9976	10486
Mirtazapine	8205	7968
Prazosin	19592	19147
Tricyclics	2661	2434

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	63.166	61.6561	-1.5099	(-1.511,-1.495)	0.0006	-2.39%	0.095
Mirtazapine	62.1685	60.6948	-1.4737	(-1.475,-1.459)	0.0028	-2.37%	0.1394
Prazosin	62.9745	61.6498	-1.32474	(-1.326,-1.31)	<.0001	-2.10%	0.4628
Tricyclics	62.1611	61.0033	-1.15782	(-1.159,-1.143)	0.0507	-1.86%	0.5098

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	923	976
Mirtazapine	832	787
Prazosin	1992	1954
Tricyclics	548	543

Changes in PTSD Checklist Score by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.02456	(-0.375,0.424)	0.03582	(-0.363,0.435)	0.03762	(-0.361,0.437)
Mirtazapine: female	0.0331	(-1.266,1.332)	0.05207	(-1.245,1.349)	0.0458	(-1.251,1.342)
p-value for 3-way interaction	0.99017		0.98128		0.99057	
Prazosin: male	-0.36329	(-0.689,-0.037)	-0.36635	(-0.692,-0.041)	-0.38478	(-0.71,-0.059)
Prazosin: female	0.16086	(-0.904,1.226)	0.15763	(-0.906,1.221)	0.14364	(-0.919,1.206)
p-value for 3-way interaction	0.35617		0.35565		0.35142	
Tricyclics: male	0.02536	(-0.574,0.625)	0.01932	(-0.579,0.618)	0.01767	(-0.581,0.616)
Tricyclics: female	0.37954	(-1.079,1.838)	0.41035	(-1.046,1.867)	0.39659	(-1.059,1.853)
p-value for 3-way interaction	0.65981		0.62647		0.63705	
overall 3-way interaction p-value	0.65479		0.66893		0.58162	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.03783	(-0.361,0.437)	0.02582	(-0.373,0.425)	0.00477	(-0.378,0.388)
Mirtazapine: female	0.0458	(-1.251,1.342)	0.04553	(-1.251,1.342)	-0.01442	(-1.234,1.205)
p-value for 3-way interaction	0.99081		0.97728		0.97651	
Prazosin: male	-0.38481	(-0.71,-0.059)	-0.39686	(-0.722,-0.071)	-0.36042	(-0.73,0.009)
Prazosin: female	0.14357	(-0.919,1.206)	0.13329	(-0.93,1.196)	0.11082	(-1.037,1.259)
p-value for 3-way interaction	0.35145		0.34988		0.44371	
Tricyclics: male	0.018	(-0.58,0.616)	0.00833	(-0.59,0.607)	-0.17843	(-0.577,0.22)
Tricyclics: female	0.39719	(-1.059,1.853)	0.3625	(-1.093,1.818)	0.22621	(-0.999,1.451)
p-value for 3-way interaction	0.63682		0.65921		0.53813	
overall 3-way interaction p-value	0.58089		0.74517		0.66005	

**Changes in PTSD Checklist Score by Augmenting Medication Group: Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	62.7627	61.2975	-1.46521	(-1.466,-1.45)	0.0119	-2.34%
Mirtazapine	60.5761	59.3198	-1.25632	(-1.257,-1.241)	0.0141	-2.07%
Prazosin	62.3778	60.4417	-1.93606	(-1.937,-1.921)	<.0001	-3.10%
Tricyclics	59.4138	59.5736	0.15982	(0.159,0.175)	0.893	0.27%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	731	586
Mirtazapine	986	730
Prazosin	2054	1607
Tricyclics	191	144

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	63.0586	62.2821	-0.77646	(-0.777,-0.761)	<.0001	-1.23%	0.2483
Mirtazapine	62.1467	61.3795	-0.76726	(-0.768,-0.752)	<.0001	-1.24%	0.36
Prazosin	62.756	61.7024	-1.05365	(-1.055,-1.039)	<.0001	-1.68%	0.0141
Tricyclics	62.0807	61.2177	-0.86291	(-0.864,-0.848)	0.0007	-1.39%	0.3999

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	10168	10876
Mirtazapine	8051	8025
Prazosin	19530	19494
Tricyclics	3018	2833

Changes in PTSD Checklist Score by Augmenting Medication Group: Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	0.16663	(-1.354,1.687)	0.13991	(-1.377,1.657)	0.14382	(-1.372,1.66)
Mirtazapine: <65	0.00652	(-0.389,0.402)	0.02676	(-0.369,0.422)	0.02783	(-0.367,0.423)
p-value for 3-way interaction	0.84173		0.88752		0.88463	
Prazosin: >=65	-0.52488	(-1.86,0.811)	-0.55925	(-1.892,0.773)	-0.5909	(-1.922,0.74)
Prazosin: <65	-0.29266	(-0.614,0.028)	-0.29004	(-0.611,0.03)	-0.30724	(-0.628,0.013)
p-value for 3-way interaction	0.74038		0.70022		0.68473	
Tricyclics: >=65	1.61394	(-0.977,4.205)	1.64847	(-0.936,4.232)	1.67839	(-0.903,4.26)
Tricyclics: <65	-0.0712	(-0.634,0.492)	-0.07736	(-0.64,0.485)	-0.08117	(-0.643,0.481)
p-value for 3-way interaction	0.21282		0.20081		0.19175	
overall 3-way interaction p-value	0.48538		0.45161		0.42715	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	0.14373	(-1.372,1.66)	0.13269	(-1.383,1.648)	0.03381	(-1.424,1.491)
Mirtazapine: <65	0.028	(-0.367,0.423)	0.01781	(-0.377,0.413)	-0.01228	(-0.39,0.365)
p-value for 3-way interaction	0.88489		0.88569		0.95216	
Prazosin: >=65	-0.59115	(-1.922,0.74)	-0.6064	(-1.937,0.724)	-0.60775	(-2.008,0.793)
Prazosin: <65	-0.30725	(-0.628,0.013)	-0.31792	(-0.638,0.003)	-0.30472	(-0.668,0.059)
p-value for 3-way interaction	0.68448		0.67958		0.68147	
Tricyclics: >=65	1.67857	(-0.903,4.26)	1.69264	(-0.888,4.273)	1.63182	(0.027,3.236)
Tricyclics: <65	-0.08085	(-0.643,0.481)	-0.09555	(-0.658,0.466)	-0.26174	(-0.652,0.128)
p-value for 3-way interaction	0.19178		0.18447		0.0246	
overall 3-way interaction p-value	0.42711		0.74517		0.03205	

**Changes in PTSD Checklist Score by Augmenting Medication Group: Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	62.9247	62.2411	-0.68358	(-0.685,-0.669)	<.0001	-1.09%
Mirtazapine	61.7225	60.958	-0.76449	(-0.765,-0.749)	<.0001	-1.24%
Prazosin	61.9812	61.0131	-0.96806	(-0.969,-0.953)	<.0001	-1.56%
Tricyclics	62.0536	61.1534	-0.90021	(-0.901,-0.885)	0.0047	-1.45%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	6230	6948
Mirtazapine	4552	4740
Prazosin	11735	12394
Tricyclics	1777	1647

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	63.1896	62.1716	-1.01796	(-1.019,-1.003)	<.0001	-1.61%	0.2077
Mirtazapine	62.1987	61.4231	-0.7756	(-0.777,-0.761)	0.0006	-1.25%	0.9702
Prazosin	63.5233	62.2882	-1.23515	(-1.236,-1.22)	<.0001	-1.94%	0.1641
Tricyclics	61.7486	61.0991	-0.6495	(-0.65,-0.634)	0.1027	-1.05%	0.6228

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	4669	4514
Mirtazapine	4485	4015
Prazosin	9849	8707
Tricyclics	1432	1330

**Changes in PTSD Checklist Score by Augmenting Medication Group: Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.07982	(-0.572,0.413)	-0.05864	(-0.55,0.433)	-0.0606	(-0.552,0.431)
Mirtazapine: other era	0.22584	(-0.383,0.835)	0.2214	(-0.386,0.829)	0.22609	(-0.381,0.833)
p-value for 3-way interaction	0.44435		0.48262		0.47204	
Prazosin: OEF/OIF	-0.29408	(-0.686,0.098)	-0.28849	(-0.68,0.103)	-0.2936	(-0.685,0.098)
Prazosin: other era	-0.25613	(-0.771,0.258)	-0.2739	(-0.787,0.239)	-0.30906	(-0.822,0.204)
p-value for 3-way interaction	0.90843		0.96465		0.96253	
Tricyclics: OEF/OIF	-0.20524	(-0.907,0.497)	-0.19458	(-0.896,0.507)	-0.21823	(-0.919,0.483)
Tricyclics: other era	0.38306	(-0.503,1.269)	0.37399	(-0.51,1.258)	0.40382	(-0.479,1.287)
p-value for 3-way interaction	0.30769		0.32321		0.27952	
overall 3-way interaction p-value	0.65479		0.66893		0.58162	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.06057	(-0.552,0.431)	-0.07242	(-0.564,0.419)	-0.07362	(-0.536,0.389)
Mirtazapine: other era	0.22642	(-0.381,0.834)	0.22069	(-0.386,0.828)	0.16684	(-0.43,0.764)
p-value for 3-way interaction	0.47159		0.46216		0.53245	
Prazosin: OEF/OIF	-0.29359	(-0.685,0.098)	-0.30933	(-0.701,0.082)	-0.29256	(-0.74,0.155)
Prazosin: other era	-0.30911	(-0.822,0.204)	-0.31206	(-0.825,0.201)	-0.26826	(-0.839,0.302)
p-value for 3-way interaction	0.9624		0.99339		0.94763	
Tricyclics: OEF/OIF	-0.21815	(-0.919,0.483)	-0.24418	(-0.946,0.457)	-0.30522	(-0.783,0.173)
Tricyclics: other era	0.40437	(-0.478,1.287)	0.40674	(-0.476,1.289)	0.11869	(-0.503,0.74)
p-value for 3-way interaction	0.27916		0.25777		0.28921	
overall 3-way interaction p-value	0.58089		0.74517		0.66005	



**Changes in Primary Care PTSD Score by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	2.8378	2.7778	-0.06005	(-0.09,-0.03)	0.0006	-2.12%
Mirtazapine	2.6702	2.5869	-0.08334	(-0.13,-0.04)	0.0001	-3.12%
Prazosin	3.002	2.9844	-0.01759	(-0.05,0.01)	0.2197	-0.59%
Tricyclics	2.6418	2.479	-0.16286	(-0.23,-0.09)	<.0001	-6.17%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	21534	12128
Mirtazapine	15679	8211
Prazosin	30137	13614
Tricyclics	5695	3406

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	2.5574	2.6348	0.077423	(0.04,0.11)	<.0001	3.03%	<.0001
Mirtazapine	2.3698	2.3193	-0.05058	(-0.07,-0.04)	<.0001	-2.13%	<.0001
Prazosin	2.8978	2.9879	0.090099	(-0.41,0.59)	0.7219	3.11%	0.0354
Tricyclics	2.2941	2.3138	0.019668	(0.01,0.03)	<.0001	0.86%	<.0001

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	2122	1215
Mirtazapine	1678	932
Prazosin	3021	1287
Tricyclics	1240	773

Changes in Primary Care PTSD Score by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	-0.02329	(-0.07,0.02)	-0.02594	(-0.07,0.02)	-0.02464	(-0.07,0.02)
Mirtazapine: female	-0.128	(-0.28,0.02)	-0.11961	(-0.27,0.03)	-0.11983	(-0.27,0.03)
p-value for 3-way interaction	0.20784		0.23532		0.23069	
Prazosin: male	0.04246	(0,0.09)	0.04023	(0,0.09)	0.04203	(0,0.09)
Prazosin: female	0.01268	(-0.81,0.84)	0.01771	(-0.37,0.41)	0.02502	(-0.23,0.28)
p-value for 3-way interaction	0.59419		0.66961		0.72703	
Tricyclics: male	-0.10281	(-0.17,-0.04)	-0.09876	(-0.17,-0.03)	-0.09706	(-0.16,-0.03)
Tricyclics: female	-0.05776	(-0.24,0.12)	-0.06366	(-0.24,0.11)	-0.0598	(-0.23,0.12)
p-value for 3-way interaction	0.56299		0.67376		0.65678	
overall 3-way interaction p-value	0.40389		0.51708		0.50396	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	-0.02466	(-0.07,0.02)	-0.02065	(-0.07,0.03)	-0.01838	(-0.06,0.03)
Mirtazapine: female	-0.11986	(-0.27,0.03)	-0.11752	(-0.27,0.03)	-0.12471	(-0.27,0.02)
p-value for 3-way interaction	0.23069		0.2247		0.18727	
Prazosin: male	0.04203	(0,0.09)	0.03546	(-0.01,0.08)	0.0456	(-0.01,0.1)
Prazosin: female	0.02502	(-0.23,0.28)	0.01997	(-0.24,0.28)	0.02196	(-0.28,0.32)
p-value for 3-way interaction	0.72705		0.74747		0.69829	
Tricyclics: male	-0.09708	(-0.16,-0.03)	-0.09212	(-0.16,-0.03)	-0.14055	(-0.19,-0.09)
Tricyclics: female	-0.05978	(-0.23,0.12)	-0.0606	(-0.23,0.11)	-0.06639	(-0.22,0.09)
p-value for 3-way interaction	0.65649		0.70271		0.37028	
overall 3-way interaction p-value	0.50381		0.51862		0.18344	

**Changes in Primary Care PTSD Score by Augmenting Medication: Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	2.2945	2.1948	-0.09969	(-0.19,-0.01)	0.0246	-4.35%
Mirtazapine	2.2539	2.1633	-0.09062	(-0.19,0.01)	0.0641	-4.02%
Prazosin	2.6599	2.5325	-0.12743	(-0.2,-0.06)	0.0003	-4.79%
Tricyclics	2.1189	1.8279	-0.29096	(-0.46,-0.12)	0.001	-13.73%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	2438	1569
Mirtazapine	2415	1379
Prazosin	4001	2061
Tricyclics	619	455

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	2.8722	2.8407	-0.0315	(-0.04,-0.03)	<.0001	-1.10%	<.0001
Mirtazapine	2.7038	2.63	-0.07378	(-0.09,-0.06)	<.0001	-2.73%	<.0001
Prazosin	3.0381	3.0573	0.01916	(0.02,0.02)	<.0001	0.63%	<.0001
Tricyclics	2.6248	2.5242	-0.10059	(-0.13,-0.07)	<.0001	-3.83%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	21218	11774
Mirtazapine	14942	7764
Prazosin	29157	12840
Tricyclics	6316	3724

Changes in Primary Care PTSD Score by Augmenting Medication: Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	0.00907	(-0.14,0.16)	0.00975	(-0.16,0.18)	0.01619	(-0.14,0.17)
Mirtazapine: <65	-0.04228	(-0.09,0.01)	-0.04009	(-0.09,0.01)	-0.04014	(-0.09,0.01)
p-value for 3-way interaction	0.50079		0.53172		0.47594	
Prazosin: >=65	-0.02774	(-0.31,0.26)	-0.02817	(-0.32,0.27)	-0.02357	(-0.37,0.32)
Prazosin: <65	0.05066	(0,0.1)	0.04795	(0,0.09)	0.04955	(0,0.1)
p-value for 3-way interaction	0.39518		0.41867		0.4361	
Tricyclics: >=65	-0.19127	(-0.35,-0.03)	-0.21219	(-0.39,-0.04)	-0.21993	(-0.4,-0.04)
Tricyclics: <65	-0.06909	(-0.13,0)	-0.06797	(-0.13,0)	-0.06575	(-0.13,0)
p-value for 3-way interaction	0.10167		0.09185		0.08109	
overall 3-way interaction p-value	0.15722		0.16386		0.13364	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	0.0161	(-0.14,0.17)	0.02502	(-0.12,0.17)	0.02223	(-0.13,0.17)
Mirtazapine: <65	-0.04023	(-0.09,0.01)	-0.03664	(-0.09,0.01)	-0.04143	(-0.09,0.01)
p-value for 3-way interaction	0.47619		0.42352		0.42135	
Prazosin: >=65	-0.02371	(-0.37,0.32)	-0.03322	(-0.3,0.23)	-0.02817	(-0.23,0.17)
Prazosin: <65	0.04958	(0,0.1)	0.04396	(0,0.09)	0.05406	(0,0.11)
p-value for 3-way interaction	0.43474		0.40967		0.37464	
Tricyclics: >=65	-0.22018	(-0.4,-0.04)	-0.2052	(-0.38,-0.03)	-0.24745	(-0.36,-0.13)
Tricyclics: <65	-0.06579	(-0.13,0)	-0.06214	(-0.13,0)	-0.11153	(-0.16,-0.06)
p-value for 3-way interaction	0.08081		0.09832		0.00923	
overall 3-way interaction p-value	0.13307		0.12734		0.00767	

## Changes in Primary Care PTSD Score by Augmenting Medication: Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	3.2306	3.1854	-0.0452	(-0.11,0.02)	0.1574	-1.40%
Mirtazapine	3.0898	3.0191	-0.07069	(-0.15,0.01)	0.0909	-2.29%
Prazosin	3.2163	3.2435	0.02722	(-0.02,0.07)	0.2389	0.85%
Tricyclics	3.1005	2.9938	-0.10671	(-0.23,0.02)	0.0995	-3.44%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	8003	3879
Mirtazapine	5364	2391
Prazosin	13247	5450
Tricyclics	2228	1106

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	2.599	2.5923	-0.006635	(-0.01,-0.01)	<.0001	-0.26%	<.0001
Mirtazapine	2.4406	2.3969	-0.043653	(-0.05,-0.04)	<.0001	-1.79%	<.0001
Prazosin	2.8436	2.8354	-0.00814	(-0.01,-0.01)	<.0001	-0.29%	<.0001
Tricyclics	2.3331	2.2521	-0.08099	(-0.09,-0.07)	<.0001	-3.47%	<.0001

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	15653	9464
Mirtazapine	11993	6752
Prazosin	19911	9451
Tricyclics	4707	3073

Changes in Primary Care PTSD Score by Augmenting Medication: Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.02548	(-0.11,0.06)	-0.0229	(-0.11,0.06)	-0.02581	(-0.11,0.06)
Mirtazapine: other era	-0.03702	(-0.09,0.02)	-0.03802	(-0.09,0.02)	-0.03623	(-0.09,0.02)
p-value for 3-way interaction	0.7418		0.72453		0.79471	
Prazosin: OEF/OIF	0.07243	(-0.01,0.15)	0.06825	(-0.01,0.14)	0.06516	(-0.01,0.14)
Prazosin: other era	-0.00151	(-0.09,0.09)	0.0035	(-0.05,0.06)	0.00785	(-0.05,0.06)
p-value for 3-way interaction	0.15266		0.1869		0.2383	
Tricyclics: OEF/OIF	-0.06151	(-0.18,0.06)	-0.0552	(-0.17,0.06)	-0.0503	(-0.17,0.07)
Tricyclics: other era	-0.07436	(-0.14,-0.01)	-0.07628	(-0.15,-0.01)	-0.07736	(-0.15,-0.01)
p-value for 3-way interaction	0.65227		0.61579		0.56818	
overall 3-way interaction p-value	0.5321		0.60547		0.6704	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.02583	(-0.11,0.06)	-0.02408	(-0.11,0.06)	-0.03034	(-0.12,0.06)
Mirtazapine: other era	-0.03625	(-0.09,0.02)	-0.03155	(-0.09,0.02)	-0.02346	(-0.08,0.03)
p-value for 3-way interaction	0.79455		0.84301		0.96428	
Prazosin: OEF/OIF	0.06518	(-0.01,0.14)	0.05451	(-0.02,0.13)	0.07653	(-0.02,0.17)
Prazosin: other era	0.00784	(-0.05,0.06)	0.00513	(-0.04,0.05)	0.00723	(-0.05,0.07)
p-value for 3-way interaction	0.23813		0.321		0.26972	
Tricyclics: OEF/OIF	-0.05031	(-0.17,0.07)	-0.05187	(-0.17,0.06)	-0.08242	(-0.18,0.01)
Tricyclics: other era	-0.07738	(-0.15,-0.01)	-0.07113	(-0.14,0)	-0.13148	(-0.19,-0.08)
p-value for 3-way interaction	0.56807		0.64362		0.14221	
overall 3-way interaction p-value	0.67017		0.77527		0.32473	

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	17.5833	13.8044	-3.7789	(-4.5,-3.06)	<.0001	-21.49%
Mirtazapine	13.8712	11.0057	-2.86551	(-3.56,-2.17)	<.0001	-20.66%
Prazosin	11.9046	9.3414	-2.56319	(-3.05,-2.08)	<.0001	-21.53%
Tricyclics	7.6742	6.741	-0.93313	(-1.73,-0.14)	0.0211	-12.16%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	65363	65363
Mirtazapine	50183	50183
Prazosin	92502	92502
Tricyclics	18647	18647

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	19.3426	17.3198	-2.02276	(-16.73,12.68)	0.7875	-10.46%	<.0001
Mirtazapine	16.0838	12.3858	-3.69793	(-8.15,0.76)	0.1037	-22.99%	0.0044
Prazosin	14.8191	11.7935	-3.02562	(-38.67,32.61)	0.8678	-20.42%	<.0001
Tricyclics	8.0611	7.5517	-0.50944	(-6.67,5.65)	0.8713	-6.32%	0.2426

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	5537	5537
Mirtazapine	4489	4489
Prazosin	7767	7767
Tricyclics	3337	3337

Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.91338	(-5.36,7.19)	0.56246	(-3.09,4.22)	0.87335	(-4.1,5.85)
Mirtazapine: female	-1.67517	(-4.21,0.86)	-0.98254	(-2.39,0.42)	-2.21388	(-4.99,0.56)
p-value for 3-way interaction	0.18595		0.16217		0.11074	
Prazosin: male	1.21571	(-)	0.89814	(-)	1.13771	(-117.8,120.08)
Prazosin: female	-1.00287	(-2.7,0.69)	-0.53573	(-1.39,0.32)	-1.51957	(-3.65,0.61)
p-value for 3-way interaction	0.27087		0.24458		0.18429	
Tricyclics: male	2.84577	(-0.46,6.15)	2.15852	(-0.21,4.53)	3.56245	(0.13,6.99)
Tricyclics: female	1.51332	(-8.93,11.96)	0.81067	(-4.48,6.11)	1.28234	(-6.06,8.62)
p-value for 3-way interaction	0.69702		0.68073		0.63873	
overall 3-way interaction p-value	0.55268		0.50468		0.38431	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.67543	(-3.14,4.49)	0.26175	(-1.22,1.74)	0.57267	(-2.5,3.65)
Mirtazapine: female	-1.83493	(-4.11,0.44)	-0.70755	(-1.59,0.17)	-1.9903	(-4.75,0.77)
p-value for 3-way interaction	0.10758		0.10896		0.14558	
Prazosin: male	0.93829	(-96.28,98.16)	0.33467	(-34.48,35.15)	0.52199	(-2.22,3.26)
Prazosin: female	-1.24984	(-2.98,0.48)	-0.45658	(-1.09,0.18)	-1.28319	(-3.76,1.19)
p-value for 3-way interaction	0.18038		0.18209		0.39745	
Tricyclics: male	2.92404	(0.13,5.72)	1.08681	(0.04,2.13)	1.67282	(-0.96,4.31)
Tricyclics: female	1.06205	(-4.96,7.09)	0.39379	(-1.85,2.64)	0.45972	(-3.75,4.67)
p-value for 3-way interaction	0.63572		0.63704		0.55975	
overall 3-way interaction p-value	0.37605		0.37966		0.53884	



**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	8.6539	5.9618	-2.69213	(-3.89,-1.5)	<.0001	-31.11%
Mirtazapine	6.2223	4.5606	-1.6617	(-2.61,-0.71)	0.0006	-26.71%
Prazosin	4.9804	3.4807	-1.49964	(-2.2,-0.8)	<.0001	-30.11%
Tricyclics	2.2323	3.0411	0.8088	(-0.35,1.97)	0.1727	36.23%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	10735	10735
Mirtazapine	11073	11073
Prazosin	18071	18071
Tricyclics	3091	3091

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	19.3385	15.5273	-3.81119	(-4.53,-3.09)	<.0001	-19.71%	<.0001
Mirtazapine	16.0417	12.7847	-3.25696	(-3.81,-2.7)	<.0001	-20.30%	<.0001
Prazosin	13.7023	10.8616	-2.8407	(-3.25,-2.43)	<.0001	-20.73%	<.0001
Tricyclics	8.6328	7.4895	-1.14328	(-1.47,-0.82)	<.0001	-13.24%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	60165	60165
Mirtazapine	43599	43599
Prazosin	82198	82198
Tricyclics	18893	18893

Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	1.03043	(-3.04,5.1)	1.57735	(-4.41,7.56)	3.2621	(-7.54,14.07)
Mirtazapine: <65	0.55423	(-4.76,5.87)	0.32216	(-2.64,3.29)	0.4037	(-2.84,3.65)
p-value for 3-way interaction	0.5938		0.5785		0.5246	
Prazosin: >=65	1.19249	(-17.86,20.24)	1.82067	(-26.1,29.74)	3.3443	(-41.43,48.12)
Prazosin: <65	0.97048	(-3.75,5.69)	0.66777	(-2.45,3.78)	0.7112	(-2.19,3.61)
p-value for 3-way interaction	0.82267		0.81541		0.7892	
Tricyclics: >=65	3.50093	(0.81,6.19)	5.13219	(1.35,8.92)	10.8301	(3.86,17.8)
Tricyclics: <65	2.66791	(-1.54,6.88)	1.84223	(-0.95,4.63)	2.8575	(-0.92,6.64)
p-value for 3-way interaction	0.02761		0.02176		0.0086	
overall 3-way interaction p-value	0.1739		0.14508		0.0695	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: >=65	2.68954	(-6.14,11.52)	1.09023	(-2.5,4.68)	0.9337	(-3.68,5.54)
Mirtazapine: <65	0.29215	(-2.04,2.62)	0.1155	(-0.81,1.04)	0.23248	(-1.49,1.96)
p-value for 3-way interaction	0.52101		0.52159		0.6498	
Prazosin: >=65	2.72088	(-33.4,38.84)	1.11658	(-13.73,15.96)	1.033	(-7.46,9.52)
Prazosin: <65	0.59271	(-1.8,2.99)	0.20645	(-0.63,1.04)	0.22809	(-0.31,0.77)
p-value for 3-way interaction	0.7874		0.78769		0.65069	
Tricyclics: >=65	9.06562	(3.28,14.85)	3.66804	(1.32,6.01)	3.53619	(2.06,5.01)
Tricyclics: <65	2.33982	(-0.73,5.41)	0.85816	(-0.27,1.99)	1.17037	(-55.94,58.28)
p-value for 3-way interaction	0.00803		0.00812		0.00001	
overall 3-way interaction p-value	0.06582		0.06642		0.00004	

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	25.1641	20.0967	-5.06745	(-6.78,-3.36)	<.0001	-20.14%
Mirtazapine	19.7344	15.9372	-3.79713	(-5.55,-2.04)	<.0001	-19.24%
Prazosin	16.352	13.436	-2.91599	(-3.96,-1.88)	<.0001	-17.83%
Tricyclics	9.9356	9.0558	-0.87983	(-2.7,0.94)	0.344	-8.86%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	16754	16754
Mirtazapine	11219	11219
Prazosin	28498	28498
Tricyclics	4660	4660

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	15.4176	12.217	-3.20061	(-3.49,-2.91)	<.0001	-20.76%	<.0001
Mirtazapine	12.586	9.875	-2.71098	(-3.03,-2.39)	<.0001	-21.54%	<.0001
Prazosin	10.4541	7.9809	-2.47314	(-2.69,-2.25)	<.0001	-23.66%	<.0001
Tricyclics	7.1404	6.2745	-0.86585	(-1.16,-0.57)	<.0001	-12.13%	<.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	54146	54146
Mirtazapine	43453	43453
Prazosin	71771	71771
Tricyclics	17324	17324

**Changes in Mental Health Emergency Visit (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	1.27032	(-12.95,15.49)	0.48614	(-4.65,5.62)	0.69558	(-5.75,7.14)
Mirtazapine: other era	0.48963	(-3.63,4.61)	0.32329	(-2.24,2.89)	0.49012	(-2.93,3.91)
p-value for 3-way interaction	0.7834		0.77083		0.73986	
Prazosin: OEF/OIF	2.15145	(-5.48,9.79)	0.82291	(-1.93,3.58)	1.24446	(-2.41,4.9)
Prazosin: other era	0.72746	(-0.77,2.22)	0.54281	(-0.51,1.59)	0.48629	(-0.34,1.31)
p-value for 3-way interaction	0.30927		0.28127		0.21939	
Tricyclics: OEF/OIF	4.18762	(-2.98,11.35)	1.73214	(-1.06,4.53)	3.17853	(-1.32,7.68)
Tricyclics: other era	2.33475	(-0.87,5.54)	2.14447	(-0.64,4.92)	3.45268	(-0.47,7.38)
p-value for 3-way interaction	0.83301		0.8232		0.79897	
overall 3-way interaction p-value	0.78546		0.7539		0.66979	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	0.54423	(-4.45,5.54)	0.20961	(-1.71,2.13)	0.6884	(-16.36,17.74)
Mirtazapine: other era	0.35853	(-2.12,2.84)	0.1451	(-0.86,1.15)	0.25977	(-2.72,3.24)
p-value for 3-way interaction	0.73765		0.73734		0.8705	
Prazosin: OEF/OIF	1.03626	(-1.98,4.05)	0.38975	(-0.74,1.52)	0.95379	(-67.53,69.44)
Prazosin: other era	0.39776	(-0.27,1.07)	0.14602	(-0.1,0.39)	0.21565	(-0.26,0.7)
p-value for 3-way interaction	0.21534		0.21478		0.58797	
Tricyclics: OEF/OIF	2.63027	(-1.06,6.32)	1.03448	(-0.42,2.49)	2.35647	(-3.94,8.65)
Tricyclics: other era	2.82849	(-0.36,6.02)	1.03685	(-0.13,2.2)	1.3285	(-1.76,4.42)
p-value for 3-way interaction	0.79724		0.797		0.8939	
overall 3-way interaction p-value	0.6635		0.66263		0.95844	

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	22.4684	16.7847	-5.68364	(-6.37,-5)	<.0001	-25.30%
Mirtazapine	17.0476	13.3073	-3.74031	(-4.43,-3.05)	<.0001	-21.94%
Prazosin	15.3326	11.3327	-3.99991	(-4.47,-3.53)	<.0001	-26.09%
Tricyclics	9.4921	7.76	-1.73218	(-2.54,-0.93)	<.0001	-18.25%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	65363	65363
Mirtazapine	50183	50183
Prazosin	92502	92502
Tricyclics	18647	18647

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	22.6838	17.5546	-5.12913	(-7.05,-3.21)	<.0001	-22.61%	0.3913
Mirtazapine	17.2421	13.0096	-4.23257	(-6.1,-2.36)	<.0001	-24.55%	0.8898
Prazosin	16.4542	12.4372	-4.01699	(-5.79,-2.24)	<.0001	-24.41%	0.0096
Tricyclics	7.3419	6.8025	-0.53941	(-0.84,-0.24)	0.0004	-7.35%	0.0034

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	5537	5537
Mirtazapine	4489	4489
Prazosin	7767	7767
Tricyclics	3337	3337

Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	1.94333	(-0.59,4.47)	1.35582	(-0.32,3.03)	1.94414	(-0.2,4.09)
Mirtazapine: female	0.89656	(-5.92,7.72)	0.4307	(-2.68,3.54)	0.25756	(-1.4,1.92)
p-value for 3-way interaction	0.49942		0.47701		0.42608	
Prazosin: male	1.68373	(-6.22,9.59)	1.25032	(-4.33,6.83)	1.31736	(-3.93,6.57)
Prazosin: female	1.11214	(-6.79,9.01)	0.63267	(-3.64,4.9)	0.40473	(-2.04,2.85)
p-value for 3-way interaction	0.88487		0.87883		0.86451	
Tricyclics: male	3.95146	(-0.62,8.52)	3.02009	(-0.3,6.34)	4.16615	(0.07,8.26)
Tricyclics: female	4.58972	(-2.59,11.77)	2.54642	(-1.24,6.33)	4.03864	(-1.32,9.4)
p-value for 3-way interaction	0.55755		0.5369		0.48947	
overall 3-way interaction p-value	0.78465		0.75668		0.68595	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	1.55403	(-0.15,3.26)	0.63276	(-0.04,1.3)	1.32411	(-0.47,3.12)
Mirtazapine: female	0.1907	(-1.03,1.41)	0.04584	(-0.24,0.33)	0.04569	(-0.16,0.25)
p-value for 3-way interaction	0.4232		0.4057		0.40539	
Prazosin: male	1.08897	(-3.22,5.4)	0.40283	(-1.13,1.94)	0.53827	(-0.52,1.6)
Prazosin: female	0.33036	(-1.65,2.31)	0.15727	(-0.75,1.07)	0.01969	(-0.06,0.1)
p-value for 3-way interaction	0.86367		0.85852		0.86279	
Tricyclics: male	3.42709	(0.08,6.77)	1.34248	(0.08,2.6)	1.58384	(-3.33,6.5)
Tricyclics: female	3.33933	(-1.07,7.74)	1.33764	(-0.36,3.04)	2.42287	(-7.64,12.49)
p-value for 3-way interaction	0.48677		0.47028		0.52871	
overall 3-way interaction p-value	0.68166		0.65494		0.61556	

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	9.5575	6.1574	-3.40009	(-4.47,-2.33)	<.0001	-35.58%
Mirtazapine	6.999	4.8948	-2.10422	(-3.01,-1.2)	<.0001	-30.06%
Prazosin	5.827	3.7021	-2.12495	(-2.76,-1.49)	<.0001	-36.47%
Tricyclics	2.4911	2.7823	0.29117	(-0.8,1.38)	0.6006	11.69%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	10735	10735
Mirtazapine	11073	11073
Prazosin	18071	18071
Tricyclics	3091	3091

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	24.7918	18.7518	-6.04006	(-6.85,-5.23)	<.0001	-24.36%	<.0001
Mirtazapine	19.6197	15.4132	-4.20652	(-4.76,-3.65)	<.0001	-21.44%	<.0001
Prazosin	17.5284	13.1147	-4.41373	(-4.9,-3.93)	<.0001	-25.18%	<.0001
Tricyclics	10.2578	8.4052	-1.85254	(-2.32,-1.38)	<.0001	-18.06%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	60165	60165
Mirtazapine	43599	43599
Prazosin	82198	82198
Tricyclics	18893	18893

Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	1.29588	(-1.96,4.55)	1.75745	(-2.49,6)	3.31417	(-3.82,10.45)
Mirtazapine: <65	1.83354	(-0.89,4.56)	1.27374	(-0.55,3.1)	1.74818	(-0.48,3.98)
p-value for 3-way interaction	0.68525		0.67362		0.63679	
Prazosin: >=65	1.27514	(-16.36,18.91)	1.72776	(-21.27,24.73)	2.87204	(-31.23,36.97)
Prazosin: <65	1.62632	(-5.7,8.96)	1.1509	(-3.84,6.14)	1.12859	(-3.24,5.49)
p-value for 3-way interaction	0.9758		0.97485		0.97181	
Tricyclics: >=65	3.69126	(0.66,6.72)	4.84258	(1.01,8.67)	9.11075	(2.68,15.54)
Tricyclics: <65	4.18752	(-1,9.37)	3.01373	(-0.58,6.6)	3.99214	(-0.25,8.23)
p-value for 3-way interaction	0.0465		0.03857		0.02038	
overall 3-way interaction p-value	0.23633		0.20507		0.12392	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	2.74305	(-3.13,8.61)	1.18761	(-1.26,3.63)	1.33069	(-1.73,4.39)
Mirtazapine: <65	1.39188	(-0.37,3.16)	0.56251	(-0.12,1.25)	1.18851	(-1.06,3.44)
p-value for 3-way interaction	0.63449		0.6212		0.57816	
Prazosin: >=65	2.32428	(-25.08,29.73)	1.03842	(-10.74,12.82)	1.20552	(-28.92,31.33)
Prazosin: <65	0.94133	(-2.68,4.56)	0.34747	(-0.94,1.63)	0.34111	(-0.2,0.88)
p-value for 3-way interaction	0.97161		0.9705		0.69721	
Tricyclics: >=65	7.66737	(2.3,13.04)	3.31894	(1.08,5.56)	3.59911	(1.92,5.28)
Tricyclics: <65	3.27971	(-0.18,6.74)	1.27045	(-0.02,2.56)	1.26357	(-0.34,2.87)
p-value for 3-way interaction	0.01954		0.01522		0.00001	
overall 3-way interaction p-value	0.11974		0.09757		0.00007	



**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	30.0764	23.863	-6.21344	(-7.81,-4.62)	<.0001	-20.66%
Mirtazapine	22.6313	17.8626	-4.7687	(-6.46,-3.08)	<.0001	-21.07%
Prazosin	19.1978	15.6958	-3.502	(-4.48,-2.52)	<.0001	-18.24%
Tricyclics	12.1674	10.5365	-1.6309	(-3.48,0.22)	0.0838	-13.40%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	16754	16754
Mirtazapine	11219	11219
Prazosin	28498	28498
Tricyclics	4660	4660

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	20.1363	14.6733	-5.46301	(-5.85,-5.08)	<.0001	-27.13%	<.0001
Mirtazapine	15.6261	12.1004	-3.52565	(-3.91,-3.14)	<.0001	-22.56%	<.0001
Prazosin	13.9193	9.7198	-4.19947	(-4.51,-3.89)	<.0001	-30.17%	<.0001
Tricyclics	8.3583	6.8287	-1.52967	(-1.89,-1.17)	<.0001	-18.30%	<.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	54146	54146
Mirtazapine	43453	43453
Prazosin	71771	71771
Tricyclics	17324	17324

**Changes in Mental Health Hospitalization (per 100 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	1.44475	(-26.85,29.74)	0.60048	(-10.51,11.71)	0.71445	(-11.11,12.54)
Mirtazapine: other era	1.93736	(-0.15,4.03)	1.60525	(-0.03,3.24)	2.34872	(0.21,4.49)
p-value for 3-way interaction	0.28635		0.25907		0.2071	
Prazosin: OEF/OIF	2.71144	(-4.65,10.07)	1.1352	(-1.78,4.05)	1.50368	(-1.95,4.95)
Prazosin: other era	1.26354	(-0.51,3.04)	0.94859	(-0.31,2.21)	0.80763	(-0.15,1.77)
p-value for 3-way interaction	0.15906		0.13604		0.09564	
Tricyclics: OEF/OIF	4.58254	(-4.93,14.09)	2.0277	(-1.95,6)	3.0204	(-2.28,8.32)
Tricyclics: other era	3.93334	(-0.08,7.95)	3.56641	(0.13,7)	4.91794	(0.68,9.16)
p-value for 3-way interaction	0.80728		0.79624		0.77285	
overall 3-way interaction p-value	0.13922		0.10445		0.05293	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Antipsychotics (Reference)</b>						
Mirtazapine: OEF/OIF	0.56093	(-8.66,9.79)	0.22891	(-3.39,3.85)	0.26643	(-0.61,1.14)
Mirtazapine: other era	1.88006	(0.18,3.58)	0.75978	(0.1,1.42)	1.51445	(-0.02,3.05)
p-value for 3-way interaction	0.20425		0.18705		0.11373	
Prazosin: OEF/OIF	1.25677	(-1.61,4.12)	0.4963	(-0.59,1.59)	0.62917	(-2.09,3.35)
Prazosin: other era	0.6602	(-0.12,1.44)	0.25966	(-0.03,0.55)	0.4463	(-0.31,1.2)
p-value for 3-way interaction	0.09357		0.08139		0.76369	
Tricyclics: OEF/OIF	2.51549	(-1.87,6.9)	1.0466	(-0.71,2.8)	0.98712	(-0.91,2.89)
Tricyclics: other era	4.03688	(0.58,7.5)	1.56421	(0.27,2.85)	1.8576	(-33.97,37.68)
p-value for 3-way interaction	0.77146		0.76276		0.36895	
overall 3-way interaction p-value	0.05068		0.0383		0.24085	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	21.4276	18.5135	-2.91413	(-3.73,-2.1)	<.0001	-13.60%
Mirtazapine	19.1937	16.9474	-2.24636	(-3.13,-1.36)	<.0001	-11.70%
Prazosin	19.2644	16.6445	-2.61987	(-3.25,-1.99)	<.0001	-13.60%
Tricyclics	16.6971	15.7316	-0.96543	(-2.4,0.47)	0.1885	-5.78%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	16916	14677
Mirtazapine	13932	11234
Prazosin	28346	21589
Tricyclics	4676	4176

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	22.2293	19.8749	-2.35433	(-5.54,0.83)	0.1478	-10.59%	0.1213
Mirtazapine	18.3656	17.2921	-1.0735	(-2.34,0.19)	0.0956	-5.85%	0.7769
Prazosin	19.7329	16.641	-3.09192	(-5.06,-1.13)	0.002	-15.67%	0.6985
Tricyclics	14.0213	12.4322	-1.58904	(-2.56,-0.62)	0.0013	-11.33%	0.0008

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	1630	1364
Mirtazapine	1329	1107
Prazosin	2688	2002
Tricyclics	937	791

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.66777	(-1.05,2.39)	0.61472	(-1.03,2.26)	0.656	(-1.08,2.4)
Mirtazapine: female	1.28084	(-3.46,6.02)	1.1984	(-3.33,5.72)	1.36953	(-3.38,6.12)
p-value for 3-way interaction	0.78052		0.78157		0.74933	
Prazosin: male	0.29427	(-4.11,4.69)	0.25311	(-6.29,6.8)	0.11329	(-3.06,3.29)
Prazosin: female	-0.73758	(-3.13,1.66)	-0.66061	(-2.88,1.56)	-0.76272	(-3.5,1.98)
p-value for 3-way interaction	0.53838		0.5621		0.61696	
Tricyclics: male	1.9487	(-0.1,3.99)	1.91774	(-0.06,3.9)	2.29139	(0.17,4.42)
Tricyclics: female	0.76529	(-73.26,74.79)	0.70612	(-)	0.7575	(-20.66,22.17)
p-value for 3-way interaction	0.5185		0.50473		0.49195	
overall 3-way interaction p-value	0.76633		0.77347		0.77511	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	0.67314	(-1.03,2.38)	0.56387	(-0.97,2.1)	0.74785	(-0.69,2.19)
Mirtazapine: female	1.31581	(-3.39,6.02)	1.04358	(-3.19,5.28)	0.87176	(-3.6,5.35)
p-value for 3-way interaction	0.76958		0.8051		0.95892	
Prazosin: male	0.14005	(-5.96,6.24)	0.09966	(-1.65,1.85)	0.09102	(-1.98,2.16)
Prazosin: female	-0.80019	(-3.48,1.88)	-0.73998	(-3.05,1.57)	-0.99713	(-4.15,2.15)
p-value for 3-way interaction	0.58512		0.57181		0.57324	
Tricyclics: male	2.29645	(0.2,4.39)	1.93479	(0.11,3.76)	1.64655	(0.3,3)
Tricyclics: female	0.73691	(-24.9,26.37)	0.62366	(-24.5,25.75)	0.63343	(-13.37,14.64)
p-value for 3-way interaction	0.47694		0.48811		0.53707	
overall 3-way interaction p-value	0.76322		0.7819		0.8616	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	16.7807	14.2121	-2.56857	(-4.52,-0.61)	0.0101	-15.31%
Mirtazapine	16.4406	12.8597	-3.58094	(-5.43,-1.73)	0.0002	-21.78%
Prazosin	16.5969	13.0481	-3.54879	(-4.97,-2.13)	<.0001	-21.38%
Tricyclics	13.651	13.7238	0.07277	(-3.53,3.68)	0.9684	0.53%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	2316	1989
Mirtazapine	2671	2086
Prazosin	4697	3596
Tricyclics	629	561

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	22.1712	19.2544	-2.91676	(-4.78,-1.05)	0.0021	-13.16%	<.0001
Mirtazapine	19.6904	17.8161	-1.87432	(-3.91,0.16)	0.0708	-9.52%	<.0001
Prazosin	19.7879	17.291	-2.49697	(-6.48,1.49)	0.2192	-12.62%	<.0001
Tricyclics	16.5784	15.395	-1.18348	(-3.08,0.71)	0.2201	-7.14%	0.0289

**Number of Windows - Age 65**

Medications	n(pre)	n(post)
Antipsychotics	16230	14052
Mirtazapine	12590	10255
Prazosin	26337	19995
Tricyclics	4984	4406

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	-1.01238	(-3.42,1.4)	-0.99189	(-3.41,1.42)	-1.26096	(-4.19,1.67)
Mirtazapine: <65	1.04244	(-0.5,2.58)	1.00521	(-0.49,2.5)	1.10083	(-0.51,2.71)
p-value for 3-way interaction	0.21663		0.22447		0.20762	
Prazosin: >=65	-0.98022	(-3.18,1.22)	-0.96847	(-3.17,1.23)	-1.16326	(-3.87,1.54)
Prazosin: <65	0.41979	(-1.9,2.74)	0.3941	(-1.99,2.78)	0.25193	(-2.91,3.41)
p-value for 3-way interaction	0.34654		0.35621		0.39682	
Tricyclics: >=65	2.64134	(-1.84,7.12)	2.69076	(-1.83,7.21)	3.45811	(-1.87,8.78)
Tricyclics: <65	1.73328	(-0.49,3.96)	1.68536	(-0.47,3.84)	1.94761	(-0.27,4.17)
p-value for 3-way interaction	0.54114		0.53465		0.50882	
overall 3-way interaction p-value	0.39898		0.40728		0.38732	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	-1.16017	(-4.04,1.72)	-1.04674	(-3.53,1.44)	-0.66884	(-2.9,1.56)
Mirtazapine: <65	1.09364	(-0.49,2.68)	0.92859	(-0.48,2.33)	0.98964	(-0.44,2.42)
p-value for 3-way interaction	0.22492		0.21915		0.3061	
Prazosin: >=65	-1.10641	(-3.77,1.55)	-0.97264	(-3.24,1.29)	-0.57084	(-2.65,1.51)
Prazosin: <65	0.26472	(-3.03,3.56)	0.20679	(-4.38,4.79)	0.09742	(-2.57,2.76)
p-value for 3-way interaction	0.4118		0.41113		0.63109	
Tricyclics: >=65	3.46023	(-1.77,8.69)	2.85466	(-1.69,7.4)	2.90075	(0.01,5.79)
Tricyclics: <65	1.95343	(-0.25,4.15)	1.66183	(-0.26,3.58)	1.37196	(-0.13,2.88)
p-value for 3-way interaction	0.49951		0.53121		0.2187	
overall 3-way interaction p-value	0.40535		0.41848		0.14996	

**Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	21.7347	19.9329	-1.80185	(-3.22,-0.39)	0.0126	-8.29%
Mirtazapine	19.2346	18.8018	-0.43279	(-2.14,1.28)	0.6202	-2.25%
Prazosin	18.4914	17.1863	-1.30506	(-2.34,-0.27)	0.0137	-7.06%
Tricyclics	17.0027	16.4372	-0.56551	(-3.07,1.93)	0.6575	-3.33%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	6197	4904
Mirtazapine	4144	3025
Prazosin	10914	7748
Tricyclics	1749	1327

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	21.3793	18.0552	-3.32409	(-4.34,-2.3)	<.0001	-15.55%	0.0065
Mirtazapine	19.0795	16.3862	-2.69331	(-3.9,-1.49)	<.0001	-14.12%	0.0068
Prazosin	19.7463	16.3791	-3.36719	(-4.72,-2.01)	<.0001	-17.05%	0.6304
Tricyclics	15.9099	14.7575	-1.15243	(-2.14,-0.17)	0.0221	-7.24%	0.0569

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	12349	11137
Mirtazapine	11117	9316
Prazosin	20120	15843
Tricyclics	3864	3640

Changes in Suicidal Thought (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	1.36906	(-0.99,3.73)	1.24803	(-0.88,3.37)	1.48574	(-0.96,3.93)
Mirtazapine: other era	0.63078	(-1.6,2.86)	0.55548	(-1.72,2.83)	0.552	(-1.8,2.91)
p-value for 3-way interaction	0.51197		0.47826		0.4504	
Prazosin: OEF/OIF	0.49679	(-2.23,3.23)	0.42403	(-2.14,2.99)	0.39118	(-2.39,3.18)
Prazosin: other era	-0.04309	(-0.23,0.15)	-0.07909	(-0.41,0.25)	-0.24612	(-1.09,0.6)
p-value for 3-way interaction	0.58512		0.59265		0.57958	
Tricyclics: OEF/OIF	1.23634	(-2.31,4.78)	1.09488	(-2.11,4.3)	1.15106	(-2.51,4.81)
Tricyclics: other era	2.17167	(-0.17,4.51)	2.18757	(-0.17,4.54)	2.61588	(0.18,5.05)
p-value for 3-way interaction	0.66131		0.65241		0.5126	
overall 3-way interaction p-value	0.79302		0.77364		0.66324	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	1.45592	(-0.95,3.87)	1.22083	(-0.88,3.32)	1.3423	(-0.85,3.53)
Mirtazapine: other era	0.57782	(-1.7,2.85)	0.48427	(-1.63,2.6)	0.55124	(-1.36,2.46)
p-value for 3-way interaction	0.46728		0.47456		0.49781	
Prazosin: OEF/OIF	0.40123	(-2.41,3.22)	0.30835	(-2.39,3.01)	0.15666	(-14.2,14.52)
Prazosin: other era	-0.22412	(-1,0.55)	-0.20539	(-0.86,0.45)	-0.14352	(-0.86,0.58)
p-value for 3-way interaction	0.5796		0.59244		0.81158	
Tricyclics: OEF/OIF	1.16227	(-2.47,4.79)	1.02908	(-2.08,4.14)	0.52909	(-2.29,3.35)
Tricyclics: other era	2.61097	(0.21,5.01)	2.19279	(0.09,4.29)	2.07889	(0.54,3.62)
p-value for 3-way interaction	0.51023		0.55168		0.2309	
overall 3-way interaction p-value	0.67124		0.70965		0.29321	



**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	12.2581	11.9871	-0.27095	(-1.48,0.93)	0.6596	-2.21%
Mirtazapine	11.4576	11.0324	-0.42527	(-1.73,0.88)	0.5244	-3.71%
Prazosin	11.0792	10.2032	-0.87605	(-1.81,0.06)	0.0666	-7.91%
Tricyclics	9.7088	9.2822	-0.42653	(-2.52,1.66)	0.6891	-4.39%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	5585	4617
Mirtazapine	4627	3562
Prazosin	8865	6532
Tricyclics	1479	1305

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	14.5457	12.1896	-2.35608	(-)	0.9641	-16.20%	0.2551
Mirtazapine	13.4122	11.1065	-2.30568	(-23.78,19.17)	0.8333	-17.19%	0.3986
Prazosin	12.2887	12.619	0.33032	(-0.2,0.86)	0.2191	2.69%	0.0256
Tricyclics	6.23	7.1181	0.88803	(-0.42,2.19)	0.1828	14.25%	0.0322

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	526	450
Mirtazapine	426	352
Prazosin	852	610
Tricyclics	275	240

Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	-0.15431	(-1.71,1.4)	-0.16281	(-1.71,1.38)	-0.25643	(-2.26,1.74)
Mirtazapine: female	0.0504	(-2.43,2.53)	0.00894	(-0.3,0.31)	-0.02618	(-1.35,1.29)
p-value for 3-way interaction	0.98303		0.99331		0.96849	
Prazosin: male	-0.6051	(-1.97,0.76)	-0.61261	(-1.96,0.74)	-0.94615	(-2.63,0.74)
Prazosin: female	2.6864	(-2.61,7.99)	2.56549	(-2.62,7.75)	2.6548	(-3.18,8.49)
p-value for 3-way interaction	0.2248		0.23124		0.23492	
Tricyclics: male	-0.15558	(-1.87,1.56)	-0.15022	(-1.83,1.53)	-0.29692	(-3.11,2.52)
Tricyclics: female	3.24411	(-3.74,10.23)	3.12997	(-3.74,10)	3.37554	(-4.27,11.02)
p-value for 3-way interaction	0.35909		0.3684		0.37646	
overall 3-way interaction p-value	0.50839		0.51754		0.53706	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: male	-0.19859	(-2.08,1.68)	-0.18765	(-1.81,1.44)	-0.27623	(-1.99,1.44)
Mirtazapine: female	-0.17277	(-4,3.66)	-0.25712	(-4.11,3.59)	0.54915	(-6.16,7.26)
p-value for 3-way interaction	0.98312		0.95563		0.80176	
Prazosin: male	-0.96549	(-2.53,0.6)	-0.8318	(-2.17,0.51)	-0.88877	(-2.58,0.8)
Prazosin: female	2.32105	(-3.18,7.82)	2.05717	(-2.74,6.85)	2.34488	(-3.44,8.13)
p-value for 3-way interaction	0.24558		0.2396		0.27904	
Tricyclics: male	-0.1582	(-2.7,2.38)	-0.14744	(-2.42,2.12)	-0.35093	(-1.87,1.17)
Tricyclics: female	3.23405	(-3.77,10.24)	2.80359	(-3.27,8.88)	2.66381	(-3.79,9.11)
p-value for 3-way interaction	0.372		0.37098		0.36646	
overall 3-way interaction p-value	0.52837		0.50747		0.64962	

**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	10.4306	10.6209	0.19032	(-3.02,3.4)	0.9075	1.83%
Mirtazapine	9.9746	10.4371	0.46247	(-2.52,3.45)	0.7613	4.64%
Prazosin	9.3344	7.1704	-2.16405	(-4.29,-0.04)	0.0456	-23.18%
Tricyclics	8.3333	8.8207	0.48733	(-5.04,6.01)	0.8628	5.85%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	688	561
Mirtazapine	832	603
Prazosin	1418	983
Tricyclics	188	171

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	12.7118	12.1774	-0.53437	(-1.29,0.22)	0.1647	-4.20%	0.041
Mirtazapine	11.9472	11.1487	-0.79855	(-2.32,0.73)	0.3048	-6.68%	0.1264
Prazosin	11.5015	10.9265	-0.57503	(-1.18,0.03)	0.0641	-5.00%	<.0001
Tricyclics	9.263	8.9617	-0.30134	(-2.29,1.69)	0.7663	-3.25%	0.7262

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	5423	4506
Mirtazapine	4221	3311
Prazosin	8299	6159
Tricyclics	1566	1374

Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: >=65	0.27216	(-4,4.55)	0.28114	(-3.74,4.3)	0.26376	(-4.5,5.03)
Mirtazapine: <65	-0.26418	(-1.87,1.34)	-0.26408	(-1.82,1.29)	-0.35941	(-2.34,1.62)
p-value for 3-way interaction	0.81844		0.80701		0.82167	
Prazosin: >=65	-2.35437	(-5.78,1.07)	-2.23519	(-5.44,0.97)	-2.98914	(-7.05,1.07)
Prazosin: <65	-0.04066	(-0.74,0.66)	-0.03407	(-0.65,0.59)	-0.27285	(-1.97,1.42)
p-value for 3-way interaction	0.21486		0.20799		0.20526	
Tricyclics: >=65	0.29701	(-5.23,5.83)	0.31835	(-5.03,5.67)	0.41688	(-5.7,6.54)
Tricyclics: <65	0.23303	(-4.64,5.1)	0.22852	(-5.14,5.6)	0.09345	(-4.94,5.13)
p-value for 3-way interaction	0.94451		0.93332		0.90861	
overall 3-way interaction p-value	0.41625		0.39633		0.3943	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Reference	95% CI	Reference	95% CI	Reference	95% CI
Mirtazapine: >=65	0.65603	(-4.22,5.53)	0.52577	(-3.44,5.06)	-0.52437	(-2.07,2.42)
Mirtazapine: <65	-0.36962	(-2.25,1.51)	-0.33923	(-3.26,2.21)	-0.15104	(-8.15,6.95)
p-value for 3-way interaction	0.70272		0.70797		0.87653	
Prazosin: >=65	-2.63319	(-6.46,1.2)	-2.28319	(-5.42,1.42)	-2.52816	(-5.24,1.59)
Prazosin: <65	-0.3902	(-1.97,1.19)	-0.33082	(-1.39,0.37)	-0.30043	(-2.15,0.65)
p-value for 3-way interaction	0.26225		0.25223		0.29418	
Tricyclics: >=65	0.66414	(-5.67,6.99)	0.47409	(-11.12,12.64)	-0.76115	(-0.46,0.34)
Tricyclics: <65	0.19607	(-3.07,3.47)	0.17002	(-0.22,0.19)	0.0423	(-3.15,2.34)
p-value for 3-way interaction	0.87521		0.90014		0.77212	
overall 3-way interaction p-value	0.41876		0.41032		0.73349	

**Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	11.9514	11.0599	-0.8915	(-2.86,1.08)	0.3747	-7.46%
Mirtazapine	11.2298	10.1997	-1.03014	(-3.42,1.36)	0.3983	-9.17%
Prazosin	10.1987	10.8118	0.61307	(-0.91,2.14)	0.4299	6.01%
Tricyclics	10.199	9.256	-0.94298	(-4.56,2.68)	0.6098	-9.25%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	2082	1599
Mirtazapine	1353	1010
Prazosin	3304	2392
Tricyclics	536	429

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	12.7152	12.4409	-0.2743	(-1.22,0.67)	0.57	-2.16%	0.0867
Mirtazapine	11.766	11.331	-0.43502	(-8.76,7.89)	0.9184	-3.70%	0.2474
Prazosin	11.6936	10.207	-1.48661	(-)	0.9898	-12.71%	0.3813
Tricyclics	8.7076	8.8269	0.1193	(-0.13,0.37)	0.3474	1.37%	0.3693

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	4029	3468
Mirtazapine	3700	2904
Prazosin	6413	4750
Tricyclics	1218	1116

Changes in Suicidal Plan (% endorsing) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.13864	(-2.32,2.04)	-0.14767	(-2.31,2.01)	-0.18027	(-3.23,2.87)
Mirtazapine: other era	-0.16072	(-1.93,1.61)	-0.19051	(-2.01,1.62)	-0.30519	(-2.63,2.02)
p-value for 3-way interaction	0.98944		0.99439		0.97168	
Prazosin: OEF/OIF	1.50457	(-0.99,4)	1.39168	(-0.97,3.75)	1.51913	(-1.28,4.32)
Prazosin: other era	-1.21232	(-2.86,0.43)	-1.24121	(-2.9,0.42)	-1.71378	(-3.72,0.29)
p-value for 3-way interaction	0.07316		0.07473		0.06775	
Tricyclics: OEF/OIF	-0.05148	(-1.22,1.12)	-0.03894	(-1.04,0.96)	-0.38944	(-4.54,3.76)
Tricyclics: other era	0.39359	(-2.59,3.37)	0.38739	(-2.63,3.41)	0.37052	(-2.33,3.07)
p-value for 3-way interaction	0.82937		0.83882		0.76252	
overall 3-way interaction p-value	0.19411		0.2008		0.17622	
Medications	Model 3		Model 4		Model 5	
Antipsychotics (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Mirtazapine: OEF/OIF	-0.12474	(-2.82,2.57)	-0.16381	(-2.6,2.28)	-0.12311	(-2.42,2.17)
Mirtazapine: other era	-0.29155	(-2.5,1.92)	-0.2595	(-2.16,1.64)	-0.22513	(-2.22,1.77)
p-value for 3-way interaction	0.95406		0.97777		0.97502	
Prazosin: OEF/OIF	1.43484	(-1.2,4.07)	1.18688	(-1.07,3.44)	1.22757	(-1.72,4.17)
Prazosin: other era	-1.74843	(-3.62,0.12)	-1.47808	(-3.07,0.12)	-1.41749	(-3.4,0.57)
p-value for 3-way interaction	0.0553		0.0605		0.146	
Tricyclics: OEF/OIF	-0.22955	(-3.62,3.16)	-0.20357	(-3.3,2.9)	0.24344	(-4.27,4.76)
Tricyclics: other era	0.44875	(-2.09,2.99)	0.37591	(-1.79,2.54)	-0.16697	(-1.8,1.47)
p-value for 3-way interaction	0.76216		0.76715		0.84163	
overall 3-way interaction p-value	0.14639		0.15697		0.41112	

**Changes in Weight (pounds) by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	208.36	210.7	2.33773	(2.337,2.353)	<.0001	1.12%
Mirtazapine	204.68	207.76	3.0754	(3.074,3.09)	<.0001	1.50%
Prazosin	215.17	216.82	1.65572	(1.655,1.671)	<.0001	0.77%
Tricyclics	215.37	217.25	1.87346	(1.872,1.888)	<.0001	0.87%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	62280	61746
Mirtazapine	48135	47490
Prazosin	87894	86461
Tricyclics	18183	17953

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	177.06	180.46	3.39781	(3.397,3.413)	<.0001	1.92%	<.0001
Mirtazapine	171.51	176.26	4.75132	(4.75,4.766)	<.0001	2.77%	<.0001
Prazosin	180.64	183.02	2.3745	(2.374,2.39)	<.0001	1.31%	<.0001
Tricyclics	179.87	183.13	3.26152	(3.261,3.277)	<.0001	1.81%	<.0001

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	5279	5278
Mirtazapine	4280	4216
Prazosin	7330	7253
Tricyclics	3260	3208

Changes in Weight (pounds) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.68103	(0.559,0.803)	0.68084	(0.559,0.803)	0.68114	(0.559,0.803)
Antipsychotics: female	1.02193	(0.603,1.44)	1.01981	(0.601,1.439)	1.02176	(0.602,1.441)
p-value for 3-way interaction	0.12524		0.12773		0.12665	
Mirtazapine: male	1.41921	(1.287,1.551)	1.4195	(1.288,1.551)	1.42007	(1.288,1.552)
Mirtazapine: female	2.3762	(1.929,2.824)	2.37399	(1.926,2.822)	2.375	(1.926,2.824)
p-value for 3-way interaction	0.00006		0.00006		0.00006	
Tricyclics: male	0.21778	(0.029,0.406)	0.21729	(0.029,0.406)	0.21637	(0.027,0.405)
Tricyclics: female	0.88735	(0.4,1.375)	0.88467	(0.397,1.373)	0.88724	(0.398,1.376)
p-value for 3-way interaction	0.01208		0.01244		0.01216	
overall 3-way interaction p-value	0.02386		0.0237		0.02368	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.681	(0.559,0.803)	0.68286	(0.561,0.805)	0.59268	(0.45,0.735)
Antipsychotics: female	1.02115	(0.601,1.441)	1.02054	(0.602,1.439)	1.04135	(0.573,1.51)
p-value for 3-way interaction	0.12716		0.12901		0.07269	
Mirtazapine: male	1.42009	(1.288,1.552)	1.41972	(1.288,1.552)	1.60249	(1.46,1.745)
Mirtazapine: female	2.37541	(1.926,2.824)	2.3718	(1.924,2.82)	2.65301	(2.183,3.123)
p-value for 3-way interaction	0.00006		0.00006		0.00003	
Tricyclics: male	0.21639	(0.027,0.405)	0.21714	(0.029,0.406)	0.38124	(0.238,0.524)
Tricyclics: female	0.88758	(0.398,1.377)	0.88429	(0.396,1.372)	1.12689	(0.659,1.595)
p-value for 3-way interaction	0.01212		0.01243		0.00283	
overall 3-way interaction p-value	0.02379		0.0005		0.07429	



**Changes in Weight (pounds) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	205.32	205.21	-0.11169	(-0.113,-0.097)	0.3566	-0.05%
Mirtazapine	201.68	202.77	1.08679	(1.086,1.102)	<.0001	0.54%
Prazosin	212.98	212.89	-0.08807	(-0.089,-0.073)	0.3074	-0.04%
Tricyclics	212.53	212.57	0.04035	(0.039,0.055)	0.8437	0.02%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	10397	10172
Mirtazapine	10759	10653
Prazosin	17510	17324
Tricyclics	3027	2984

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	205.98	208.86	2.87991	(2.879,2.895)	<.0001	1.40%	<.0001
Mirtazapine	202.01	205.78	3.76878	(3.768,3.784)	<.0001	1.87%	<.0001
Prazosin	212.34	214.47	2.12403	(2.123,2.139)	<.0001	1.00%	<.0001
Tricyclics	209.65	212.07	2.42117	(2.42,2.436)	<.0001	1.16%	<.0001

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	57162	56852
Mirtazapine	41656	41053
Prazosin	77714	76390
Tricyclics	18416	18177

Changes in Weight (pounds) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.02485	(-0.311,0.261)	-0.02292	(-0.309,0.263)	-0.02112	(-0.308,0.265)
Antipsychotics: <65	0.75512	(0.627,0.883)	0.75533	(0.628,0.883)	0.75532	(0.627,0.883)
p-value for 3-way interaction	<0.0001		<0.0001		<0.0001	
Mirtazapine: >=65	1.17457	(0.893,1.457)	1.17493	(0.893,1.457)	1.17442	(0.892,1.457)
Mirtazapine: <65	1.6443	(1.503,1.785)	1.64439	(1.503,1.785)	1.64507	(1.504,1.786)
p-value for 3-way interaction	0.0035		0.00354		0.0035	
Tricyclics: >=65	0.12689	(-0.326,0.58)	0.12895	(-0.324,0.582)	0.12771	(-0.326,0.582)
Tricyclics: <65	0.29767	(0.108,0.487)	0.29722	(0.108,0.487)	0.29696	(0.107,0.487)
p-value for 3-way interaction	0.49519		0.50186		0.50002	
overall 3-way interaction p-value	<0.0001		<0.0001		<0.0001	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.02135	(-0.308,0.265)	-0.02076	(-0.307,0.265)	0.23251	(-0.091,0.556)
Antipsychotics: <65	0.75514	(0.627,0.883)	0.75681	(0.629,0.884)	0.70443	(0.554,0.854)
p-value for 3-way interaction	<0.0001		<0.0001		0.00944	
Mirtazapine: >=65	1.17433	(0.892,1.457)	1.17742	(0.895,1.459)	1.41202	(1.09,1.734)
Mirtazapine: <65	1.64516	(1.504,1.786)	1.64388	(1.503,1.785)	1.75125	(1.601,1.902)
p-value for 3-way interaction	0.00349		0.00373		0.06162	
Tricyclics: >=65	0.12772	(-0.326,0.582)	0.12713	(-0.326,0.58)	0.28928	(-0.036,0.614)
Tricyclics: <65	0.29702	(0.107,0.487)	0.29769	(0.109,0.487)	0.46017	(0.31,0.61)
p-value for 3-way interaction	0.49989		0.49568		0.34958	
overall 3-way interaction p-value	<0.0001		<0.0001		0.05471	

**Changes in Weight (pounds) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	203.6	207.75	4.15603	(4.155,4.171)	<.0001	2.04%
Mirtazapine	201.05	206.1	5.04756	(5.047,5.063)	<.0001	2.51%
Prazosin	208.71	211.89	3.18033	(3.179,3.195)	<.0001	1.52%
Tricyclics	203.45	206.85	3.4035	(3.403,3.419)	<.0001	1.67%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	15592	15312
Mirtazapine	10431	10109
Prazosin	26226	25439
Tricyclics	4489	4392

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	206.58	208.49	1.91567	(1.915,1.931)	<.0001	0.93%	<.0001
Mirtazapine	202.16	204.94	2.77705	(2.776,2.792)	<.0001	1.37%	<.0001
Prazosin	213.93	215.11	1.17677	(1.176,1.192)	<.0001	0.55%	<.0001
Tricyclics	211.85	213.6	1.74279	(1.742,1.758)	<.0001	0.82%	<.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	51967	51712
Mirtazapine	41984	41597
Prazosin	68998	68275
Tricyclics	16954	16769

Changes in Weight (pounds) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Reference	95% CI	Reference	95% CI	Reference	95% CI
<b>Prazosin (Reference)</b>	<b>Reference</b>	<b>95% CI</b>	<b>Reference</b>	<b>95% CI</b>	<b>Reference</b>	<b>95% CI</b>
Antipsychotics: OEF/OIF	0.97478	(0.737,1.212)	0.97584	(0.738,1.214)	0.97626	(0.738,1.214)
Antipsychotics: other era	0.7382	(0.604,0.872)	0.73795	(0.604,0.872)	0.73804	(0.604,0.872)
p-value for 3-way interaction	0.08915		0.08769		0.0877	
Mirtazapine: OEF/OIF	1.86706	(1.594,2.141)	1.86747	(1.594,2.141)	1.86941	(1.595,2.144)
Mirtazapine: other era	1.59988	(1.457,1.743)	1.59988	(1.457,1.743)	1.59983	(1.457,1.743)
p-value for 3-way interaction	0.08969		0.08949		0.08757	
Tricyclics: OEF/OIF	0.22343	(-0.153,0.6)	0.22312	(-0.154,0.6)	0.22335	(-0.154,0.601)
Tricyclics: other era	0.56623	(0.369,0.763)	0.56551	(0.368,0.763)	0.56478	(0.367,0.762)
p-value for 3-way interaction	0.11417		0.11494		0.11648	
overall 3-way interaction p-value	0.02386		0.0237		0.02368	
Medications	Model 3		Model 4		Model 5	
	Reference	95% CI	Reference	95% CI	Reference	95% CI
<b>Prazosin (Reference)</b>	<b>Reference</b>	<b>95% CI</b>	<b>Reference</b>	<b>95% CI</b>	<b>Reference</b>	<b>95% CI</b>
Antipsychotics: OEF/OIF	0.9765	(0.738,1.215)	0.98234	(0.745,1.22)	0.77433	(0.493,1.056)
Antipsychotics: other era	0.73772	(0.603,0.872)	0.7378	(0.604,0.872)	0.65367	(0.498,0.809)
p-value for 3-way interaction	0.08697		0.07897		0.46223	
Mirtazapine: OEF/OIF	1.86936	(1.595,2.144)	1.87064	(1.597,2.144)	1.80228	(1.521,2.084)
Mirtazapine: other era	1.59991	(1.457,1.743)	1.59887	(1.456,1.742)	1.72015	(1.564,1.876)
p-value for 3-way interaction	0.08772		0.08435		0.61699	
Tricyclics: OEF/OIF	0.2242	(-0.153,0.602)	0.22764	(-0.149,0.605)	0.28256	(0.001,0.565)
Tricyclics: other era	0.56463	(0.367,0.762)	0.56431	(0.367,0.762)	0.55921	(0.403,0.715)
p-value for 3-way interaction	0.11756		0.12085		0.09242	
overall 3-way interaction p-value	0.02379		0.02218		0.07429	

### Changes in A1c by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	6.1388	6.1811	0.04228	(0.041,0.057)	<.0001	0.69%
Mirtazapine	6.2046	6.3347	0.13007	(0.129,0.145)	<.0001	2.10%
Prazosin	6.2252	6.2414	0.01621	(0.015,0.031)	0.0001	0.26%
Tricyclics	6.3933	6.4628	0.06953	(0.069,0.085)	<.0001	1.09%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	32820	37218
Mirtazapine	26578	27106
Prazosin	49351	50406
Tricyclics	10679	10727

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	5.7706	5.8291	0.05851	(0.058,0.074)	0.0033	1.01%	0.4295
Mirtazapine	5.834	5.9626	0.12853	(0.128,0.144)	<.0001	2.20%	0.9511
Prazosin	5.8281	5.8459	0.01784	(0.017,0.033)	0.2972	0.31%	0.9262
Tricyclics	5.9011	6.0076	0.10655	(0.106,0.122)	0.0003	1.81%	0.2318

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	2293	2755
Mirtazapine	1914	1963
Prazosin	3427	3477
Tricyclics	1391	1440

Changes in A1c by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.02626	(0.013,0.04)	0.02916	(0.016,0.042)	0.03306	(0.02,0.046)
Antipsychotics: female	0.04067	(-0.012,0.094)	0.0445	(-0.008,0.097)	0.04497	(-0.008,0.098)
p-value for 3-way interaction	0.60451		0.57896		0.66694	
Mirtazapine: male	0.11398	(0.1,0.128)	0.11373	(0.099,0.128)	0.11442	(0.1,0.129)
Mirtazapine: female	0.11072	(0.054,0.168)	0.11172	(0.055,0.168)	0.1097	(0.053,0.166)
p-value for 3-way interaction	0.9136		0.94645		0.87452	
Tricyclics: male	0.05329	(0.033,0.073)	0.05339	(0.033,0.073)	0.05323	(0.033,0.073)
Tricyclics: female	0.08853	(0.025,0.152)	0.08644	(0.024,0.149)	0.08804	(0.025,0.151)
p-value for 3-way interaction	0.2969		0.32433		0.30015	
overall 3-way interaction p-value	0.70205		0.73541		0.70478	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.03304	(0.02,0.046)	0.03299	(0.02,0.046)	0.02651	(0.011,0.042)
Antipsychotics: female	0.04497	(-0.008,0.098)	0.04514	(-0.007,0.098)	0.04295	(-0.016,0.102)
p-value for 3-way interaction	0.66655		0.66062		0.59548	
Mirtazapine: male	0.11439	(0.1,0.129)	0.11433	(0.1,0.129)	0.1154	(0.1,0.131)
Mirtazapine: female	0.10968	(0.053,0.166)	0.10935	(0.053,0.166)	0.11117	(0.051,0.171)
p-value for 3-way interaction	0.87471		0.86768		0.89355	
Tricyclics: male	0.05325	(0.033,0.073)	0.05323	(0.033,0.073)	0.06331	(0.048,0.079)
Tricyclics: female	0.08779	(0.025,0.151)	0.08764	(0.025,0.15)	0.09026	(0.03,0.15)
p-value for 3-way interaction	0.30382		0.30561		0.39403	
overall 3-way interaction p-value	0.70896		0.70718		0.74646	

**Changes in A1c by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	6.3504	6.3651	0.01471	(0.014,0.03)	0.1809	0.23%
Mirtazapine	6.3649	6.467	0.10214	(0.101,0.117)	<.0001	1.61%
Prazosin	6.4401	6.4367	-0.00348	(-0.004,0.012)	0.6737	-0.05%
Tricyclics	6.5703	6.6204	0.0501	(0.049,0.065)	0.02	0.76%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	6713	7066
Mirtazapine	6978	7064
Prazosin	12036	12224
Tricyclics	2180	2163

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	6.0614	6.1131	0.05165	(0.051,0.067)	<.0001	0.85%	0.0027
Mirtazapine	6.1209	6.261	0.14015	(0.139,0.155)	<.0001	2.29%	0.0055
Prazosin	6.1311	6.1543	0.0232	(0.022,0.038)	<.0001	0.38%	0.0051
Tricyclics	6.2832	6.3618	0.07858	(0.078,0.094)	<.0001	1.25%	0.2351

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	28400	32907
Mirtazapine	21514	22005
Prazosin	40742	41659
Tricyclics	9890	10004

Changes in A1c by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.01845	(-0.009,0.046)	0.01763	(-0.01,0.045)	0.02558	(-0.002,0.053)
Antipsychotics: <65	0.02862	(0.014,0.043)	0.03132	(0.017,0.046)	0.03375	(0.019,0.048)
p-value for 3-way interaction	0.52514		0.38994		0.60972	
Mirtazapine: >=65	0.10598	(0.078,0.134)	0.107	(0.08,0.134)	0.10983	(0.082,0.137)
Mirtazapine: <65	0.117	(0.101,0.133)	0.11626	(0.1,0.132)	0.11592	(0.1,0.132)
p-value for 3-way interaction	0.49935		0.56847		0.70917	
Tricyclics: >=65	0.05368	(0.011,0.096)	0.0541	(0.012,0.096)	0.05375	(0.011,0.096)
Tricyclics: <65	0.05532	(0.034,0.077)	0.05568	(0.034,0.077)	0.05586	(0.035,0.077)
p-value for 3-way interaction	0.94573		0.94759		0.93072	
overall 3-way interaction p-value	0.88236		0.83632		0.95884	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.02549	(-0.002,0.053)	0.02568	(-0.002,0.053)	0.02207	(-0.009,0.053)
Antipsychotics: <65	0.03375	(0.019,0.048)	0.0337	(0.019,0.048)	0.02997	(0.013,0.047)
p-value for 3-way interaction	0.60592		0.61638		0.66178	
Mirtazapine: >=65	0.10978	(0.082,0.137)	0.10974	(0.082,0.137)	0.10677	(0.076,0.138)
Mirtazapine: <65	0.11589	(0.1,0.132)	0.11584	(0.1,0.132)	0.11749	(0.1,0.135)
p-value for 3-way interaction	0.70839		0.70842		0.5562	
Tricyclics: >=65	0.05376	(0.011,0.096)	0.05366	(0.011,0.096)	0.06041	(0.029,0.091)
Tricyclics: <65	0.05584	(0.035,0.077)	0.05592	(0.035,0.077)	0.06577	(0.049,0.083)
p-value for 3-way interaction	0.93155		0.92579		0.76652	
overall 3-way interaction p-value	0.95779		0.9605		0.9446	



## Changes in A1c by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	5.5786	5.6374	0.05877	(0.058,0.074)	<.0001	1.05%
Mirtazapine	5.6358	5.7404	0.1046	(0.104,0.12)	<.0001	1.86%
Prazosin	5.692	5.739	0.04696	(0.046,0.062)	<.0001	0.83%
Tricyclics	5.6692	5.7556	0.08647	(0.085,0.101)	0.0019	1.53%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	6029	7226
Mirtazapine	4068	4040
Prazosin	10621	10757
Tricyclics	1740	1709

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	6.243	6.2839	0.04097	(0.04,0.056)	<.0001	0.66%	0.1937
Mirtazapine	6.2839	6.4161	0.13216	(0.131,0.147)	<.0001	2.10%	0.1411
Prazosin	6.3458	6.3556	0.00981	(0.009,0.025)	0.0296	0.16%	0.0007
Tricyclics	6.4638	6.5341	0.07036	(0.069,0.085)	<.0001	1.09%	0.5864

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	29084	32747
Mirtazapine	24424	25029
Prazosin	42157	43126
Tricyclics	10330	10458

Changes in A1c by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.01176	(-0.021,0.044)	0.01343	(-0.019,0.046)	0.01075	(-0.022,0.043)
Antipsychotics: other era	0.03147	(0.017,0.046)	0.03342	(0.019,0.047)	0.0383	(0.024,0.052)
p-value for 3-way interaction	0.27532		0.26665		0.12569	
Mirtazapine: OEF/OIF	0.05746	(0.019,0.096)	0.05672	(0.018,0.095)	0.05623	(0.018,0.095)
Mirtazapine: other era	0.12253	(0.108,0.138)	0.12282	(0.108,0.138)	0.12352	(0.109,0.139)
p-value for 3-way interaction	0.00211		0.0017		0.00139	
Tricyclics: OEF/OIF	0.03948	(-0.015,0.094)	0.03633	(-0.018,0.09)	0.03791	(-0.016,0.092)
Tricyclics: other era	0.06053	(0.04,0.081)	0.06101	(0.041,0.081)	0.06097	(0.041,0.081)
p-value for 3-way interaction	0.47582		0.40119		0.43254	
3way interaction p-value	0.02369		0.01949		0.01493	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.01071	(-0.022,0.043)	0.01049	(-0.022,0.043)	0.01264	(-0.026,0.051)
Antipsychotics: other era	0.03829	(0.024,0.052)	0.03835	(0.024,0.052)	0.03163	(0.015,0.048)
p-value for 3-way interaction	0.12538		0.12137		0.37123	
Mirtazapine: OEF/OIF	0.05629	(0.018,0.095)	0.0565	(0.018,0.095)	0.05585	(0.016,0.095)
Mirtazapine: other era	0.12348	(0.108,0.138)	0.12338	(0.108,0.138)	0.12438	(0.108,0.141)
p-value for 3-way interaction	0.00141		0.00148		0.00167	
Tricyclics: OEF/OIF	0.03793	(-0.016,0.092)	0.03861	(-0.015,0.092)	0.04401	(0.004,0.084)
Tricyclics: other era	0.06096	(0.041,0.081)	0.06089	(0.041,0.081)	0.06899	(0.053,0.085)
p-value for 3-way interaction	0.43305		0.44811		0.25848	
3way interaction p-value	0.01512		0.0156		0.01598	

### Changes in Glucose by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	111.83	113.91	2.08689	(2.086,2.102)	<.0001	1.87%
Mirtazapine	112.95	116.5	3.55081	(3.55,3.566)	<.0001	3.14%
Prazosin	112.93	114.58	1.64769	(1.647,1.663)	<.0001	1.46%
Tricyclics	117.34	119.63	2.28867	(2.288,2.304)	<.0001	1.95%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	56365	55854
Mirtazapine	44047	42942
Prazosin	79072	76780
Tricyclics	16763	16289

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	99.3944	101.46	2.06692	(2.066,2.082)	0.0002	2.08%	0.9725
Mirtazapine	100.97	103.58	2.60148	(2.601,2.616)	<.0001	2.58%	0.1511
Prazosin	100.38	101.88	1.49889	(1.498,1.514)	0.0018	1.49%	0.7648
Tricyclics	101.15	103.24	2.09164	(2.091,2.107)	0.0046	2.07%	0.8053

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	4677	4654
Mirtazapine	3831	3651
Prazosin	6410	6158
Tricyclics	2939	2830

Changes in Glucose by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.44005	(0.028,0.852)	0.49907	(0.088,0.91)	0.53038	(0.118,0.943)
Antipsychotics: female	0.57031	(-0.882,2.023)	0.6074	(-0.841,2.056)	0.62551	(-0.826,2.077)
p-value for 3-way interaction	0.86571		0.88787		0.90168	
Mirtazapine: male	1.90741	(1.462,2.353)	1.93305	(1.489,2.378)	1.92475	(1.479,2.371)
Mirtazapine: female	1.10789	(-0.447,2.663)	1.1479	(-0.403,2.699)	1.13115	(-0.423,2.685)
p-value for 3-way interaction	0.33275		0.34021		0.33605	
Tricyclics: male	0.64967	(0.014,1.285)	0.66647	(0.032,1.3)	0.62922	(-0.007,1.265)
Tricyclics: female	0.59941	(-1.084,2.282)	0.63941	(-1.039,2.318)	0.64448	(-1.038,2.327)
p-value for 3-way interaction	0.95633		0.97642		0.98674	
overall 3-way interaction p-value	0.72283		0.73777		0.73286	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.53045	(0.118,0.943)	0.53735	(0.125,0.95)	0.51092	(0.035,0.987)
Antipsychotics: female	0.6268	(-0.825,2.079)	0.63308	(-0.819,2.085)	0.65076	(-0.953,2.254)
p-value for 3-way interaction	0.90042		0.90106		0.86985	
Mirtazapine: male	1.925	(1.479,2.371)	1.92602	(1.48,2.372)	1.87133	(1.393,2.349)
Mirtazapine: female	1.1313	(-0.423,2.686)	1.12495	(-0.429,2.679)	1.03932	(-0.573,2.652)
p-value for 3-way interaction	0.33599		0.33149		0.33218	
Tricyclics: male	0.62921	(-0.007,1.265)	0.62617	(-0.01,1.262)	0.48643	(0.008,0.965)
Tricyclics: female	0.64513	(-1.038,2.328)	0.62729	(-1.055,2.31)	0.59102	(-1.014,2.197)
p-value for 3-way interaction	0.98616		0.99903		0.90261	
overall 3-way interaction p-value	0.73229		0.72892		0.62492	

**Changes in Glucose by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	118.16	120.11	1.94408	(1.943,1.959)	<.0001	1.65%
Mirtazapine	117.95	121.74	3.78737	(3.786,3.802)	<.0001	3.21%
Prazosin	119.63	120.45	0.81795	(0.817,0.833)	0.0045	0.68%
Tricyclics	123.33	125.1	1.77561	(1.775,1.791)	0.0148	1.44%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	9773	9607
Mirtazapine	10144	9976
Prazosin	16558	16326
Tricyclics	2886	2841

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	109.5	111.62	2.11598	(2.115,2.131)	<.0001	1.93%	0.6789
Mirtazapine	110.41	113.8	3.39257	(3.392,3.408)	<.0001	3.07%	0.3565
Prazosin	110.19	112.02	1.83631	(1.835,1.851)	<.0001	1.67%	0.0016
Tricyclics	113.53	115.88	2.34286	(2.342,2.358)	<.0001	2.06%	0.4732

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	51269	50901
Mirtazapine	37734	36617
Prazosin	68924	66612
Tricyclics	16816	16278

Changes in Glucose by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	1.12629	(0.185,2.067)	1.19391	(0.255,2.133)	1.29128	(0.348,2.234)
Antipsychotics: <65	0.28106	(-0.157,0.719)	0.33225	(-0.105,0.769)	0.3513	(-0.087,0.79)
p-value for 3-way interaction	0.11049		0.10311		0.07641	
Mirtazapine: >=65	2.96952	(2.04,3.9)	3.00297	(2.075,3.931)	3.03046	(2.099,3.962)
Mirtazapine: <65	1.56202	(1.079,2.045)	1.58326	(1.102,2.065)	1.56736	(1.085,2.05)
p-value for 3-way interaction	0.00847		0.0078		0.00628	
Tricyclics: >=65	0.96311	(-0.521,2.447)	0.9796	(-0.502,2.461)	0.88912	(-0.598,2.376)
Tricyclics: <65	0.51678	(-0.129,1.162)	0.54665	(-0.098,1.191)	0.5286	(-0.118,1.175)
p-value for 3-way interaction	0.58887		0.59944		0.66303	
overall 3-way interaction p-value	0.0602		0.05523		0.04121	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	1.29126	(0.348,2.234)	1.29726	(0.354,2.24)	1.2854	(0.237,2.334)
Antipsychotics: <65	0.35137	(-0.087,0.79)	0.35829	(-0.08,0.797)	0.34507	(-0.162,0.852)
p-value for 3-way interaction	0.07644		0.0767		0.11349	
Mirtazapine: >=65	3.03046	(2.099,3.962)	3.03297	(2.101,3.965)	2.96632	(1.919,4.014)
Mirtazapine: <65	1.56746	(1.085,2.05)	1.56861	(1.086,2.051)	1.53332	(1.024,2.043)
p-value for 3-way interaction	0.00629		0.00624		0.01591	
Tricyclics: >=65	0.8891	(-0.598,2.376)	0.89187	(-0.595,2.379)	1.11187	(0.056,2.168)
Tricyclics: <65	0.52863	(-0.117,1.175)	0.52431	(-0.122,1.17)	0.34821	(-0.161,0.857)
p-value for 3-way interaction	0.66307		0.65684		0.2017	
overall 3-way interaction p-value	0.04123		0.04116		0.11126	

## Changes in Glucose by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	97.6711	99.7084	2.03733	(2.036,2.052)	<.0001	2.09%
Mirtazapine	98.5602	101.3	2.74387	(2.743,2.759)	<.0001	2.78%
Prazosin	99.4502	101.52	2.06663	(2.066,2.082)	<.0001	2.08%
Tricyclics	99.1189	100.82	1.70151	(1.701,1.717)	0.0106	1.72%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	13109	12691
Mirtazapine	8834	8258
Prazosin	21905	20377
Tricyclics	3848	3584

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	114.66	116.71	2.05514	(2.054,2.07)	<.0001	1.79%	0.9628
Mirtazapine	115.27	118.85	3.58176	(3.581,3.597)	<.0001	3.11%	0.0754
Prazosin	116.57	118	1.42704	(1.426,1.442)	<.0001	1.22%	0.0355
Tricyclics	119.05	121.37	2.32305	(2.322,2.338)	<.0001	1.95%	0.3981

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	47933	47817
Mirtazapine	39044	38335
Prazosin	63577	62561
Tricyclics	15854	15535

Changes in Glucose by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	-0.02785	(-0.883,0.827)	-0.00788	(-0.861,0.845)	-0.04448	(-0.899,0.81)
Antipsychotics: other era	0.62938	(0.182,1.077)	0.66071	(0.213,1.108)	0.71023	(0.262,1.159)
p-value for 3-way interaction	0.18191		0.17379		0.12523	
Mirtazapine: OEF/OIF	0.68151	(-0.304,1.667)	0.7147	(-0.269,1.698)	0.69244	(-0.292,1.676)
Mirtazapine: other era	2.15807	(1.681,2.635)	2.16074	(1.684,2.637)	2.16093	(1.683,2.639)
p-value for 3-way interaction	0.0082		0.0095		0.00851	
Tricyclics: OEF/OIF	-0.36468	(-1.722,0.992)	-0.35674	(-1.712,0.998)	-0.39386	(-1.75,0.962)
Tricyclics: other era	0.90288	(0.246,1.56)	0.90342	(0.247,1.56)	0.88135	(0.223,1.54)
p-value for 3-way interaction	0.09946		0.10091		0.09739	
overall 3-way interaction p-value	0.04148		0.04601		0.03939	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	-0.04438	(-0.899,0.81)	-0.03303	(-0.887,0.821)	-0.09703	(-1.095,0.901)
Antipsychotics: other era	0.71034	(0.262,1.159)	0.7162	(0.268,1.165)	0.72337	(0.211,1.236)
p-value for 3-way interaction	0.12523		0.12796		0.15196	
Mirtazapine: OEF/OIF	0.69257	(-0.291,1.677)	0.70017	(-0.284,1.684)	0.62373	(-0.378,1.626)
Mirtazapine: other era	2.16107	(1.683,2.639)	2.16089	(1.683,2.639)	2.13283	(1.618,2.647)
p-value for 3-way interaction	0.00851		0.00886		0.00865	
Tricyclics: OEF/OIF	-0.39376	(-1.75,0.963)	-0.3985	(-1.755,0.958)	-0.21596	(-1.227,0.795)
Tricyclics: other era	0.88133	(0.223,1.54)	0.87892	(0.22,1.538)	0.71302	(0.199,1.227)
p-value for 3-way interaction	0.09742		0.09678		0.10842	
overall 3-way interaction p-value	0.03939		0.04056		0.07045	



**Changes in Triglycerides by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	174.51	183.23	8.7193	(8.718,8.734)	<.0001	5.00%
Mirtazapine	170.75	183.72	12.9635	(12.963,12.979)	<.0001	7.59%
Prazosin	178	178.34	0.3414	(0.34,0.356)	0.4635	0.19%
Tricyclics	189.22	194.53	5.3042	(5.303,5.319)	<.0001	2.80%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	52286	52287
Mirtazapine	41136	39540
Prazosin	73821	71193
Tricyclics	15591	14923

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	138.41	148.01	9.60395	(9.603,9.619)	<.0001	6.94%	0.6619
Mirtazapine	141.58	150.51	8.93089	(8.93,8.946)	<.0001	6.31%	0.0871
Prazosin	135.78	137.51	1.73366	(1.733,1.749)	0.3286	1.28%	0.448
Tricyclics	141.92	146.63	4.70635	(4.705,4.721)	0.0743	3.32%	0.8327

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	4042	4086
Mirtazapine	3355	3114
Prazosin	5491	5182
Tricyclics	2524	2358

Changes in Triglycerides by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	8.4377	(7.036,9.839)	8.4147	(7.014,9.815)	8.4628	(7.061,9.864)
Antipsychotics: female	7.9154	(2.693,13.138)	7.8105	(2.593,13.028)	7.9026	(2.684,13.121)
p-value for 3-way interaction	0.8499		0.8265		0.839	
Mirtazapine: male	12.6408	(11.123,14.159)	12.5933	(11.076,14.11)	12.6315	(11.114,14.149)
Mirtazapine: female	7.2176	(1.611,12.825)	7.2613	(1.661,12.862)	7.2879	(1.686,12.89)
p-value for 3-way interaction	0.0673		0.0717		0.0712	
Tricyclics: male	5.0657	(2.895,7.237)	5.1426	(2.973,7.312)	5.1319	(2.961,7.303)
Tricyclics: female	3.0382	(-3.086,9.162)	3.2608	(-2.856,9.378)	3.2663	(-2.853,9.385)
p-value for 3-way interaction	0.5408		0.5699		0.5733	
overall 3-way interaction p-value	0.29005		0.31104		0.30678	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	8.4649	(7.063,9.866)	8.4754	(7.074,9.877)	8.3947	(6.782,10.008)
Antipsychotics: female	7.8976	(2.679,13.116)	7.8862	(2.668,13.105)	8.1449	(2.392,13.898)
p-value for 3-way interaction	0.837		0.8308		0.9347	
Mirtazapine: male	12.6344	(11.117,14.152)	12.6378	(11.12,14.155)	13.1932	(11.57,14.816)
Mirtazapine: female	7.2903	(1.688,12.892)	7.2459	(1.644,12.848)	7.9011	(2.091,13.711)
p-value for 3-way interaction	0.0711		0.0686		0.0855	
Tricyclics: male	5.1318	(2.961,7.303)	5.1258	(2.955,7.297)	5.6336	(4.007,7.261)
Tricyclics: female	3.2604	(-2.859,9.379)	3.2226	(-2.896,9.341)	3.651	(-2.163,9.465)
p-value for 3-way interaction	0.5721		0.5656		0.5198	
overall 3-way interaction p-value	0.30709		0.29993		0.28037	

**Changes in Triglycerides by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	156.73	159.77	3.03409	(3.033,3.049)	0.0167	1.94%
Mirtazapine	153.44	163.02	9.58555	(9.585,9.601)	<.0001	6.25%
Prazosin	162.66	160.1	-2.56257	(-2.564,-2.548)	0.0096	-1.58%
Tricyclics	172.35	174.49	2.14479	(2.144,2.16)	0.3749	1.24%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	9159	8905
Mirtazapine	9573	9177
Prazosin	15698	15344
Tricyclics	2723	2657

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	174.57	184.41	9.8451	(9.844,9.86)	<.0001	5.64%	<.0001
Mirtazapine	172.43	186.02	13.588	(13.587,13.603)	<.0001	7.88%	0.0061
Prazosin	177.78	179.04	1.2599	(1.259,1.275)	0.0128	0.71%	0.0006
Tricyclics	184.18	190.06	5.8805	(5.88,5.896)	<.0001	3.19%	0.156

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	47169	47468
Mirtazapine	34918	33477
Prazosin	63614	61031
Tricyclics	15392	14624

Changes in Triglycerides by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	5.607	(2.416,8.798)	5.6226	(2.433,8.812)	5.7282	(2.537,8.919)
Antipsychotics: <65	8.6512	(7.153,10.15)	8.6949	(7.198,10.192)	8.7324	(7.235,10.23)
p-value for 3-way interaction	0.0906		0.0875		0.0949	
Mirtazapine: >=65	12.1564	(9.001,15.312)	12.1413	(8.987,15.295)	12.2186	(9.063,15.374)
Mirtazapine: <65	12.347	(10.692,14.002)	12.3233	(10.669,13.977)	12.3438	(10.689,13.998)
p-value for 3-way interaction	0.9165		0.9202		0.9451	
Tricyclics: >=65	4.7629	(-0.257,9.783)	4.7758	(-0.242,9.793)	4.7796	(-0.241,9.8)
Tricyclics: <65	4.7457	(2.514,6.978)	4.831	(2.601,7.061)	4.812	(2.581,7.043)
p-value for 3-way interaction	0.9951		0.9843		0.9908	
overall 3-way interaction p-value	0.34697		0.33952		0.3551	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	5.7316	(2.54,8.923)	5.7501	(2.559,8.941)	6.048	(2.51,9.586)
Antipsychotics: <65	8.7332	(7.235,10.231)	8.7409	(7.243,10.238)	8.7817	(7.052,10.511)
p-value for 3-way interaction	0.0952		0.0963		0.1737	
Mirtazapine: >=65	12.2214	(9.066,15.377)	12.2178	(9.062,15.373)	12.3178	(8.777,15.859)
Mirtazapine: <65	12.3457	(10.691,14)	12.3494	(10.695,14.004)	12.9146	(11.172,14.657)
p-value for 3-way interaction	0.9455		0.9423		0.767	
Tricyclics: >=65	4.7786	(-0.242,9.799)	4.7869	(-0.233,9.807)	5.7177	(2.161,9.274)
Tricyclics: <65	4.8118	(2.581,7.043)	4.8074	(2.577,7.038)	5.4358	(3.69,7.182)
p-value for 3-way interaction	0.9905		0.9942		0.8891	
overall 3-way interaction p-value	0.35584		0.35941		0.43182	

**Changes in Triglycerides by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	174.13	188.62	14.489	(14.488,14.504)	<.0001	8.32%
Mirtazapine	174.51	191.01	16.5039	(16.503,16.519)	<.0001	9.46%
Prazosin	179.59	185.04	5.4508	(5.45,5.466)	<.0001	3.04%
Tricyclics	181.87	191.96	10.0903	(10.089,10.105)	<.0001	5.55%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	11602	11455
Mirtazapine	7822	7235
Prazosin	19331	18010
Tricyclics	3383	3009

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	171.03	178.45	7.4203	(7.419,7.435)	<.0001	4.34%	<.0001
Mirtazapine	166.99	179	12.0123	(12.011,12.027)	<.0001	7.19%	0.0065
Prazosin	173.14	172.19	-0.9452	(-0.946,-0.93)	0.0644	-0.55%	<.0001
Tricyclics	182.55	186.87	4.3222	(4.321,4.337)	<.0001	2.37%	0.0251

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	44726	44918
Mirtazapine	36669	35419
Prazosin	59981	58365
Tricyclics	14732	14272

Changes in Triglycerides by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	9.1186	(6.117,12.12)	9.2344	(6.237,12.232)	9.2462	(6.248,12.244)
Antipsychotics: other era	8.4147	(6.896,9.933)	8.3922	(6.875,9.91)	8.449	(6.931,9.967)
p-value for 3-way interaction	0.6817		0.6232		0.642	
Mirtazapine: OEF/OIF	11.0787	(7.6,14.557)	11.0175	(7.544,14.491)	11.0271	(7.553,14.501)
Mirtazapine: other era	12.9705	(11.349,14.592)	12.9513	(11.331,14.572)	12.9892	(11.368,14.611)
p-value for 3-way interaction	0.334		0.3227		0.3158	
Tricyclics: OEF/OIF	4.8766	(0.009,9.744)	5.033	(0.173,9.893)	5.0174	(0.156,9.879)
Tricyclics: other era	5.3456	(3.099,7.592)	5.4046	(3.16,7.65)	5.3957	(3.15,7.642)
p-value for 3-way interaction	0.8638		0.8918		0.8899	
overall 3-way interaction p-value	0.66445		0.61983		0.62263	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	9.2481	(6.25,12.246)	9.272	(6.274,12.27)	8.8129	(5.314,12.312)
Antipsychotics: other era	8.4502	(6.932,9.969)	8.4552	(6.937,9.973)	8.3525	(6.619,10.086)
p-value for 3-way interaction	0.6417		0.6338		0.8173	
Mirtazapine: OEF/OIF	11.0289	(7.555,14.503)	11.0275	(7.553,14.502)	11.4365	(7.906,14.967)
Mirtazapine: other era	12.9915	(11.37,14.613)	12.992	(11.371,14.613)	13.2863	(11.542,15.03)
p-value for 3-way interaction	0.3157		0.3152		0.3572	
Tricyclics: OEF/OIF	5.0208	(0.159,9.882)	5.0033	(0.142,9.865)	5.5384	(1.955,9.122)
Tricyclics: other era	5.3939	(3.148,7.64)	5.3915	(3.145,7.638)	5.7006	(3.957,7.445)
p-value for 3-way interaction	0.8914		0.887		0.9364	
overall 3-way interaction p-value	0.6224		0.61702		0.6861	

### Changes in HDL by Augmenting Medication Group - Male vs. Female

#### Male

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	43.1786	42.7903	-0.38829	(-0.389,-0.373)	<.0001	-0.90%
Mirtazapine	43.6347	43.1034	-0.53129	(-0.532,-0.516)	<.0001	-1.22%
Prazosin	43.0899	43.0708	-0.01907	(-0.02,-0.004)	0.5792	-0.04%
Tricyclics	41.6816	41.6076	-0.07393	(-0.075,-0.059)	0.3212	-0.18%

#### Number of Windows - Male

Medications	n(pre)	n(post)
Antipsychotics	51807	51987
Mirtazapine	40809	39288
Prazosin	73317	70830
Tricyclics	15512	14890

#### Female

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	53.5297	53.54	0.01034	(0.009,0.025)	0.9476	0.02%	0.0146
Mirtazapine	54.2478	53.5026	-0.74513	(-0.746,-0.73)	<.0001	-1.37%	0.2657
Prazosin	53.9396	54.2306	0.29098	(0.29,0.306)	0.0278	0.54%	0.0233
Tricyclics	52.9661	53.1659	0.19988	(0.199,0.215)	0.2982	0.38%	0.184

#### Number of Windows - Female

Medications	n(pre)	n(post)
Antipsychotics	4042	4081
Mirtazapine	3333	3106
Prazosin	5483	5169
Tricyclics	2514	2348

Changes in HDL by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	-0.36749	(-0.476,-0.259)	-0.36712	(-0.475,-0.259)	-0.37051	(-0.479,-0.262)
Antipsychotics: female	-0.27939	(-0.685,0.126)	-0.27343	(-0.678,0.132)	-0.27836	(-0.684,0.128)
p-value for 3-way interaction	0.68077		0.6614		0.6674	
Mirtazapine: male	-0.51098	(-0.628,-0.394)	-0.50796	(-0.625,-0.391)	-0.51164	(-0.629,-0.394)
Mirtazapine: female	-1.02752	(-1.464,-0.591)	-1.0306	(-1.467,-0.594)	-1.03386	(-1.471,-0.597)
p-value for 3-way interaction	0.02519		0.02338		0.02381	
Tricyclics: male	-0.05352	(-0.221,0.114)	-0.05629	(-0.224,0.111)	-0.05625	(-0.224,0.112)
Tricyclics: female	-0.08882	(-0.565,0.387)	-0.10005	(-0.576,0.376)	-0.10164	(-0.578,0.375)
p-value for 3-way interaction	0.89097		0.86492		0.86031	
overall 3-way interaction p-value	0.06505		0.05863		0.06054	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	-0.37048	(-0.479,-0.262)	-0.37196	(-0.481,-0.263)	-0.31582	(-0.441,-0.19)
Antipsychotics: female	-0.27844	(-0.684,0.128)	-0.27787	(-0.684,0.128)	-0.30514	(-0.754,0.144)
p-value for 3-way interaction	0.66778		0.66084		0.96419	
Mirtazapine: male	-0.5116	(-0.629,-0.394)	-0.51135	(-0.629,-0.394)	-0.51087	(-0.637,-0.384)
Mirtazapine: female	-1.03385	(-1.471,-0.597)	-1.03004	(-1.467,-0.593)	-1.12125	(-1.576,-0.666)
p-value for 3-way interaction	0.0238		0.02477		0.01133	
Tricyclics: male	-0.05625	(-0.224,0.112)	-0.05491	(-0.223,0.113)	-0.09158	(-0.218,0.035)
Tricyclics: female	-0.1017	(-0.578,0.375)	-0.09704	(-0.574,0.38)	-0.16276	(-0.618,0.292)
p-value for 3-way interaction	0.86008		0.87023		0.76768	
overall 3-way interaction p-value	0.06057		0.06206		0.02549	



**Changes in HDL by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	44.5936	44.5684	-0.02521	(-0.026,-0.01)	0.8047	-0.06%
Mirtazapine	44.982	44.6442	-0.33778	(-0.339,-0.323)	0.0012	-0.75%
Prazosin	44.2358	44.5187	0.28291	(0.282,0.298)	<.0001	0.64%
Tricyclics	43.3031	43.4371	0.13394	(0.133,0.149)	0.4426	0.31%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	9082	8879
Mirtazapine	9507	9144
Prazosin	15612	15286
Tricyclics	2713	2654

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	43.8577	43.434	-0.42368	(-0.425,-0.409)	<.0001	-0.97%	0.0004
Mirtazapine	44.341	43.7287	-0.61232	(-0.613,-0.597)	<.0001	-1.38%	0.0199
Prazosin	43.8273	43.7498	-0.07748	(-0.078,-0.062)	0.0388	-0.18%	<.0001
Tricyclics	43.3045	43.2244	-0.08014	(-0.081,-0.065)	0.2912	-0.19%	0.2605

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	46767	47189
Mirtazapine	34635	33250
Prazosin	63188	60713
Tricyclics	15313	14584

Changes in HDL by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.30737	(-0.553,-0.062)	-0.3092	(-0.555,-0.064)	-0.31739	(-0.564,-0.071)
Antipsychotics: <65	-0.34421	(-0.46,-0.228)	-0.34774	(-0.464,-0.232)	-0.34952	(-0.466,-0.233)
p-value for 3-way interaction	0.7904		0.78096		0.81707	
Mirtazapine: >=65	-0.62123	(-0.864,-0.378)	-0.62013	(-0.863,-0.377)	-0.62235	(-0.866,-0.379)
Mirtazapine: <65	-0.53204	(-0.66,-0.404)	-0.53	(-0.658,-0.402)	-0.53309	(-0.662,-0.404)
p-value for 3-way interaction	0.52475		0.52029		0.52525	
Tricyclics: >=65	-0.14924	(-0.535,0.236)	-0.14839	(-0.534,0.237)	-0.14901	(-0.535,0.237)
Tricyclics: <65	-0.00196	(-0.175,0.171)	-0.00474	(-0.177,0.168)	-0.0046	(-0.178,0.168)
p-value for 3-way interaction	0.4942		0.50485		0.50358	
overall 3-way interaction p-value	0.77216		0.77089		0.78859	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.31719	(-0.563,-0.071)	-0.31771	(-0.564,-0.072)	-0.27876	(-0.553,-0.005)
Antipsychotics: <65	-0.34945	(-0.466,-0.233)	-0.35078	(-0.467,-0.234)	-0.31125	(-0.446,-0.176)
p-value for 3-way interaction	0.81638		0.81184		0.83479	
Mirtazapine: >=65	-0.62226	(-0.866,-0.379)	-0.62184	(-0.865,-0.378)	-0.63403	(-0.908,-0.36)
Mirtazapine: <65	-0.53296	(-0.662,-0.404)	-0.53272	(-0.661,-0.404)	-0.53693	(-0.673,-0.401)
p-value for 3-way interaction	0.52508		0.52588		0.53434	
Tricyclics: >=65	-0.14904	(-0.535,0.237)	-0.14936	(-0.536,0.237)	-0.08802	(-0.363,0.187)
Tricyclics: <65	-0.00457	(-0.178,0.168)	-0.00322	(-0.176,0.17)	-0.09686	(-0.233,0.039)
p-value for 3-way interaction	0.50343		0.49849		0.95494	
overall 3-way interaction p-value	0.78814		0.7842		0.85018	

**Changes in HDL by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	43.6551	43.0983	-0.55673	(-0.558,-0.542)	<.0001	-1.28%
Mirtazapine	43.9505	43.4121	-0.5384	(-0.539,-0.523)	<.0001	-1.23%
Prazosin	43.7991	43.5165	-0.2826	(-0.284,-0.268)	<.0001	-0.65%
Tricyclics	43.6562	43.3723	-0.28398	(-0.285,-0.269)	0.0994	-0.65%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	11532	11406
Mirtazapine	7767	7204
Prazosin	19215	17960
Tricyclics	3369	3020

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	44.0643	43.7508	-0.31347	(-0.314,-0.298)	<.0001	-0.71%	0.0219
Mirtazapine	44.5965	44.0418	-0.55464	(-0.556,-0.54)	<.0001	-1.24%	0.9044
Prazosin	43.948	44.0237	0.07565	(0.075,0.091)	0.0444	0.17%	<.0001
Tricyclics	43.2193	43.2207	0.00138	(0,0.016)	0.9856	0.00%	0.1298

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	44317	44662
Mirtazapine	36375	35190
Prazosin	59585	58039
Tricyclics	14657	14218

Changes in HDL by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.27298	(-0.508,-0.038)	-0.27779	(-0.512,-0.043)	-0.27718	(-0.512,-0.042)
Antipsychotics: other era	-0.38734	(-0.505,-0.27)	-0.38949	(-0.507,-0.272)	-0.39302	(-0.51,-0.276)
p-value for 3-way interaction	0.39308		0.40384		0.38751	
Mirtazapine: OEF/OIF	-0.25208	(-0.525,0.021)	-0.24957	(-0.522,0.023)	-0.2552	(-0.528,0.018)
Mirtazapine: other era	-0.62849	(-0.754,-0.503)	-0.62713	(-0.752,-0.502)	-0.62971	(-0.755,-0.504)
p-value for 3-way interaction	0.01401		0.01363		0.01459	
Tricyclics: OEF/OIF	-0.00175	(-0.382,0.379)	-0.00677	(-0.387,0.373)	-0.012	(-0.393,0.369)
Tricyclics: other era	-0.07366	(-0.247,0.1)	-0.07523	(-0.248,0.098)	-0.07417	(-0.248,0.099)
p-value for 3-way interaction	0.73596		0.74798		0.77085	
overall 3-way interaction p-value	0.10777		0.10523		0.11013	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.27708	(-0.512,-0.042)	-0.27969	(-0.515,-0.045)	-0.21911	(-0.494,0.056)
Antipsychotics: other era	-0.39296	(-0.51,-0.275)	-0.39391	(-0.511,-0.276)	-0.33699	(-0.472,-0.202)
p-value for 3-way interaction	0.38739		0.39417		0.45104	
Mirtazapine: OEF/OIF	-0.25515	(-0.528,0.018)	-0.25516	(-0.528,0.018)	-0.2524	(-0.531,0.026)
Mirtazapine: other era	-0.62961	(-0.755,-0.504)	-0.6293	(-0.755,-0.504)	-0.6346	(-0.77,-0.499)
p-value for 3-way interaction	0.01461		0.01469		0.01559	
Tricyclics: OEF/OIF	-0.01193	(-0.393,0.369)	-0.009	(-0.39,0.372)	-0.0798	(-0.362,0.203)
Tricyclics: other era	-0.07419	(-0.248,0.099)	-0.07354	(-0.247,0.1)	-0.11183	(-0.247,0.024)
p-value for 3-way interaction	0.77055		0.76235		0.84109	
overall 3-way interaction p-value	0.11022		0.11103		0.07021	

**Changes in LDL Cholesterol by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	108.91	107.18	-1.72553	(-1.727,-1.711)	<.0001	-1.58%
Mirtazapine	106.16	104.82	-1.34533	(-1.346,-1.33)	<.0001	-1.27%
Prazosin	108.85	106.12	-2.73065	(-2.732,-2.716)	<.0001	-2.51%
Tricyclics	107.51	104.81	-2.69734	(-2.698,-2.682)	<.0001	-2.51%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	51418	51588
Mirtazapine	40551	39095
Prazosin	73064	70618
Tricyclics	15347	14762

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	116.92	115.82	-1.09832	(-1.099,-1.083)	0.0226	-0.94%	0.2093
Mirtazapine	116.19	116.02	-0.16996	(-0.171,-0.155)	0.7574	-0.15%	0.0395
Prazosin	116.4	115.05	-1.34487	(-1.346,-1.33)	0.0015	-1.16%	0.0015
Tricyclics	117.73	117.29	-0.43728	(-0.438,-0.422)	0.4835	-0.37%	0.0007

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	4012	4061
Mirtazapine	3308	3105
Prazosin	5459	5159
Tricyclics	2498	2340

Changes in LDL Cholesterol by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.00186	(0.663,1.341)	0.93742	(0.599,1.276)	0.91235	(0.574,1.25)
Antipsychotics: female	0.23718	(-1.023,1.497)	0.15142	(-1.105,1.407)	0.08165	(-1.173,1.337)
p-value for 3-way interaction	0.25064		0.2363		0.21034	
Mirtazapine: male	1.37891	(1.012,1.746)	1.36886	(1.003,1.735)	1.35276	(0.987,1.719)
Mirtazapine: female	1.15461	(-0.2,2.509)	1.12902	(-0.221,2.479)	1.11656	(-0.233,2.466)
p-value for 3-way interaction	0.75411		0.7369		0.74053	
Tricyclics: male	0.02932	(-0.496,0.554)	0.05576	(-0.468,0.58)	0.07336	(-0.451,0.597)
Tricyclics: female	0.89556	(-0.585,2.376)	0.89619	(-0.58,2.372)	0.90757	(-0.567,2.382)
p-value for 3-way interaction	0.2797		0.29287		0.29608	
overall 3-way interaction p-value	0.26642		0.26339		0.2409	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.91202	(0.574,1.25)	0.90284	(0.565,1.241)	1.02296	(0.632,1.414)
Antipsychotics: female	0.08265	(-1.172,1.338)	0.0811	(-1.174,1.336)	0.45618	(-0.934,1.846)
p-value for 3-way interaction	0.21107		0.21518		0.44163	
Mirtazapine: male	1.35212	(0.986,1.718)	1.34891	(0.983,1.715)	1.45701	(1.064,1.85)
Mirtazapine: female	1.11651	(-0.233,2.466)	1.12288	(-0.226,2.472)	1.34851	(-0.058,2.755)
p-value for 3-way interaction	0.74114		0.75126		0.88423	
Tricyclics: male	0.07344	(-0.45,0.597)	0.07147	(-0.452,0.595)	0.21259	(-0.182,0.607)
Tricyclics: female	0.90853	(-0.566,2.383)	0.9223	(-0.552,2.396)	1.04011	(-0.367,2.447)
p-value for 3-way interaction	0.29557		0.28645		0.26696	
overall 3-way interaction p-value	0.24126		0.23872		0.28927	

**Changes in LDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	97.5031	95.8157	-1.68742	(-1.688,-1.672)	<.0001	-1.73%
Mirtazapine	95.6731	94.7638	-0.9093	(-0.91,-0.894)	0.0034	-0.95%
Prazosin	97.863	95.5492	-2.31384	(-2.315,-2.299)	<.0001	-2.36%
Tricyclics	96.1815	94.0211	-2.16042	(-2.161,-2.145)	0.0001	-2.25%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	9051	8857
Mirtazapine	9455	9116
Prazosin	15593	15270
Tricyclics	2709	2646

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	111.77	110.06	-1.70364	(-1.705,-1.689)	<.0001	-1.52%	0.9622
Mirtazapine	109.95	108.59	-1.36118	(-1.362,-1.346)	<.0001	-1.24%	0.1998
Prazosin	112.14	109.43	-2.70965	(-2.711,-2.695)	<.0001	-2.42%	0.1334
Tricyclics	111.17	108.73	-2.43816	(-2.439,-2.423)	<.0001	-2.19%	0.6543

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	46379	46792
Mirtazapine	34404	33084
Prazosin	62930	60507
Tricyclics	15136	14456

Changes in LDL Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.62482	(-0.143,1.393)	0.58113	(-0.185,1.347)	0.51552	(-0.251,1.282)
Antipsychotics: <65	1.00288	(0.641,1.365)	0.96242	(0.601,1.324)	0.94213	(0.581,1.304)
p-value for 3-way interaction	0.38279		0.37778		0.32376	
Mirtazapine: >=65	1.40068	(0.641,2.16)	1.37095	(0.613,2.129)	1.34072	(0.583,2.099)
Mirtazapine: <65	1.33994	(0.94,1.74)	1.34642	(0.947,1.746)	1.33618	(0.937,1.735)
p-value for 3-way interaction	0.8897		0.95525		0.99171	
Tricyclics: >=65	0.15384	(-1.052,1.36)	0.16483	(-1.039,1.368)	0.21235	(-0.991,1.416)
Tricyclics: <65	0.27056	(-0.269,0.811)	0.29235	(-0.246,0.831)	0.30685	(-0.232,0.846)
p-value for 3-way interaction	0.86253		0.84966		0.8883	
overall 3-way interaction p-value	0.7978		0.81277		0.76705	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.51482	(-0.252,1.281)	0.50934	(-0.257,1.276)	0.56881	(-0.284,1.421)
Antipsychotics: <65	0.94189	(0.581,1.303)	0.93362	(0.572,1.295)	1.05226	(0.634,1.471)
p-value for 3-way interaction	0.32324		0.32632		0.31845	
Mirtazapine: >=65	1.34015	(0.582,2.098)	1.33924	(0.581,2.097)	1.2907	(0.437,2.144)
Mirtazapine: <65	1.3354	(0.936,1.735)	1.33263	(0.934,1.732)	1.48806	(1.066,1.91)
p-value for 3-way interaction	0.99134		0.98795		0.6846	
Tricyclics: >=65	0.21292	(-0.991,1.417)	0.20551	(-0.998,1.409)	0.14395	(-0.712,1)
Tricyclics: <65	0.30687	(-0.232,0.846)	0.30795	(-0.231,0.846)	0.31779	(-0.105,0.741)
p-value for 3-way interaction	0.88896		0.87897		0.72127	
overall 3-way interaction p-value	0.76635		0.76912		0.79563	



**Changes in LDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	117.6	117.43	-0.16778	(-0.169,-0.153)	0.5643	-0.14%
Mirtazapine	116.35	117.01	0.66379	(0.663,0.679)	0.0704	0.57%
Prazosin	118.95	117.57	-1.38845	(-1.389,-1.373)	<.0001	-1.17%
Tricyclics	119.15	117.42	-1.72879	(-1.73,-1.714)	0.0019	-1.45%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	11435	11329
Mirtazapine	7745	7176
Prazosin	19152	17880
Tricyclics	3343	2994

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	107.23	105.21	-2.01929	(-2.02,-2.004)	<.0001	-1.88%	<.0001
Mirtazapine	104.72	103.12	-1.59409	(-1.595,-1.579)	<.0001	-1.52%	<.0001
Prazosin	106	103.06	-2.9463	(-2.947,-2.931)	<.0001	-2.78%	<.0001
Tricyclics	106.45	103.97	-2.47627	(-2.477,-2.461)	<.0001	-2.33%	0.2196

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	43995	44320
Mirtazapine	36114	35024
Prazosin	59371	57897
Tricyclics	14502	14108

Changes in LDL Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	1.21784	(0.491,1.944)	1.19072	(0.466,1.915)	1.18352	(0.46,1.907)
Antipsychotics: other era	0.92631	(0.56,1.293)	0.87145	(0.505,1.237)	0.83895	(0.473,1.205)
p-value for 3-way interaction	0.48253		0.44078		0.40503	
Mirtazapine: OEF/OIF	2.04282	(1.201,2.885)	2.03546	(1.196,2.875)	2.03189	(1.193,2.87)
Mirtazapine: other era	1.34847	(0.957,1.74)	1.34366	(0.953,1.734)	1.32666	(0.936,1.717)
p-value for 3-way interaction	0.14268		0.14313		0.13513	
Tricyclics: OEF/OIF	-0.34223	(-1.519,0.835)	-0.29133	(-1.465,0.883)	-0.28187	(-1.454,0.891)
Tricyclics: other era	0.46972	(-0.073,1.012)	0.4791	(-0.063,1.021)	0.49998	(-0.042,1.042)
p-value for 3-way interaction	0.2195		0.24282		0.23546	
overall 3-way interaction p-value	0.17736		0.18723		0.16897	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	1.18333	(0.46,1.907)	1.16588	(0.442,1.889)	1.00342	(0.155,1.851)
Antipsychotics: other era	0.83871	(0.473,1.205)	0.83287	(0.467,1.199)	0.98666	(0.567,1.406)
p-value for 3-way interaction	0.40495		0.42085		0.9723	
Mirtazapine: OEF/OIF	2.03154	(1.193,2.87)	2.02582	(1.187,2.864)	1.99835	(1.143,2.854)
Mirtazapine: other era	1.32608	(0.935,1.717)	1.32448	(0.934,1.715)	1.35271	(0.931,1.775)
p-value for 3-way interaction	0.135		0.1372		0.18469	
Tricyclics: OEF/OIF	-0.28241	(-1.455,0.89)	-0.27823	(-1.45,0.894)	-0.63043	(-1.499,0.238)
Tricyclics: other era	0.50031	(-0.041,1.042)	0.4986	(-0.043,1.04)	0.54314	(0.121,0.965)
p-value for 3-way interaction	0.23493		0.23836		0.0172	
overall 3-way interaction p-value	0.16851		0.17544		0.0033	

**Changes in Total Cholesterol by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	183.73	182.8	-0.92407	(-0.925,-0.909)	<.0001	-0.50%
Mirtazapine	180.79	180.55	-0.23929	(-0.24,-0.224)	0.1849	-0.13%
Prazosin	183.96	180.96	-3.00263	(-3.004,-2.988)	<.0001	-1.63%
Tricyclics	183.04	180.65	-2.39038	(-2.391,-2.375)	<.0001	-1.31%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	51203	51411
Mirtazapine	40359	38913
Prazosin	72567	70036
Tricyclics	15363	14746

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	196.04	196.25	0.21449	(0.214,0.23)	0.7032	0.11%	0.0512
Mirtazapine	196.66	197.11	0.45794	(0.457,0.473)	0.4826	0.23%	0.3029
Prazosin	195.44	194.44	-1.00116	(-1.002,-0.986)	0.0432	-0.51%	<.0001
Tricyclics	196.8	197.24	0.43593	(0.435,0.451)	0.5532	0.22%	0.0003

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	3992	4067
Mirtazapine	3313	3096
Prazosin	5453	5156
Tricyclics	2484	2335

Changes in Total Cholesterol by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	2.07327	(1.674,2.472)	2.00201	(1.604,2.4)	1.98173	(1.584,2.38)
Antipsychotics: female	1.20489	(-0.274,2.684)	1.11064	(-0.365,2.587)	1.06002	(-0.415,2.535)
p-value for 3-way interaction	0.26653		0.25315		0.23694	
Mirtazapine: male	2.7505	(2.319,3.182)	2.73764	(2.306,3.169)	2.71759	(2.286,3.149)
Mirtazapine: female	1.43209	(-0.158,3.022)	1.40244	(-0.184,2.989)	1.39794	(-0.187,2.983)
p-value for 3-way interaction	0.11681		0.11148		0.11536	
Tricyclics: male	0.60713	(-0.009,1.224)	0.63875	(0.023,1.254)	0.65326	(0.038,1.269)
Tricyclics: female	1.42614	(-0.312,3.164)	1.42388	(-0.311,3.159)	1.43931	(-0.294,3.172)
p-value for 3-way interaction	0.38407		0.40315		0.40218	
overall 3-way interaction p-value	0.13447		0.13318		0.13116	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.98154	(1.583,2.38)	1.97236	(1.574,2.37)	2.11105	(1.65,2.572)
Antipsychotics: female	1.06015	(-0.415,2.535)	1.0615	(-0.413,2.536)	1.33856	(-0.296,2.973)
p-value for 3-way interaction	0.2371		0.24244		0.37271	
Mirtazapine: male	2.71744	(2.286,3.149)	2.71417	(2.283,3.145)	2.88107	(2.418,3.345)
Mirtazapine: female	1.39779	(-0.187,2.983)	1.40145	(-0.183,2.986)	1.59428	(-0.059,3.247)
p-value for 3-way interaction	0.11536		0.11724		0.14185	
Tricyclics: male	0.65323	(0.038,1.269)	0.65068	(0.035,1.266)	0.83913	(0.375,1.303)
Tricyclics: female	1.43953	(-0.294,3.173)	1.44779	(-0.285,3.181)	1.77914	(0.125,3.433)
p-value for 3-way interaction	0.40203		0.39553		0.28346	
overall 3-way interaction p-value	0.13115		0.13204		0.05811	

**Changes in Total Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	170.56	169.29	-1.27132	(-1.272,-1.256)	0.0006	-0.75%
Mirtazapine	168.66	168.68	0.0241	(0.023,0.039)	0.9481	0.01%
Prazosin	171.48	168.68	-2.79362	(-2.795,-2.779)	<.0001	-1.63%
Tricyclics	170.22	168.44	-1.78108	(-1.782,-1.766)	0.0082	-1.05%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	8937	8761
Mirtazapine	9366	9045
Prazosin	15387	15116
Tricyclics	2679	2622

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	187.29	186.5	-0.78378	(-0.785,-0.769)	<.0001	-0.42%	0.2259
Mirtazapine	185.59	185.34	-0.25245	(-0.253,-0.237)	0.2004	-0.14%	0.51
Prazosin	187.95	185.09	-2.86546	(-2.866,-2.85)	<.0001	-1.53%	0.8171
Tricyclics	187.52	185.47	-2.0495	(-2.05,-2.034)	<.0001	-1.09%	0.7144

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	46258	46717
Mirtazapine	34306	32964
Prazosin	62633	60076
Tricyclics	15168	14459

Changes in Total Cholesterol by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	1.52019	(0.612,2.428)	1.47551	(0.569,2.382)	1.42773	(0.522,2.334)
Antipsychotics: <65	2.07619	(1.65,2.502)	2.03441	(1.609,2.46)	2.018	(1.593,2.443)
p-value for 3-way interaction	0.27716		0.27386		0.2477	
Mirtazapine: >=65	2.8136	(1.917,3.711)	2.78497	(1.889,3.68)	2.74369	(1.848,3.639)
Mirtazapine: <65	2.59703	(2.126,3.068)	2.60386	(2.134,3.074)	2.59367	(2.124,3.063)
p-value for 3-way interaction	0.67523		0.72562		0.7712	
Tricyclics: >=65	1.01516	(-0.409,2.439)	1.01728	(-0.404,2.439)	1.04287	(-0.379,2.464)
Tricyclics: <65	0.81653	(0.183,1.45)	0.84011	(0.207,1.473)	0.85504	(0.223,1.487)
p-value for 3-way interaction	0.80275		0.82342		0.81293	
overall 3-way interaction p-value	0.54733		0.57072		0.54954	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	1.42751	(0.521,2.334)	1.42108	(0.515,2.327)	1.55705	(0.547,2.567)
Antipsychotics: <65	2.0177	(1.592,2.443)	2.01032	(1.585,2.435)	2.13501	(1.641,2.629)
p-value for 3-way interaction	0.24777		0.24849		0.31352	
Mirtazapine: >=65	2.74355	(1.848,3.639)	2.74124	(1.846,3.636)	2.71517	(1.705,3.725)
Mirtazapine: <65	2.59339	(2.124,3.063)	2.59096	(2.121,3.061)	2.79221	(2.295,3.29)
p-value for 3-way interaction	0.77099		0.77079		0.89334	
Tricyclics: >=65	1.04265	(-0.379,2.464)	1.03723	(-0.384,2.459)	1.12285	(0.11,2.136)
Tricyclics: <65	0.85503	(0.223,1.487)	0.85487	(0.223,1.487)	0.87421	(0.376,1.372)
p-value for 3-way interaction	0.81314		0.81826		0.66598	
overall 3-way interaction p-value	0.5496		0.55175		0.53771	

## Changes in Total Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

### Iraq and Afghanistan Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	192.26	193.67	1.41219	(1.411,1.427)	<.0001	0.74%
Mirtazapine	191.46	193.89	2.42703	(2.426,2.442)	<.0001	1.27%
Prazosin	194.43	193.37	-1.0626	(-1.064,-1.048)	<.0001	-0.55%
Tricyclics	195.07	194.31	-0.75571	(-0.757,-0.741)	0.2483	-0.39%

### Number of Windows - Iraq and Afghanistan Era

Medications	n(pre)	n(post)
Antipsychotics	11502	11377
Mirtazapine	7770	7167
Prazosin	19181	17876
Tricyclics	3348	2996

### Other Era

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	182.48	181.12	-1.36143	(-1.362,-1.346)	<.0001	-0.75%	<.0001
Mirtazapine	179.78	179.12	-0.66162	(-0.663,-0.647)	0.0005	-0.37%	<.0001
Prazosin	181.35	178.01	-3.34084	(-3.342,-3.326)	<.0001	-1.84%	<.0001
Tricyclics	182.49	180.27	-2.21677	(-2.218,-2.202)	<.0001	-1.22%	0.0416

### Number of Windows - Other Era

Medications	n(pre)	n(post)
Antipsychotics	43693	44101
Mirtazapine	35902	34842
Prazosin	58839	57316
Tricyclics	14499	14085

Changes in Total Cholesterol by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	2.46845	(1.618,3.319)	2.4325	(1.583,3.282)	2.42344	(1.575,3.272)
Antipsychotics: other era	1.97788	(1.546,2.41)	1.91141	(1.48,2.343)	1.88694	(1.456,2.318)
p-value for 3-way interaction	0.31361		0.2836		0.26915	
Mirtazapine: OEF/OIF	3.46785	(2.481,4.455)	3.44252	(2.458,4.427)	3.43616	(2.453,4.42)
Mirtazapine: other era	2.67181	(2.211,3.133)	2.66726	(2.207,3.128)	2.64735	(2.187,3.108)
p-value for 3-way interaction	0.15208		0.16225		0.15459	
Tricyclics: OEF/OIF	0.30737	(-1.074,1.689)	0.34837	(-1.031,1.727)	0.3447	(-1.033,1.722)
Tricyclics: other era	1.12486	(0.487,1.762)	1.14079	(0.504,1.778)	1.16112	(0.525,1.798)
p-value for 3-way interaction	0.29239		0.30652		0.2916	
overall 3-way interaction p-value	0.19636		0.20266		0.18303	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	2.42319	(1.575,3.271)	2.40604	(1.558,3.254)	2.23423	(1.238,3.23)
Antipsychotics: other era	1.88684	(1.455,2.318)	1.88159	(1.45,2.313)	2.04247	(1.547,2.538)
p-value for 3-way interaction	0.26928		0.27999		0.73541	
Mirtazapine: OEF/OIF	3.43618	(2.453,4.42)	3.42958	(2.446,4.413)	3.41033	(2.405,4.415)
Mirtazapine: other era	2.64722	(2.187,3.108)	2.64554	(2.185,3.106)	2.68566	(2.188,3.184)
p-value for 3-way interaction	0.15451		0.15705		0.20545	
Tricyclics: OEF/OIF	0.34455	(-1.033,1.722)	0.34869	(-1.028,1.726)	0.05043	(-0.971,1.072)
Tricyclics: other era	1.16116	(0.525,1.798)	1.15804	(0.522,1.795)	1.19542	(0.698,1.693)
p-value for 3-way interaction	0.29149		0.29575		0.04825	
overall 3-way interaction p-value	0.18296		0.19115		0.01357	



**Changes in Systolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	129.8	129.14	-0.65483	(-0.656,-0.64)	<.0001	-0.50%
Mirtazapine	129.64	129.97	0.32607	(0.325,0.341)	<.0001	0.25%
Prazosin	130.84	130.11	-0.72968	(-0.731,-0.715)	<.0001	-0.56%
Tricyclics	129.87	129.78	-0.08377	(-0.085,-0.069)	0.25	-0.07%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	63290	62786
Mirtazapine	48811	48317
Prazosin	89290	88093
Tricyclics	18371	18208

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	123.58	123.48	-0.103	(-0.104,-0.088)	0.4751	-0.08%	0.0002
Mirtazapine	123.84	124.51	0.67638	(0.675,0.691)	<.0001	0.55%	0.0381
Prazosin	124.47	123.92	-0.55153	(-0.553,-0.537)	<.0001	-0.44%	0.1614
Tricyclics	123.61	124.1	0.48505	(0.484,0.5)	0.0048	0.39%	0.0023

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	5386	5388
Mirtazapine	4356	4312
Prazosin	7506	7432
Tricyclics	3288	3258

Changes in Systolic Blood Pressure by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.07512	(-0.032,0.183)	0.08022	(-0.027,0.188)	0.08015	(-0.027,0.188)
Antipsychotics: female	0.44893	(0.08,0.818)	0.45143	(0.083,0.82)	0.45196	(0.083,0.821)
p-value for 3-way interaction	0.05648		0.05814		0.05774	
Mirtazapine: male	1.05605	(0.939,1.173)	1.05759	(0.941,1.174)	1.05753	(0.941,1.174)
Mirtazapine: female	1.22849	(0.834,1.623)	1.23326	(0.839,1.627)	1.23456	(0.84,1.629)
p-value for 3-way interaction	0.41099		0.40217		0.39854	
Tricyclics: male	0.64655	(0.479,0.814)	0.64966	(0.482,0.817)	0.64972	(0.482,0.817)
Tricyclics: female	1.03656	(0.605,1.469)	1.03353	(0.602,1.465)	1.03344	(0.602,1.465)
p-value for 3-way interaction	0.09891		0.10424		0.10438	
overall 3-way interaction p-value	0.1896		0.19802		0.19752	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.08023	(-0.027,0.188)	0.0797	(-0.028,0.187)	0.16617	(0.043,0.29)
Antipsychotics: female	0.45223	(0.084,0.821)	0.45143	(0.083,0.82)	0.45764	(0.053,0.862)
p-value for 3-way interaction	0.0576		0.05777		0.17669	
Mirtazapine: male	1.0576	(0.941,1.174)	1.05738	(0.941,1.174)	1.09931	(0.976,1.223)
Mirtazapine: female	1.23456	(0.84,1.629)	1.235	(0.841,1.629)	1.22567	(0.821,1.63)
p-value for 3-way interaction	0.39872		0.3969		0.55838	
Tricyclics: male	0.64975	(0.483,0.817)	0.64969	(0.482,0.817)	0.68837	(0.565,0.812)
Tricyclics: female	1.03355	(0.602,1.465)	1.03386	(0.602,1.466)	1.09322	(0.689,1.498)
p-value for 3-way interaction	0.1043		0.10395		0.06072	
overall 3-way interaction p-value	0.19717		0.19726		0.2501	

## Changes in Systolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65

### Age >=65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	130.73	129.94	-0.78218	(-0.783,-0.767)	<.0001	-0.60%
Mirtazapine	130.94	131.33	0.38804	(0.387,0.403)	0.0001	0.30%
Prazosin	132.47	131.76	-0.71223	(-0.713,-0.697)	<.0001	-0.54%
Tricyclics	131.34	131.19	-0.14829	(-0.149,-0.133)	0.4057	-0.11%

### Number of Windows - Age >=65

Medications	n(pre)	n(post)
Antipsychotics	10529	10349
Mirtazapine	10883	10806
Prazosin	17667	17539
Tricyclics	3062	3028

### Age <65

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	129.05	128.47	-0.58127	(-0.582,-0.566)	<.0001	-0.45%	0.0744
Mirtazapine	128.71	129.05	0.34544	(0.344,0.36)	<.0001	0.27%	0.7099
Prazosin	129.86	129.15	-0.71876	(-0.72,-0.704)	<.0001	-0.55%	0.9408
Tricyclics	128.54	128.56	0.02709	(0.026,0.042)	0.7084	0.02%	0.3622

### Number of Windows - Age <65

Medications	n(pre)	n(post)
Antipsychotics	58147	57825
Mirtazapine	42284	41823
Prazosin	79129	77986
Tricyclics	18597	18438

Changes in Systolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.06993	(-0.325,0.185)	-0.06385	(-0.318,0.191)	-0.06432	(-0.319,0.19)
Antipsychotics: <65	0.13788	(0.025,0.251)	0.14163	(0.029,0.255)	0.1416	(0.028,0.255)
p-value for 3-way interaction	0.14375		0.14813		0.14733	
Mirtazapine: >=65	1.10026	(0.849,1.352)	1.10136	(0.85,1.353)	1.10151	(0.85,1.353)
Mirtazapine: <65	1.06462	(0.94,1.189)	1.06627	(0.941,1.191)	1.06623	(0.941,1.191)
p-value for 3-way interaction	0.80344		0.80637		0.80538	
Tricyclics: >=65	0.56479	(0.161,0.968)	0.5649	(0.161,0.968)	0.56492	(0.161,0.969)
Tricyclics: <65	0.74645	(0.578,0.915)	0.74979	(0.581,0.918)	0.74953	(0.581,0.918)
p-value for 3-way interaction	0.41562		0.4072		0.40799	
overall 3-way interaction p-value	0.35057		0.35646		0.35498	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.06401	(-0.319,0.191)	-0.06395	(-0.318,0.191)	0.14611	(-0.136,0.428)
Antipsychotics: <65	0.14164	(0.029,0.255)	0.14102	(0.028,0.254)	0.2013	(0.071,0.331)
p-value for 3-way interaction	0.14783		0.14916		0.72757	
Mirtazapine: >=65	1.1016	(0.85,1.353)	1.10139	(0.85,1.353)	1.25113	(0.97,1.532)
Mirtazapine: <65	1.06629	(0.941,1.191)	1.06623	(0.941,1.191)	1.081	(0.951,1.211)
p-value for 3-way interaction	0.80523		0.80602		0.28191	
Tricyclics: >=65	0.56476	(0.161,0.968)	0.5646	(0.161,0.968)	0.68869	(0.405,0.972)
Tricyclics: <65	0.7496	(0.581,0.918)	0.74981	(0.582,0.918)	0.7324	(0.602,0.863)
p-value for 3-way interaction	0.40739		0.40641		0.78356	
overall 3-way interaction p-value	0.35558		0.3578		0.45694	

**Changes in Systolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	127.1	126.83	-0.27131	(-0.272,-0.256)	0.0013	-0.21%
Mirtazapine	126.81	127.04	0.22956	(0.229,0.245)	0.028	0.18%
Prazosin	127.75	127.36	-0.38592	(-0.387,-0.371)	<.0001	-0.30%
Tricyclics	126.4	126.71	0.30295	(0.302,0.318)	0.0394	0.24%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	15982	15756
Mirtazapine	10676	10427
Prazosin	26940	26275
Tricyclics	4554	4477

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	129.98	129.26	-0.71673	(-0.718,-0.702)	<.0001	-0.55%	<.0001
Mirtazapine	129.77	130.15	0.38161	(0.381,0.397)	<.0001	0.29%	0.192
Prazosin	131.36	130.51	-0.84636	(-0.847,-0.831)	<.0001	-0.64%	<.0001
Tricyclics	129.62	129.54	-0.0794	(-0.08,-0.064)	0.2922	-0.06%	0.0207

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	52694	52418
Mirtazapine	42491	42202
Prazosin	69856	69250
Tricyclics	17105	16989

Changes in Systolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.11508	(-0.093,0.323)	0.11784	(-0.09,0.326)	0.11801	(-0.09,0.326)
Antipsychotics: other era	0.12981	(0.011,0.249)	0.13422	(0.015,0.253)	0.13402	(0.015,0.253)
p-value for 3-way interaction	0.90416		0.89349		0.89585	
Mirtazapine: OEF/OIF	0.61575	(0.377,0.855)	0.61848	(0.379,0.857)	0.61845	(0.379,0.857)
Mirtazapine: other era	1.2282	(1.101,1.355)	1.22939	(1.102,1.356)	1.22943	(1.102,1.356)
p-value for 3-way interaction	0.00001		0.00001		0.00001	
Tricyclics: OEF/OIF	0.6895	(0.357,1.022)	0.69268	(0.36,1.025)	0.69179	(0.359,1.024)
Tricyclics: other era	0.76728	(0.591,0.943)	0.76857	(0.593,0.944)	0.7686	(0.593,0.944)
p-value for 3-way interaction	0.68535		0.69252		0.68906	
overall 3-way interaction p-value	<0.0001		<0.0001		<0.0001	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.11786	(-0.09,0.326)	0.11681	(-0.091,0.325)	0.12528	(-0.116,0.367)
Antipsychotics: other era	0.13419	(0.015,0.253)	0.13388	(0.015,0.253)	0.22864	(0.093,0.364)
p-value for 3-way interaction	0.89386		0.88902		0.46411	
Mirtazapine: OEF/OIF	0.61842	(0.379,0.857)	0.61804	(0.379,0.857)	0.62395	(0.383,0.865)
Mirtazapine: other era	1.22952	(1.103,1.357)	1.22959	(1.103,1.357)	1.27154	(1.136,1.407)
p-value for 3-way interaction	0.00001		0.00001		0	
Tricyclics: OEF/OIF	0.69126	(0.359,1.024)	0.69075	(0.358,1.023)	0.61041	(0.368,0.853)
Tricyclics: other era	0.76878	(0.593,0.945)	0.76919	(0.593,0.945)	0.77758	(0.642,0.913)
p-value for 3-way interaction	0.68632		0.68279		0.23777	
overall 3-way interaction p-value	<0.0001		<0.0001		<0.0001	

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

**Male**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	78.448	78.1908	-0.25721	(-0.258,-0.242)	<.0001	-0.33%
Mirtazapine	78.0677	78.1849	0.11719	(0.116,0.132)	0.0003	0.15%
Prazosin	79.1769	78.5709	-0.60603	(-0.607,-0.591)	<.0001	-0.77%
Tricyclics	78.2498	78.5996	0.34978	(0.349,0.365)	<.0001	0.45%

**Number of Windows - Male**

Medications	n(pre)	n(post)
Antipsychotics	63290	62786
Mirtazapine	48811	48317
Prazosin	89290	88093
Tricyclics	18371	18208

**Female**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (Male vs. Female)
Antipsychotics	76.5744	76.7063	0.13183	(0.131,0.147)	0.1757	0.17%	0.0001
Mirtazapine	76.4127	76.7887	0.376	(0.375,0.391)	0.0005	0.49%	0.021
Prazosin	77.0149	76.7473	-0.26762	(-0.269,-0.253)	0.0013	-0.35%	<.0001
Tricyclics	76.2191	76.8848	0.66569	(0.665,0.681)	<.0001	0.87%	0.0126

**Number of Windows - Female**

Medications	n(pre)	n(post)
Antipsychotics	5386	5388
Mirtazapine	4356	4312
Prazosin	7506	7432
Tricyclics	3288	3258

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.34901	(0.276,0.422)	0.34472	(0.272,0.417)	0.34448	(0.272,0.417)
Antipsychotics: female	0.39972	(0.151,0.648)	0.39649	(0.148,0.645)	0.39754	(0.149,0.646)
p-value for 3-way interaction	0.70119		0.69535		0.68829	
Mirtazapine: male	0.72341	(0.645,0.802)	0.72195	(0.643,0.801)	0.72162	(0.643,0.8)
Mirtazapine: female	0.64445	(0.379,0.91)	0.64199	(0.376,0.908)	0.64463	(0.379,0.911)
p-value for 3-way interaction	0.57666		0.572		0.58649	
Tricyclics: male	0.95607	(0.843,1.069)	0.95122	(0.838,1.064)	0.95146	(0.839,1.064)
Tricyclics: female	0.93332	(0.642,1.225)	0.92703	(0.636,1.218)	0.92715	(0.636,1.219)
p-value for 3-way interaction	0.88643		0.8794		0.87886	
overall 3-way interaction p-value	0.85951		0.8534		0.85797	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.34457	(0.272,0.417)	0.3444	(0.272,0.417)	0.36889	(0.285,0.452)
Antipsychotics: female	0.39782	(0.149,0.647)	0.39767	(0.149,0.647)	0.43113	(0.158,0.704)
p-value for 3-way interaction	0.68724		0.68715		0.66926	
Mirtazapine: male	0.72169	(0.643,0.8)	0.7216	(0.643,0.8)	0.77062	(0.687,0.854)
Mirtazapine: female	0.64462	(0.379,0.911)	0.64479	(0.379,0.911)	0.72013	(0.447,0.994)
p-value for 3-way interaction	0.58612		0.58748		0.72918	
Tricyclics: male	0.95148	(0.839,1.064)	0.95141	(0.839,1.064)	1.02611	(0.943,1.11)
Tricyclics: female	0.92725	(0.636,1.219)	0.92736	(0.636,1.219)	1.00638	(0.733,1.28)
p-value for 3-way interaction	0.87926		0.88016		0.89235	
overall 3-way interaction p-value	0.85729		0.85808		0.88641	



**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65**

**Age >=65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	75.0543	74.509	-0.54525	(-0.546,-0.53)	<.0001	-0.73%
Mirtazapine	74.7165	74.6902	-0.02632	(-0.027,-0.011)	0.6984	-0.04%
Prazosin	76.4034	75.5901	-0.8133	(-0.814,-0.798)	<.0001	-1.06%
Tricyclics	75.1507	75.3578	0.20711	(0.206,0.222)	0.0869	0.28%

**Number of Windows - Age >=65**

Medications	n(pre)	n(post)
Antipsychotics	10529	10349
Mirtazapine	10883	10806
Prazosin	17667	17539
Tricyclics	3062	3028

**Age <65**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (>= 65 vs. <65)
Antipsychotics	78.8852	78.7143	-0.17093	(-0.172,-0.156)	<.0001	-0.22%	<.0001
Mirtazapine	78.7529	78.9349	0.18198	(0.181,0.197)	<.0001	0.23%	0.0063
Prazosin	79.5869	79.0614	-0.52544	(-0.526,-0.51)	<.0001	-0.66%	<.0001
Tricyclics	78.3997	78.8285	0.42876	(0.428,0.444)	<.0001	0.55%	0.0896

**Number of Windows - Age <65**

Medications	n(pre)	n(post)
Antipsychotics	58147	57825
Mirtazapine	42284	41823
Prazosin	79129	77986
Tricyclics	18597	18438

Changes in Diastolic Blood Pressure by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.26805	(0.096,0.44)	0.26442	(0.093,0.436)	0.26296	(0.091,0.435)
Antipsychotics: <65	0.35458	(0.278,0.431)	0.35341	(0.277,0.43)	0.3535	(0.277,0.43)
p-value for 3-way interaction	0.3676		0.35369		0.34555	
Mirtazapine: >=65	0.78702	(0.617,0.957)	0.78578	(0.616,0.955)	0.78619	(0.616,0.956)
Mirtazapine: <65	0.70765	(0.623,0.792)	0.70767	(0.623,0.792)	0.70747	(0.623,0.792)
p-value for 3-way interaction	0.41211		0.41914		0.41571	
Tricyclics: >=65	1.02067	(0.748,1.293)	1.01942	(0.747,1.292)	1.0203	(0.748,1.293)
Tricyclics: <65	0.95433	(0.841,1.068)	0.95152	(0.838,1.065)	0.95143	(0.838,1.065)
p-value for 3-way interaction	0.65995		0.65214		0.64764	
overall 3-way interaction p-value	0.45535		0.44493		0.433	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.26326	(0.091,0.435)	0.26327	(0.091,0.435)	0.29071	(0.1,0.481)
Antipsychotics: <65	0.35355	(0.277,0.43)	0.3534	(0.277,0.43)	0.38841	(0.3,0.476)
p-value for 3-way interaction	0.3469		0.34777		0.36211	
Mirtazapine: >=65	0.78627	(0.616,0.956)	0.78623	(0.616,0.956)	0.7931	(0.603,0.983)
Mirtazapine: <65	0.70752	(0.623,0.792)	0.70755	(0.623,0.792)	0.76019	(0.672,0.848)
p-value for 3-way interaction	0.41559		0.41602		0.75838	
Tricyclics: >=65	1.02014	(0.748,1.293)	1.02012	(0.748,1.293)	1.09578	(0.904,1.288)
Tricyclics: <65	0.95148	(0.838,1.065)	0.95164	(0.838,1.065)	1.006	(0.918,1.094)
p-value for 3-way interaction	0.64868		0.64951		0.40439	
overall 3-way interaction p-value	0.43454		0.43595		0.36227	

**Changes in Diastolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

**Iraq and Afghanistan Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)
Antipsychotics	79.0584	79.3451	0.28672	(0.286,0.302)	<.0001	0.36%
Mirtazapine	79.1404	79.5968	0.45641	(0.455,0.471)	<.0001	0.58%
Prazosin	79.7855	79.6577	-0.12776	(-0.129,-0.113)	0.0039	-0.16%
Tricyclics	78.9338	79.6752	0.74139	(0.74,0.756)	<.0001	0.94%

**Number of Windows - Iraq and Afghanistan Era**

Medications	n(pre)	n(post)
Antipsychotics	15982	15756
Mirtazapine	10676	10427
Prazosin	26940	26275
Tricyclics	4554	4477

**Other Era**

Medications	Pre-Index Year mean	Post-Index Year mean	Mean change	95% CI	P-value (pre vs post)	Percent Change (post minus pre)	P-value (OEF/OIF vs. Other Era)
Antipsychotics	78.0672	77.6882	-0.37907	(-0.38,-0.364)	<.0001	-0.49%	<.0001
Mirtazapine	77.6152	77.6776	0.06237	(0.061,0.077)	0.0689	0.08%	<.0001
Prazosin	78.6984	77.9507	-0.74775	(-0.749,-0.733)	<.0001	-0.95%	<.0001
Tricyclics	77.6744	77.9828	0.30842	(0.307,0.323)	<.0001	0.40%	0.0001

**Number of Windows - Other Era**

Medications	n(pre)	n(post)
Antipsychotics	52694	52418
Mirtazapine	42491	42202
Prazosin	69856	69250
Tricyclics	17105	16989

Changes in Diastolic Blood Pressure by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.41496	(0.275,0.555)	0.41292	(0.273,0.553)	0.41475	(0.274,0.555)
Antipsychotics: other era	0.36877	(0.288,0.449)	0.36494	(0.285,0.445)	0.36407	(0.284,0.444)
p-value for 3-way interaction	0.57555		0.56099		0.53928	
Mirtazapine: OEF/OIF	0.58444	(0.423,0.746)	0.5834	(0.422,0.745)	0.5836	(0.422,0.745)
Mirtazapine: other era	0.81034	(0.725,0.896)	0.80938	(0.724,0.895)	0.80912	(0.723,0.895)
p-value for 3-way interaction	0.01528		0.01529		0.01554	
Tricyclics: OEF/OIF	0.86988	(0.646,1.094)	0.86576	(0.641,1.09)	0.86607	(0.642,1.091)
Tricyclics: other era	1.05624	(0.938,1.175)	1.05279	(0.934,1.171)	1.0527	(0.934,1.171)
p-value for 3-way interaction	0.14983		0.14856		0.14964	
overall 3-way interaction p-value	0.02219		0.02129		0.02054	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.41461	(0.274,0.555)	0.41432	(0.274,0.555)	0.41762	(0.255,0.581)
Antipsychotics: other era	0.36424	(0.284,0.445)	0.36419	(0.284,0.445)	0.381	(0.29,0.472)
p-value for 3-way interaction	0.54188		0.54378		0.70097	
Mirtazapine: OEF/OIF	0.58355	(0.422,0.745)	0.58348	(0.422,0.745)	0.60313	(0.441,0.766)
Mirtazapine: other era	0.80921	(0.724,0.895)	0.80927	(0.724,0.895)	0.83355	(0.742,0.925)
p-value for 3-way interaction	0.01548		0.01542		0.01555	
Tricyclics: OEF/OIF	0.86551	(0.641,1.09)	0.86525	(0.641,1.09)	0.83841	(0.675,1.002)
Tricyclics: other era	1.05288	(0.934,1.172)	1.0531	(0.934,1.172)	1.09936	(1.008,1.191)
p-value for 3-way interaction	0.14803		0.14703		0.00636	
overall 3-way interaction p-value	0.02046		0.02041		0.00163	

Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.81403	(0.6,1.03)	0.6605	(0.47,0.85)	0.59345	(0.42,0.76)
Antipsychotics: female	0.43604	(-0.12,1)	0.43901	(-0.21,1.08)	0.37721	(-0.17,0.93)
p-value for 2-way interaction	0.76663		0.70155		0.70269	
Mirtazapine: male	0.63036	(0.39,0.87)	0.28637	(0.09,0.48)	0.25531	(0.08,0.43)
Mirtazapine: female	0.32229	(-0.27,0.91)	0.1657	(-0.5,0.83)	0.15004	(-0.42,0.72)
p-value for 2-way interaction	0.78985		0.81331		0.83667	
Tricyclics: male	1.20954	(0.85,1.56)	1.07834	(0.77,1.39)	0.94519	(0.67,1.22)
Tricyclics: female	0.16928	(-0.48,0.82)	0.04775	(-0.69,0.78)	0.03138	(-0.59,0.65)
p-value for 2-way interaction	0.12131		0.04877		0.04949	
overall 2-way interaction p-value	0.47033		0.24508		0.2452	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.58273	(0.42,0.75)	0.6555	(0.47,0.84)	0.56957	(0.31,0.83)
Antipsychotics: female	0.37374	(-0.17,0.91)	0.41528	(-0.19,1.02)	0.32844	(-0.31,0.96)
p-value for 2-way interaction	0.71469		0.70642		0.8955	
Mirtazapine: male	0.2565	(0.08,0.43)	0.2832	(0.09,0.48)	0.36823	(0.11,0.62)
Mirtazapine: female	0.15343	(-0.4,0.71)	0.16553	(-0.46,0.79)	0.06212	(-0.55,0.68)
p-value for 2-way interaction	0.84189		0.83718		0.59609	
Tricyclics: male	0.92111	(0.65,1.19)	1.02315	(0.72,1.33)	0.81175	(0.55,1.08)
Tricyclics: female	0.02546	(-0.58,0.64)	0.01322	(-0.67,0.7)	-0.15314	(-0.76,0.45)
p-value for 2-way interaction	0.04959		0.04801		0.0512	
overall 2-way interaction p-value	0.24415		0.23908		0.18378	

Number of Windows

Medications	male	female
Antipsychotics	50616	4940
Mirtazapine	37439	3940
Prazosin	69409	6905
Tricyclics	12696	2893

**Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.82109	(0.17,1.48)	0.07397	(-0.17,0.32)	0.05369	(-0.17,0.28)
Antipsychotics: <65	0.80606	(0.59,1.02)	0.68373	(0.47,0.89)	0.63411	(0.44,0.83)
p-value for 2-way interaction	0.49951		0.04437		0.03107	
Mirtazapine: >=65	0.63189	(-0.01,1.27)	0.06556	(-0.18,0.31)	0.04838	(-0.17,0.27)
Mirtazapine: <65	0.55305	(0.32,0.79)	0.28978	(0.07,0.51)	0.26405	(0.06,0.47)
p-value for 2-way interaction	0.76091		0.51725		0.46334	
Tricyclics: >=65	1.36453	(0.26,2.47)	0.49762	(0.06,0.94)	0.43026	(0.03,0.83)
Tricyclics: <65	0.89727	(0.57,1.22)	0.84984	(0.53,1.17)	0.73143	(0.44,1.02)
p-value for 2-way interaction	0.82983		0.91851		0.90531	
overall 2-way interaction p-value	0.88836		0.21211		0.15886	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.04925	(-0.17,0.27)	0.05585	(-0.19,0.3)	0.69314	(-0.05,1.44)
Antipsychotics: <65	0.62633	(0.44,0.82)	0.68944	(0.48,0.9)	0.52426	(0.27,0.78)
p-value for 2-way interaction	0.02821		0.02926		0.978	
Mirtazapine: >=65	0.04934	(-0.17,0.27)	0.0537	(-0.19,0.3)	0.73441	(-0.01,1.47)
Mirtazapine: <65	0.26609	(0.06,0.47)	0.28919	(0.07,0.51)	0.27087	(0.02,0.52)
p-value for 2-way interaction	0.4553		0.46101		0.37432	
Tricyclics: >=65	0.41781	(0.03,0.81)	0.45755	(0.02,0.89)	0.97055	(0.2,1.74)
Tricyclics: <65	0.71381	(0.43,1)	0.77317	(0.46,1.09)	0.67616	(0.42,0.94)
p-value for 2-way interaction	0.91883		0.91244		0.84249	
overall 2-way interaction p-value	0.14854		0.15216		0.77369	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	6465	49091
Mirtazapine	6710	34669
Prazosin	10503	65811
Tricyclics	1572	14017

**Differences in Incident Diagnoses of Diabetes (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.09083	(-0.33,0.15)	-0.03257	(-0.37,0.3)	-0.01384	(-0.32,0.29)
Antipsychotics: other era	0.8981	(0.62,1.18)	0.79714	(0.57,1.02)	0.73744	(0.53,0.94)
p-value for 2-way interaction	0.00275		0.00613		0.00742	
Mirtazapine: OEF/OIF	-0.10586	(-0.39,0.17)	-0.10702	(-0.49,0.27)	-0.09239	(-0.44,0.25)
Mirtazapine: other era	0.5022	(0.21,0.8)	0.35114	(0.12,0.58)	0.32505	(0.11,0.54)
p-value for 2-way interaction	0.06158		0.11866		0.12159	
Tricyclics: OEF/OIF	0.34221	(-0.07,0.75)	0.43452	(-0.11,0.98)	0.38143	(-0.11,0.87)
Tricyclics: other era	0.85985	(0.44,1.28)	0.9619	(0.61,1.31)	0.83964	(0.52,1.16)
p-value for 2-way interaction	0.98102		0.55372		0.5757	
overall 2-way interaction p-value	0.01304		0.04516		0.05218	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.01058	(-0.31,0.29)	-0.01393	(-0.35,0.32)	-0.09217	(-0.38,0.2)
Antipsychotics: other era	0.72389	(0.52,0.93)	0.79526	(0.57,1.02)	0.65416	(0.33,0.98)
p-value for 2-way interaction	0.00797		0.0077		0.04081	
Mirtazapine: OEF/OIF	-0.0861	(-0.43,0.25)	-0.09756	(-0.47,0.28)	-0.15252	(-0.44,0.13)
Mirtazapine: other era	0.32514	(0.12,0.53)	0.35398	(0.12,0.58)	0.41129	(0.09,0.73)
p-value for 2-way interaction	0.12402		0.12369		0.05543	
Tricyclics: OEF/OIF	0.36602	(-0.12,0.85)	0.39611	(-0.14,0.93)	0.22131	(-0.08,0.52)
Tricyclics: other era	0.81724	(0.51,1.13)	0.88454	(0.54,1.23)	0.78973	(0.46,1.12)
p-value for 2-way interaction	0.56638		0.56488		0.6324	
overall 2-way interaction p-value	0.05558		0.05416		0.09435	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16032	39524
Mirtazapine	10684	30695
Prazosin	26910	49404
Tricyclics	4399	11190

Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	3.82831	(3.26,4.4)	2.98841	(2.49,3.49)	2.69162	(2.26,3.13)
Antipsychotics: female	2.88447	(1.61,4.16)	2.69216	(1.37,4.01)	2.36252	(1.25,3.48)
p-value for 2-way interaction	0.53174		0.56628		0.54376	
Mirtazapine: male	1.86268	(1.24,2.48)	0.76534	(0.23,1.3)	0.80759	(0.34,1.27)
Mirtazapine: female	2.22545	(0.86,3.59)	1.74991	(0.36,3.14)	1.58473	(0.41,2.76)
p-value for 2-way interaction	0.16571		0.12264		0.12385	
Tricyclics: male	3.92482	(3,4.85)	2.84958	(2.05,3.65)	2.51224	(1.81,3.21)
Tricyclics: female	1.18466	(-0.29,2.66)	0.84733	(-0.68,2.37)	0.63484	(-0.64,1.91)
p-value for 2-way interaction	0.15304		0.15606		0.11923	
overall 2-way interaction p-value	0.09688		0.07736		0.05692	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	2.66783	(2.24,3.1)	3.02935	(2.53,3.53)	2.83181	(2.16,3.51)
Antipsychotics: female	2.33655	(1.23,3.44)	2.78121	(1.47,4.09)	2.21754	(0.77,3.66)
p-value for 2-way interaction	0.54426		0.49998		0.6189	
Mirtazapine: male	0.81019	(0.35,1.27)	0.91379	(0.38,1.45)	0.96379	(0.3,1.63)
Mirtazapine: female	1.56834	(0.4,2.73)	1.87458	(0.49,3.26)	1.22998	(-0.19,2.65)
p-value for 2-way interaction	0.12664		0.1164		0.42372	
Tricyclics: male	2.4714	(1.78,3.17)	3.00414	(2.2,3.81)	2.5346	(1.85,3.22)
Tricyclics: female	0.61208	(-0.65,1.87)	0.88683	(-0.62,2.39)	0.02965	(-1.36,1.41)
p-value for 2-way interaction	0.11821		0.13575		0.04657	
overall 2-way interaction p-value	0.05761		0.05977		0.02203	

Number of Windows

Medications	male	female
Antipsychotics	28627	3516
Mirtazapine	19470	2650
Prazosin	37262	5001
Tricyclics	6874	1945



**Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	3.52544	(1.63,5.42)	0.85158	(-0.01,1.71)	0.75977	(0.03,1.49)
Antipsychotics: <65	3.82831	(3.28,4.37)	2.95406	(2.44,3.46)	2.68961	(2.24,3.14)
p-value for 2-way interaction	0.42235		0.08686		0.07823	
Mirtazapine: >=65	1.40823	(-0.48,3.3)	0.04794	(-0.8,0.9)	0.14745	(-0.58,0.88)
Mirtazapine: <65	1.8908	(1.29,2.49)	0.86413	(0.31,1.42)	0.89265	(0.41,1.38)
p-value for 2-way interaction	0.46617		0.34293		0.385	
Tricyclics: >=65	3.99453	(0.82,7.16)	1.58971	(0.1,3.08)	1.35588	(0.09,2.62)
Tricyclics: <65	2.65159	(1.82,3.48)	1.81833	(1.05,2.59)	1.54203	(0.87,2.21)
p-value for 2-way interaction	0.6083		0.53052		0.50489	
overall 2-way interaction p-value	0.67445		0.22061		0.2014	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	0.75109	(0.02,1.48)	0.8568	(-0.01,1.72)	2.38533	(0.21,4.56)
Antipsychotics: <65	2.67089	(2.23,3.12)	3.02736	(2.52,3.54)	2.82304	(2.18,3.47)
p-value for 2-way interaction	0.07643		0.07463		0.5019	
Mirtazapine: >=65	0.14703	(-0.58,0.87)	0.17408	(-0.68,1.03)	1.13254	(-1.02,3.29)
Mirtazapine: <65	0.89435	(0.41,1.38)	1.021	(0.46,1.58)	1.00399	(0.37,1.64)
p-value for 2-way interaction	0.37962		0.38768		0.98746	
Tricyclics: >=65	1.33265	(0.08,2.59)	1.62803	(0.13,3.12)	2.50674	(0.29,4.72)
Tricyclics: <65	1.51539	(0.85,2.18)	1.94615	(1.17,2.72)	2.22136	(1.57,2.87)
p-value for 2-way interaction	0.5102		0.56542		0.97854	
overall 2-way interaction p-value	0.19903		0.21428		0.87515	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	2644	29499
Mirtazapine	2497	19623
Prazosin	3836	38427
Tricyclics	626	8193

**Differences in Incident Diagnoses of Dyslipidemia (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	1.54192	(0.82,2.27)	1.88497	(1.11,2.66)	1.75061	(1.08,2.42)
Antipsychotics: other era	4.12217	(3.4,4.85)	3.34371	(2.76,3.93)	3.00011	(2.49,3.51)
p-value for 2-way interaction	0.01226		0.03821		0.0543	
Mirtazapine: OEF/OIF	0.17224	(-0.64,0.99)	0.24925	(-0.62,1.12)	0.31455	(-0.43,1.06)
Mirtazapine: other era	1.74943	(0.97,2.53)	1.0393	(0.42,1.66)	1.07004	(0.53,1.61)
p-value for 2-way interaction	0.05341		0.21457		0.18524	
Tricyclics: OEF/OIF	0.8754	(-0.31,2.06)	0.78519	(-0.47,2.04)	0.6726	(-0.4,1.74)
Tricyclics: other era	2.59003	(1.51,3.67)	2.51973	(1.64,3.4)	2.17844	(1.41,2.94)
p-value for 2-way interaction	0.25716		0.07136		0.07421	
overall 2-way interaction p-value	0.05673		0.10791		0.12935	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	1.74185	(1.08,2.41)	2.04132	(1.26,2.82)	1.52083	(0.66,2.38)
Antipsychotics: other era	2.97204	(2.46,3.48)	3.3591	(2.77,3.95)	2.94533	(2.1,3.79)
p-value for 2-way interaction	0.05672		0.08059		0.45629	
Mirtazapine: OEF/OIF	0.32676	(-0.42,1.07)	0.38562	(-0.48,1.26)	-0.01635	(-0.85,0.82)
Mirtazapine: other era	1.06539	(0.53,1.6)	1.21353	(0.59,1.84)	1.25978	(0.42,2.1)
p-value for 2-way interaction	0.19374		0.21057		0.10707	
Tricyclics: OEF/OIF	0.6455	(-0.41,1.71)	0.97294	(-0.28,2.23)	1.20813	(0.34,2.08)
Tricyclics: other era	2.14298	(1.39,2.9)	2.65886	(1.77,3.54)	2.33112	(1.48,3.18)
p-value for 2-way interaction	0.07235		0.09124		0.56328	
overall 2-way interaction p-value	0.132		0.18103		0.44558	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	11269	20874
Mirtazapine	7376	14744
Prazosin	18482	23781
Tricyclics	2940	5879

**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	3.29201	(2.8,3.78)	2.52941	(2.1,2.96)	2.21982	(1.84,2.6)
Antipsychotics: female	1.52779	(0.51,2.55)	1.34259	(0.26,2.42)	1.18268	(0.23,2.13)
p-value for 2-way interaction	0.55662		0.49707		0.50457	
Mirtazapine: male	2.6364	(2.1,3.18)	1.31191	(0.85,1.77)	1.18039	(0.77,1.59)
Mirtazapine: female	1.02305	(-0.06,2.11)	0.53769	(-0.59,1.66)	0.50859	(-0.48,1.5)
p-value for 2-way interaction	0.44805		0.5491		0.57063	
Tricyclics: male	3.31728	(2.53,4.11)	2.4398	(1.75,3.13)	2.06121	(1.45,2.67)
Tricyclics: female	1.93168	(0.72,3.15)	1.65218	(0.38,2.93)	1.37925	(0.26,2.49)
p-value for 2-way interaction	0.97193		0.9349		0.91919	
overall 2-way interaction p-value	0.83859		0.8824		0.89488	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	2.16425	(1.79,2.54)	2.43084	(2.01,2.85)	1.99116	(1.4,2.58)
Antipsychotics: female	1.14954	(0.23,2.07)	1.38426	(0.3,2.47)	0.96314	(-0.19,2.12)
p-value for 2-way interaction	0.50725		0.56968		0.80432	
Mirtazapine: male	1.17543	(0.78,1.57)	1.30027	(0.85,1.75)	1.34499	(0.76,1.93)
Mirtazapine: female	0.50919	(-0.45,1.47)	0.59343	(-0.54,1.72)	0.27357	(-0.85,1.4)
p-value for 2-way interaction	0.56978		0.59582		0.44094	
Tricyclics: male	1.97848	(1.39,2.57)	2.38767	(1.71,3.07)	2.09656	(1.5,2.69)
Tricyclics: female	1.30098	(0.22,2.38)	1.67965	(0.4,2.96)	1.16474	(0,2.33)
p-value for 2-way interaction	0.90041		0.95909		0.97244	
overall 2-way interaction p-value	0.89868		0.91983		0.8524	

**Number of Windows**

Medications	male	female
Antipsychotics	28791	3672
Mirtazapine	19928	2832
Prazosin	39134	5215
Tricyclics	7119	2130

**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	5.80844	(3.78,7.84)	1.5737	(0.8,2.35)	1.33766	(0.67,2.01)
<b>Antipsychotics: &lt;65</b>	2.98455	(2.52,3.44)	2.24789	(1.81,2.68)	1.98767	(1.6,2.37)
<b>p-value for 2-way interaction</b>	0.26212		0.69409		0.74925	
<b>Mirtazapine: &gt;=65</b>	2.14388	(0.18,4.11)	0.33869	(-0.4,1.08)	0.32958	(-0.31,0.97)
<b>Mirtazapine: &lt;65</b>	2.31893	(1.81,2.83)	1.25152	(0.78,1.72)	1.13326	(0.72,1.55)
<b>p-value for 2-way interaction</b>	0.25081		0.31387		0.33856	
<b>Tricyclics: &gt;=65</b>	6.84039	(3.51,10.17)	2.45275	(1.13,3.78)	1.99981	(0.86,3.14)
<b>Tricyclics: &lt;65</b>	2.29682	(1.61,2.99)	1.63139	(0.98,2.28)	1.36892	(0.8,1.94)
<b>p-value for 2-way interaction</b>	0.07858		0.06049		0.0766	
<b>overall 2-way interaction p-value</b>	0.04874		0.1019		0.13885	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
<b>Antipsychotics: &gt;=65</b>	1.28657	(0.63,1.94)	1.46006	(0.69,2.23)	3.30864	(0.99,5.63)
<b>Antipsychotics: &lt;65</b>	1.94844	(1.57,2.32)	2.20378	(1.78,2.63)	1.73732	(1.19,2.28)
<b>p-value for 2-way interaction</b>	0.81791		0.85605		0.57559	
<b>Mirtazapine: &gt;=65</b>	0.32078	(-0.31,0.95)	0.32906	(-0.4,1.06)	1.10673	(-1.15,3.36)
<b>Mirtazapine: &lt;65</b>	1.13314	(0.73,1.54)	1.27627	(0.81,1.74)	1.20621	(0.67,1.75)
<b>p-value for 2-way interaction</b>	0.31141		0.27594		0.59238	
<b>Tricyclics: &gt;=65</b>	1.93193	(0.82,3.05)	2.35532	(1.04,3.67)	5.34711	(2.95,7.75)
<b>Tricyclics: &lt;65</b>	1.30727	(0.75,1.86)	1.67377	(1.03,2.32)	1.6781	(1.13,2.23)
<b>p-value for 2-way interaction</b>	0.08032		0.0866		0.03648	
<b>overall 2-way interaction p-value</b>	0.13746		0.13233		0.03831	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	2217	30246
Mirtazapine	2184	20576
Prazosin	3503	40846
Tricyclics	551	8698

**Differences in Incident Diagnoses of Hypertension (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.56177	(0.02,1.1)	1.02319	(0.33,1.72)	0.93489	(0.33,1.54)
Antipsychotics: other era	3.71789	(3.05,4.39)	2.87906	(2.37,3.38)	2.54265	(2.1,2.99)
p-value for 2-way interaction	0.00027		0.00197		0.00291	
Mirtazapine: OEF/OIF	0.1728	(-0.44,0.78)	0.29429	(-0.49,1.08)	0.31713	(-0.37,1)
Mirtazapine: other era	2.45711	(1.74,3.17)	1.49462	(0.96,2.02)	1.36254	(0.89,1.83)
p-value for 2-way interaction	0.0066		0.04456		0.05212	
Tricyclics: OEF/OIF	0.46823	(-0.4,1.34)	0.36988	(-0.73,1.47)	0.35256	(-0.6,1.31)
Tricyclics: other era	2.44415	(1.46,3.42)	2.47179	(1.72,3.23)	2.08851	(1.42,2.75)
p-value for 2-way interaction	0.1713		0.01391		0.02224	
overall 2-way interaction p-value	0.00145		0.00472		0.00825	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.92281	(0.33,1.52)	1.10954	(0.43,1.79)	0.46804	(-0.17,1.11)
Antipsychotics: other era	2.47431	(2.04,2.91)	2.75932	(2.26,3.26)	2.10475	(1.32,2.89)
p-value for 2-way interaction	0.00331		0.00712		0.17215	
Mirtazapine: OEF/OIF	0.34303	(-0.32,1.01)	0.41957	(-0.35,1.19)	-0.02257	(-0.65,0.6)
Mirtazapine: other era	1.34633	(0.89,1.8)	1.48641	(0.96,2.01)	1.49434	(0.72,2.27)
p-value for 2-way interaction	0.05844		0.08169		0.05447	
Tricyclics: OEF/OIF	0.31572	(-0.61,1.24)	0.59136	(-0.49,1.67)	0.6925	(0.05,1.34)
Tricyclics: other era	1.99705	(1.35,2.64)	2.43811	(1.69,3.18)	2.19373	(1.4,2.98)
p-value for 2-way interaction	0.0222		0.03568		0.36823	
overall 2-way interaction p-value	0.00927		0.02147		0.26451	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	12337	20126
Mirtazapine	8127	14633
Prazosin	20520	23829
Tricyclics	3350	5899

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.31901	(-0.02,0.66)	0.40475	(0.07,0.74)	0.43878	(0.1,0.78)
Antipsychotics: female	-0.22442	(-1.62,1.17)	-0.12303	(-1.49,1.25)	-0.07027	(-1.41,1.27)
p-value for 2-way interaction	0.38911		0.37159		0.38488	
Mirtazapine: male	-0.46789	(-0.83,-0.11)	-0.2993	(-0.65,0.06)	-0.30961	(-0.67,0.05)
Mirtazapine: female	-0.96009	(-2.41,0.49)	-0.75185	(-2.18,0.68)	-0.69704	(-2.1,0.7)
p-value for 2-way interaction	0.66874		0.64597		0.68984	
Tricyclics: male	0.60863	(0.07,1.15)	0.67332	(0.14,1.2)	0.61475	(0.08,1.15)
Tricyclics: female	0.84976	(-0.85,2.55)	0.88168	(-0.78,2.54)	0.85994	(-0.77,2.49)
p-value for 2-way interaction	0.97554		0.97957		0.94392	
overall 2-way interaction p-value	0.82584		0.81896		0.81641	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.43023	(0.1,0.76)	0.41067	(0.08,0.74)	0.26194	(-0.13,0.66)
Antipsychotics: female	-0.0659	(-1.39,1.26)	-0.07341	(-1.36,1.22)	-0.61583	(-2.18,0.95)
p-value for 2-way interaction	0.38986		0.39427		0.25238	
Mirtazapine: male	-0.29512	(-0.65,0.06)	-0.30329	(-0.65,0.05)	-0.2785	(-0.67,0.11)
Mirtazapine: female	-0.66652	(-2.05,0.71)	-0.64501	(-1.99,0.7)	-1.02336	(-2.55,0.5)
p-value for 2-way interaction	0.69711		0.72055		0.43019	
Tricyclics: male	0.58578	(0.05,1.12)	0.56512	(0.04,1.09)	0.06722	(-0.33,0.47)
Tricyclics: female	0.80165	(-0.8,2.4)	0.77172	(-0.79,2.33)	0.77025	(-0.85,2.39)
p-value for 2-way interaction	0.9605		0.95825		0.43939	
overall 2-way interaction p-value	0.82587		0.83099		0.21434	

**Number of Windows**

Medications	male	female
Antipsychotics	48335	3689
Mirtazapine	37317	3138
Prazosin	63093	4948
Tricyclics	12844	2088

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	-0.58119	(-1.28,0.12)	-0.54281	(-1.22,0.14)	-0.61639	(-1.31,0.08)
Antipsychotics: <65	0.34811	(-0.02,0.72)	0.39989	(0.03,0.77)	0.46161	(0.08,0.84)
p-value for 2-way interaction	0.03146		0.02903		0.01504	
Mirtazapine: >=65	-0.86004	(-1.55,-0.17)	-0.80086	(-1.47,-0.13)	-0.87451	(-1.56,-0.19)
Mirtazapine: <65	-0.29679	(-0.7,0.1)	-0.24374	(-0.64,0.16)	-0.25503	(-0.67,0.16)
p-value for 2-way interaction	0.08184		0.08235		0.0599	
Tricyclics: >=65	0.07149	(-1.12,1.26)	0.10512	(-1.05,1.26)	0.01431	(-1.16,1.19)
Tricyclics: <65	0.87123	(0.31,1.44)	0.89577	(0.33,1.46)	0.77735	(0.2,1.36)
p-value for 2-way interaction	0.40362		0.42003		0.42139	
overall 2-way interaction p-value	0.13006		0.12475		0.07245	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	-0.62721	(-1.32,0.06)	-0.59323	(-1.26,0.07)	0.04558	(-0.75,0.84)
Antipsychotics: <65	0.45872	(0.08,0.84)	0.43211	(0.07,0.8)	0.21935	(-0.21,0.65)
p-value for 2-way interaction	0.01294		0.0152		0.80953	
Mirtazapine: >=65	-0.86789	(-1.55,-0.19)	-0.8304	(-1.49,-0.18)	-0.44189	(-1.22,0.33)
Mirtazapine: <65	-0.23681	(-0.65,0.17)	-0.2424	(-0.64,0.15)	-0.30438	(-0.73,0.12)
p-value for 2-way interaction	0.0556		0.06226		0.57577	
Tricyclics: >=65	-0.0167	(-1.18,1.15)	0.0028	(-1.12,1.13)	-0.19585	(-1,0.61)
Tricyclics: <65	0.74678	(0.17,1.32)	0.69744	(0.14,1.25)	0.14513	(-0.29,0.58)
p-value for 2-way interaction	0.40499		0.43846		0.50309	
overall 2-way interaction p-value	0.06359		0.07427		0.9048	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	7816	44208
Mirtazapine	8089	32366
Prazosin	11752	56289
Tricyclics	1980	12952

**Differences in Incident Diagnoses of Obesity (Per 100 Person Years) by Augmenting Mediation Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.17492	(-0.8,0.45)	-0.18398	(-0.71,0.34)	-0.12959	(-0.67,0.41)
Antipsychotics: other era	0.41075	(0.02,0.8)	0.46246	(0.06,0.87)	0.50576	(0.09,0.92)
p-value for 2-way interaction	0.12507		0.08199		0.1044	
Mirtazapine: OEF/OIF	-0.35477	(-1.06,0.35)	-0.26364	(-0.86,0.34)	-0.25923	(-0.88,0.36)
Mirtazapine: other era	-0.54309	(-0.95,-0.14)	-0.39066	(-0.82,0.03)	-0.40709	(-0.84,0.03)
p-value for 2-way interaction	0.65542		0.88624		0.84884	
Tricyclics: OEF/OIF	0.49107	(-0.54,1.52)	0.47871	(-0.39,1.35)	0.4054	(-0.49,1.3)
Tricyclics: other era	0.9859	(0.39,1.58)	0.93392	(0.32,1.55)	0.84005	(0.21,1.47)
p-value for 2-way interaction	0.44454		0.60966		0.61719	
overall 2-way interaction p-value	0.28769		0.29381		0.341	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.11845	(-0.65,0.42)	-0.17366	(-0.69,0.35)	-0.19944	(-0.93,0.54)
Antipsychotics: other era	0.49192	(0.08,0.9)	0.49484	(0.1,0.89)	0.31094	(-0.14,0.76)
p-value for 2-way interaction	0.11454		0.06935		0.25238	
Mirtazapine: OEF/OIF	-0.24145	(-0.85,0.37)	-0.27681	(-0.87,0.32)	-0.3772	(-1.1,0.35)
Mirtazapine: other era	-0.39181	(-0.82,0.04)	-0.36961	(-0.79,0.05)	-0.32052	(-0.76,0.12)
p-value for 2-way interaction	0.83468		0.94688		0.88626	
Tricyclics: OEF/OIF	0.3685	(-0.51,1.25)	0.27847	(-0.58,1.13)	-0.51832	(-1.25,0.22)
Tricyclics: other era	0.80617	(0.19,1.43)	0.79058	(0.19,1.39)	0.32358	(-0.13,0.78)
p-value for 2-way interaction	0.59884		0.48255		0.05839	
overall 2-way interaction p-value	0.35841		0.2611		0.1936	

Medications	OEF/OIF	other era
Antipsychotics	12937	39087
Mirtazapine	8743	31712
Prazosin	21081	46960
Tricyclics	3472	11460



Differences in Incident Myocardial Infarction (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.8254	(0.22,1.43)	0.44769	(0.04,0.86)	0.32557	(-0.12,0.77)
Antipsychotics: female	-0.64375	(-87.88,86.59)	-0.81473	(-)	-0.96842	(-)
p-value for 2-way interaction	0.98829		0.98738		0.98716	
Mirtazapine: male	1.21202	(0.55,1.87)	0.41497	(-0.02,0.85)	0.17641	(-0.28,0.63)
Mirtazapine: female	-0.42098	(-1.26,0.42)	-0.57987	(-1.52,0.36)	-0.70339	(-1.78,0.37)
p-value for 2-way interaction	0.20693		0.1734		0.18157	
Tricyclics: male	0.99258	(0.07,1.92)	0.62432	(-0.01,1.26)	0.25682	(-0.4,0.91)
Tricyclics: female	0.25526	(-0.83,1.34)	0.23745	(-1,1.48)	0.255	(-1.19,1.7)
p-value for 2-way interaction	0.91977		0.96413		0.83295	
overall 2-way interaction p-value	0.61988		0.57003		0.55167	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.31233	(-0.12,0.75)	0.26364	(-0.1,0.63)	0.31511	(-0.41,1.04)
Antipsychotics: female	-0.94029	(-116.68,114.8)	-0.78712	(-97.29,95.72)	-0.67341	(-94.38,93.03)
p-value for 2-way interaction	0.9872		0.98715		0.9887	
Mirtazapine: male	0.17349	(-0.27,0.62)	0.13887	(-0.24,0.51)	0.21284	(-0.51,0.93)
Mirtazapine: female	-0.68289	(-1.73,0.37)	-0.57432	(-1.45,0.3)	-0.49335	(-1.33,0.34)
p-value for 2-way interaction	0.18276		0.17863		0.22927	
Tricyclics: male	0.24049	(-0.4,0.88)	0.15163	(-0.38,0.69)	-0.00278	(-0.71,0.71)
Tricyclics: female	0.24324	(-1.16,1.65)	0.17157	(-0.98,1.32)	0.0185	(-0.97,1.01)
p-value for 2-way interaction	0.83355		0.84666		0.97018	
overall 2-way interaction p-value	0.55404		0.5503		0.64673	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Differences in Incident Myocardial Infarction (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	2.97271	(1.13,4.81)	0.33242	(-0.08,0.75)	0.22174	(-0.21,0.65)
Antipsychotics: <65	0.37203	(-0.2,0.94)	0.20932	(-0.26,0.68)	0.11917	(-0.4,0.63)
p-value for 2-way interaction	0.04755		0.38792		0.53904	
Mirtazapine: >=65	2.37547	(0.59,4.16)	0.26316	(-0.15,0.67)	0.12815	(-0.29,0.55)
Mirtazapine: <65	0.67743	(0.04,1.32)	0.26313	(-0.25,0.77)	0.02973	(-0.51,0.57)
p-value for 2-way interaction	0.31564		0.62759		0.66168	
Tricyclics: >=65	3.65251	(0.85,6.46)	0.89475	(0.19,1.6)	0.67723	(-0.03,1.38)
Tricyclics: <65	0.28396	(-0.56,1.13)	0.07922	(-0.61,0.77)	-0.25954	(-0.98,0.46)
p-value for 2-way interaction	0.07644		0.0494		0.04955	
overall 2-way interaction p-value	0.14709		0.26279		0.27272	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	0.20964	(-0.21,0.63)	0.17723	(-0.18,0.53)	1.60104	(-0.54,3.74)
Antipsychotics: <65	0.11781	(-0.39,0.62)	0.10139	(-0.32,0.52)	-0.04751	(-0.73,0.63)
p-value for 2-way interaction	0.56245		0.56533		0.19318	
Mirtazapine: >=65	0.12295	(-0.29,0.54)	0.09471	(-0.25,0.44)	1.22564	(-0.88,3.33)
Mirtazapine: <65	0.03361	(-0.5,0.57)	0.02801	(-0.42,0.47)	-0.07428	(-0.75,0.6)
p-value for 2-way interaction	0.67766		0.70702		0.28274	
Tricyclics: >=65	0.65422	(-0.04,1.35)	0.52368	(-0.06,1.1)	1.32726	(-0.8,3.46)
Tricyclics: <65	-0.25748	(-0.96,0.45)	-0.26156	(-0.85,0.32)	-0.26453	(-0.93,0.4)
p-value for 2-way interaction	0.05203		0.04912		0.14823	
overall 2-way interaction p-value	0.28158		0.26798		0.47348	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Myocardial Infarction (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.35124	(-0.03,0.73)	0.68552	(-0.01,1.38)	0.75081	(-0.03,1.53)
Antipsychotics: other era	0.56581	(-0.18,1.32)	0.34641	(-0.14,0.83)	0.22024	(-0.33,0.77)
p-value for 2-way interaction	0.12664		0.09288		0.08446	
Mirtazapine: OEF/OIF	0.11091	(-0.25,0.48)	0.2032	(-0.44,0.85)	0.23195	(-0.51,0.98)
Mirtazapine: other era	0.90959	(0.1,1.72)	0.35971	(-0.15,0.87)	0.0878	(-0.48,0.65)
p-value for 2-way interaction	0.77666		0.67719		0.57352	
Tricyclics: OEF/OIF	0.18355	(-0.33,0.7)	0.31472	(-0.59,1.22)	0.33484	(-0.68,1.35)
Tricyclics: other era	0.44189	(-0.65,1.54)	0.46186	(-0.27,1.19)	0.07343	(-0.72,0.87)
p-value for 2-way interaction	0.57103		0.62692		0.54273	
overall 2-way interaction p-value	0.46337		0.39268		0.38444	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: OEF/OIF	0.73518	(-0.03,1.5)	0.60207	(-0.02,1.23)	0.35051	(-0.13,0.83)
Antipsychotics: other era	0.20874	(-0.33,0.75)	0.16985	(-0.27,0.61)	0.03046	(-0.85,0.91)
p-value for 2-way interaction	0.08413		0.08243		0.15815	
Mirtazapine: OEF/OIF	0.22895	(-0.5,0.96)	0.1875	(-0.41,0.78)	0.06447	(-0.32,0.45)
Mirtazapine: other era	0.08632	(-0.47,0.64)	0.06292	(-0.39,0.51)	0.04195	(-0.84,0.92)
p-value for 2-way interaction	0.57115		0.56571		0.75366	
Tricyclics: OEF/OIF	0.32258	(-0.67,1.32)	0.24816	(-0.55,1.05)	0.09665	(-0.3,0.49)
Tricyclics: other era	0.0597	(-0.72,0.84)	-0.00998	(-0.64,0.62)	-0.21582	(-1.09,0.66)
p-value for 2-way interaction	0.54537		0.54459		0.58737	
overall 2-way interaction p-value	0.38375		0.37907		0.4809	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

Differences in Incident Heart Failure (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	4.94214	(3.88,6)	2.1603	(1.65,2.67)	1.33191	(0.94,1.72)
Antipsychotics: female	1.75595	(0.34,3.17)	1.77756	(0.39,3.17)	1.55138	(0.38,2.72)
p-value for 2-way interaction	0.12696		0.09374		0.0572	
Mirtazapine: male	9.33003	(8.1,10.56)	3.36656	(2.81,3.93)	1.81042	(1.4,2.22)
Mirtazapine: female	4.35114	(2.29,6.41)	3.69954	(1.87,5.53)	3.03966	(1.56,4.52)
p-value for 2-way interaction	0.01044		0.00682		0.00225	
Tricyclics: male	5.6988	(4.11,7.28)	2.96899	(2.18,3.76)	1.18405	(0.63,1.74)
Tricyclics: female	0.72585	(-0.57,2.03)	0.66577	(-0.6,1.93)	0.61613	(-0.47,1.7)
p-value for 2-way interaction	0.77884		0.86225		0.54418	
overall 2-way interaction p-value	0.02891		0.01441		0.00874	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.20451	(0.85,1.56)	1.13922	(0.81,1.47)	2.95987	(1.66,4.26)
Antipsychotics: female	1.39833	(0.34,2.46)	1.24428	(0.28,2.21)	1.50872	(-0.06,3.08)
p-value for 2-way interaction	0.05624		0.06502		0.14471	
Mirtazapine: male	1.68602	(1.31,2.06)	1.55436	(1.2,1.91)	4.16007	(2.83,5.49)
Mirtazapine: female	2.75359	(1.41,4.1)	2.46607	(1.25,3.69)	3.12209	(1.07,5.17)
p-value for 2-way interaction	0.00227		0.0027		0.01753	
Tricyclics: male	1.04551	(0.54,1.56)	0.84706	(0.38,1.32)	0.58273	(-0.65,1.82)
Tricyclics: female	0.54282	(-0.44,1.52)	0.43739	(-0.44,1.31)	0.52511	(-0.72,1.77)
p-value for 2-way interaction	0.54594		0.58009		0.46027	
overall 2-way interaction p-value	0.00883		0.00983		0.05281	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Differences in Incident Heart Failure (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	16.8575	(13.1,20.62)	1.58805	(1,2.17)	0.83729	(0.43,1.25)
Antipsychotics: <65	2.9228	(2.01,3.84)	1.91516	(1.3,2.53)	1.24055	(0.77,1.71)
p-value for 2-way interaction	0.0034		0.70152		0.96518	
Mirtazapine: >=65	21.0234	(17.15,24.9)	2.51765	(1.9,3.14)	1.3644	(0.94,1.79)
Mirtazapine: <65	5.4645	(4.4,6.53)	3.12338	(2.44,3.81)	1.60161	(1.11,2.1)
p-value for 2-way interaction	0.1036		0.69169		0.42186	
Tricyclics: >=65	8.9144	(3.6,14.23)	1.5293	(0.6,2.46)	0.49795	(-0.12,1.12)
Tricyclics: <65	4.1253	(2.79,5.46)	2.6592	(1.77,3.55)	1.03933	(0.41,1.67)
p-value for 2-way interaction	0.4995		0.53933		0.61627	
overall 2-way interaction p-value	0.0073		0.8172		0.68869	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	0.74273	(0.36,1.13)	0.70306	(0.34,1.07)	7.7831	(3.41,12.15)
Antipsychotics: <65	1.15044	(0.72,1.58)	1.09835	(0.7,1.5)	1.8439	(0.73,2.96)
p-value for 2-way interaction	0.82419		0.7737		0.514	
Mirtazapine: >=65	1.27593	(0.88,1.68)	1.17046	(0.79,1.55)	10.7932	(6.3,15.28)
Mirtazapine: <65	1.50274	(1.04,1.96)	1.40857	(0.98,1.84)	2.6619	(1.52,3.8)
p-value for 2-way interaction	0.47438		0.56566		0.4492	
Tricyclics: >=65	0.41605	(-0.16,1)	0.32918	(-0.21,0.87)	-0.9513	(-4.98,3.08)
Tricyclics: <65	0.93668	(0.36,1.52)	0.74674	(0.22,1.28)	0.9527	(-0.13,2.04)
p-value for 2-way interaction	0.54724		0.58336		0.1565	
overall 2-way interaction p-value	0.65948		0.7412		0.0984	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Heart Failure (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	0.30927	(-0.18,0.8)	0.81519	(-0.23,1.86)	0.82463	(-0.21,1.86)
Antipsychotics: other era	5.3478	(4.03,6.66)	2.34938	(1.76,2.94)	1.47107	(1.03,1.91)
p-value for 2-way interaction	0.8349		0.61469		0.50385	
Mirtazapine: OEF/OIF	0.36499	(-0.19,0.92)	0.80306	(-0.34,1.95)	0.82913	(-0.31,1.97)
Mirtazapine: other era	9.98018	(8.49,11.47)	3.72543	(3.09,4.37)	2.03072	(1.57,2.49)
p-value for 2-way interaction	0.8012		0.98086		0.71689	
Tricyclics: OEF/OIF	0.33202	(-0.42,1.08)	0.64104	(-0.86,2.14)	0.61235	(-0.87,2.1)
Tricyclics: other era	4.38302	(2.53,6.23)	2.76625	(1.89,3.64)	1.07652	(0.46,1.69)
p-value for 2-way interaction	0.77173		0.95043		0.7162	
overall 2-way interaction p-value	0.96281		0.95884		0.92449	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	0.76808	(-0.19,1.72)	0.70549	(-0.18,1.59)	0.19582	(-0.4,0.79)
Antipsychotics: other era	1.32845	(0.92,1.73)	1.22629	(0.86,1.6)	3.16546	(1.59,4.74)
p-value for 2-way interaction	0.48119		0.49751		0.88129	
Mirtazapine: OEF/OIF	0.7769	(-0.27,1.83)	0.71124	(-0.27,1.69)	0.24292	(-0.36,0.85)
Mirtazapine: other era	1.88681	(1.46,2.31)	1.70054	(1.31,2.09)	4.87363	(3.25,6.5)
p-value for 2-way interaction	0.70298		0.70908		0.95778	
Tricyclics: OEF/OIF	0.54176	(-0.81,1.89)	0.43992	(-0.79,1.67)	0.29013	(-0.33,0.91)
Tricyclics: other era	0.93911	(0.38,1.5)	0.72113	(0.21,1.23)	0.12225	(-1.37,1.61)
p-value for 2-way interaction	0.71729		0.7353		0.37413	
overall 2-way interaction p-value	0.91445		0.92317		0.76928	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

Differences in Incident Unstable Angina (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.87427	(0.36,1.38)	0.47096	(0.17,0.77)	0.40218	(0.11,0.7)
Antipsychotics: female	0.80108	(-0.31,1.91)	0.73154	(-0.3,1.76)	0.69534	(-0.32,1.71)
p-value for 2-way interaction	0.41114		0.40517		0.38702	
Mirtazapine: male	0.53377	(0,1.07)	0.12617	(-0.17,0.42)	0.0052	(-0.28,0.29)
Mirtazapine: female	0.69285	(-0.43,1.82)	0.51183	(-0.49,1.51)	0.48064	(-0.5,1.46)
p-value for 2-way interaction	0.40302		0.40091		0.3465	
Tricyclics: male	1.64504	(0.85,2.44)	0.93239	(0.47,1.39)	0.72843	(0.28,1.17)
Tricyclics: female	0.25526	(-0.84,1.35)	0.19148	(-0.82,1.2)	0.20473	(-0.81,1.22)
p-value for 2-way interaction	0.76459		0.71303		0.8343	
overall 2-way interaction p-value	0.63235		0.59346		0.61752	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.35285	(0.09,0.62)	0.31617	(0.08,0.55)	0.67746	(0.06,1.29)
Antipsychotics: female	0.61697	(-0.28,1.51)	0.54331	(-0.24,1.33)	0.65312	(-0.6,1.91)
p-value for 2-way interaction	0.37781		0.37473		0.53372	
Mirtazapine: male	0.00736	(-0.25,0.27)	0.00131	(-0.23,0.23)	-0.00946	(-0.58,0.56)
Mirtazapine: female	0.43147	(-0.43,1.3)	0.38126	(-0.38,1.14)	0.34114	(-0.8,1.48)
p-value for 2-way interaction	0.3413		0.33362		0.5612	
Tricyclics: male	0.63527	(0.24,1.03)	0.55364	(0.2,0.91)	0.76259	(0.14,1.38)
Tricyclics: female	0.17268	(-0.72,1.06)	0.13978	(-0.63,0.91)	0.11188	(-0.95,1.18)
p-value for 2-way interaction	0.83424		0.82406		0.8575	
overall 2-way interaction p-value	0.60734		0.59331		0.78194	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

Differences in Incident Unstable Angina (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	1.09023	(-0.27,2.45)	0.0685	(-0.2,0.34)	0.02444	(-0.25,0.3)
Antipsychotics: <65	0.85797	(0.35,1.36)	0.55547	(0.21,0.9)	0.52292	(0.16,0.88)
p-value for 2-way interaction	0.86484		0.30333		0.23752	
Mirtazapine: >=65	1.15143	(-0.2,2.51)	0.10586	(-0.17,0.38)	0.04261	(-0.23,0.32)
Mirtazapine: <65	0.35928	(-0.17,0.89)	0.09122	(-0.26,0.44)	-0.02739	(-0.38,0.33)
p-value for 2-way interaction	0.47664		0.71056		0.73546	
Tricyclics: >=65	3.32468	(1.08,5.57)	0.72417	(0.23,1.22)	0.6086	(0.12,1.09)
Tricyclics: <65	1.02971	(0.3,1.76)	0.62428	(0.13,1.12)	0.46652	(-0.03,0.96)
p-value for 2-way interaction	0.25536		0.20581		0.22377	
overall 2-way interaction p-value	0.56234		0.22		0.18649	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	0.00893	(-0.24,0.26)	0.00935	(-0.21,0.23)	0.82395	(-0.77,2.42)
Antipsychotics: <65	0.47172	(0.15,0.79)	0.41048	(0.13,0.69)	0.64673	(0.04,1.25)
p-value for 2-way interaction	0.20038		0.20063		0.9026	
Mirtazapine: >=65	0.0339	(-0.22,0.29)	0.0262	(-0.19,0.25)	0.58106	(-0.98,2.14)
Mirtazapine: <65	-0.01592	(-0.33,0.3)	-0.01474	(-0.29,0.26)	-0.09811	(-0.65,0.46)
p-value for 2-way interaction	0.7821		0.79911		0.42114	
Tricyclics: >=65	0.53492	(0.1,0.97)	0.46409	(0.08,0.85)	2.25513	(0.48,4.03)
Tricyclics: <65	0.40778	(-0.04,0.85)	0.33615	(-0.05,0.72)	0.39295	(-0.2,0.98)
p-value for 2-way interaction	0.24083		0.23278		0.14087	
overall 2-way interaction p-value	0.17202		0.16937		0.29128	

Number of Windows

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893



**Differences in Incident Unstable Angina (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.12265	(-0.49,0.25)	-0.14147	(-0.6,0.31)	-0.17836	(-0.69,0.34)
Antipsychotics: other era	1.02729	(0.39,1.66)	0.60835	(0.24,0.97)	0.56589	(0.18,0.95)
p-value for 2-way interaction	0.22167		0.22934		0.22867	
Mirtazapine: OEF/OIF	-0.15368	(-0.58,0.27)	-0.19263	(-0.71,0.32)	-0.23091	(-0.82,0.36)
Mirtazapine: other era	0.48611	(-0.16,1.13)	0.19235	(-0.17,0.56)	0.05389	(-0.32,0.43)
p-value for 2-way interaction	0.34618		0.37015		0.41909	
Tricyclics: OEF/OIF	-0.20649	(-0.83,0.42)	-0.26583	(-1.01,0.48)	-0.3098	(-1.16,0.54)
Tricyclics: other era	1.51276	(0.59,2.44)	0.98601	(0.44,1.53)	0.81188	(0.26,1.37)
p-value for 2-way interaction	0.28909		0.24648		0.27884	
overall 2-way interaction p-value	0.4569		0.44195		0.48145	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.15793	(-0.62,0.3)	-0.14378	(-0.55,0.26)	-0.13187	(-0.57,0.31)
Antipsychotics: other era	0.49712	(0.16,0.84)	0.42093	(0.13,0.71)	0.82965	(0.08,1.58)
p-value for 2-way interaction	0.23216		0.22165		0.32426	
Mirtazapine: OEF/OIF	-0.20395	(-0.73,0.32)	-0.18323	(-0.64,0.28)	-0.19938	(-0.62,0.22)
Mirtazapine: other era	0.05129	(-0.28,0.38)	0.0407	(-0.24,0.32)	0.01207	(-0.69,0.71)
p-value for 2-way interaction	0.4215		0.41433		0.35986	
Tricyclics: OEF/OIF	-0.28257	(-1.03,0.47)	-0.25626	(-0.91,0.4)	-0.27503	(-0.69,0.14)
Tricyclics: other era	0.70371	(0.21,1.19)	0.57381	(0.16,0.98)	0.89771	(0.15,1.65)
p-value for 2-way interaction	0.27136		0.26332		0.10279	
overall 2-way interaction p-value	0.47977		0.46236		0.39058	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

Differences in Incident Stroke (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.79486	(0.36,1.23)	0.6265	(0.26,1)	0.6259	(0.18,1.08)
Antipsychotics: female	-0.30759	(-1.34,0.73)	-0.51668	(-1.95,0.92)	-0.784	(-2.68,1.12)
p-value for 2-way interaction	0.2134		0.18939		0.19175	
Mirtazapine: male	1.02468	(0.55,1.5)	0.62639	(0.24,1.01)	0.50809	(0.05,0.97)
Mirtazapine: female	0.3066	(-0.93,1.54)	0.15881	(-1.46,1.77)	0.08727	(-2.04,2.21)
p-value for 2-way interaction	0.65127		0.61066		0.68871	
Tricyclics: male	0.86734	(0.22,1.51)	0.78789	(0.22,1.35)	0.67117	(0,1.34)
Tricyclics: female	-1.03	(-)	-1.56314	(-)	-2.15499	(-)
p-value for 2-way interaction	0.99057		0.98967		0.98947	
overall 2-way interaction p-value	0.671		0.63192		0.63345	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.56534	(0.15,0.98)	0.41041	(0.12,0.71)	0.55209	(0.03,1.08)
Antipsychotics: female	-0.70997	(-2.43,1.01)	-0.50459	(-1.72,0.71)	-0.57698	(-1.78,0.63)
p-value for 2-way interaction	0.19361		0.18924		0.18412	
Mirtazapine: male	0.47374	(0.05,0.9)	0.33966	(0.04,0.64)	0.41201	(-0.1,0.93)
Mirtazapine: female	0.08724	(-1.84,2.01)	0.06447	(-1.3,1.43)	-0.10202	(-1.42,1.22)
p-value for 2-way interaction	0.69012		0.69099		0.60838	
Tricyclics: male	0.59802	(-0.01,1.21)	0.40705	(-0.03,0.84)	0.31381	(-0.2,0.82)
Tricyclics: female	-1.95395	(-)	-1.38415	(-)	-1.27812	(-)
p-value for 2-way interaction	0.9894		0.98937		0.9882	
overall 2-way interaction p-value	0.63662		0.62885		0.6222	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

Differences in Incident Stroke (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	1.63163	(0.2,3.06)	0.28189	(-0.2,0.76)	0.19482	(-0.38,0.77)
Antipsychotics: <65	0.60282	(0.2,1.01)	0.63636	(0.19,1.08)	0.68036	(0.13,1.23)
p-value for 2-way interaction	0.88809		0.50758		0.39959	
Mirtazapine: >=65	1.67292	(0.25,3.1)	0.36159	(-0.13,0.85)	0.23649	(-0.34,0.81)
Mirtazapine: <65	0.73441	(0.29,1.18)	0.65437	(0.18,1.13)	0.56148	(-0.01,1.13)
p-value for 2-way interaction	0.91063		0.64462		0.60775	
Tricyclics: >=65	1.27288	(-0.87,3.41)	0.48462	(-0.31,1.28)	0.36528	(-0.57,1.3)
Tricyclics: <65	0.50151	(-0.07,1.07)	0.50432	(-0.12,1.13)	0.39519	(-0.36,1.15)
p-value for 2-way interaction	0.9782		0.8975		0.93829	
overall 2-way interaction p-value	0.99586		0.89094		0.82996	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.15689	(-0.38,0.69)	0.11624	(-0.26,0.49)	0.68508	(-1,2.37)
Antipsychotics: <65	0.62891	(0.13,1.13)	0.45274	(0.1,0.81)	0.41384	(-0.07,0.9)
p-value for 2-way interaction	0.35323		0.35263		0.72922	
Mirtazapine: >=65	0.21231	(-0.32,0.75)	0.14752	(-0.23,0.53)	0.50156	(-1.16,2.17)
Mirtazapine: <65	0.53125	(0.01,1.06)	0.38222	(0.01,0.76)	0.34083	(-0.14,0.82)
p-value for 2-way interaction	0.56604		0.54649		0.72767	
Tricyclics: >=65	0.31196	(-0.55,1.18)	0.20751	(-0.4,0.82)	-0.13783	(-1.75,1.47)
Tricyclics: <65	0.35445	(-0.33,1.04)	0.23207	(-0.25,0.72)	0.252	(-0.22,0.72)
p-value for 2-way interaction	0.9713		0.96717		0.45891	
overall 2-way interaction p-value	0.79387		0.78856		0.9074	

Number of Windows

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Stroke (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	-0.03148	(-0.3,0.24)	-0.05467	(-0.73,0.62)	-0.10896	(-1.02,0.8)
Antipsychotics: other era	0.82385	(0.28,1.37)	0.68325	(0.23,1.14)	0.7142	(0.13,1.3)
p-value for 2-way interaction	0.48115		0.52805		0.53506	
Mirtazapine: OEF/OIF	-0.03227	(-0.34,0.28)	-0.07652	(-0.84,0.69)	-0.11907	(-1.16,0.93)
Mirtazapine: other era	1.04046	(0.45,1.63)	0.72495	(0.25,1.2)	0.61602	(0.02,1.21)
p-value for 2-way interaction	0.48007		0.53031		0.60484	
Tricyclics: OEF/OIF	0.00405	(-0.45,0.45)	0.00129	(-1.1,1.1)	-0.01538	(-1.51,1.48)
Tricyclics: other era	0.51951	(-0.25,1.28)	0.60593	(-0.06,1.27)	0.47956	(-0.35,1.31)
p-value for 2-way interaction	0.84755		0.78052		0.84265	
overall 2-way interaction p-value	0.85654		0.89216		0.91712	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	-0.0969	(-0.93,0.74)	-0.06877	(-0.64,0.5)	-0.06076	(-0.37,0.25)
Antipsychotics: other era	0.64323	(0.11,1.18)	0.45154	(0.08,0.82)	0.53792	(-0.11,1.19)
p-value for 2-way interaction	0.54258		0.5322		0.53209	
Mirtazapine: OEF/OIF	-0.10336	(-1.06,0.86)	-0.07216	(-0.73,0.58)	-0.06294	(-0.37,0.25)
Mirtazapine: other era	0.57226	(0.02,1.12)	0.39767	(0.02,0.77)	0.44047	(-0.21,1.09)
p-value for 2-way interaction	0.61005		0.60509		0.54799	
Tricyclics: OEF/OIF	-0.0231	(-1.38,1.33)	-0.02654	(-0.94,0.89)	0.02581	(-0.32,0.37)
Tricyclics: other era	0.4165	(-0.34,1.18)	0.26413	(-0.25,0.78)	0.13773	(-0.49,0.76)
p-value for 2-way interaction	0.83875		0.83027		0.94656	
overall 2-way interaction p-value	0.92078		0.91604		0.84337	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

**Differences in Incident Coronary Artery Bypass Graft (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.39911	(0.02,0.77)	0.16852	(-0.01,0.34)	0.09469	(-0.01,0.2)
Antipsychotics: female	0	(0,0)	0	(0,0)	0	(0,0)
p-value for 2-way interaction	0.99985		0.99981		0.99981	
Mirtazapine: male	0.48366	(0.08,0.89)	0.1243	(-0.06,0.31)	0.06292	(-0.05,0.17)
Mirtazapine: female	0.44553	(-50.81,51.7)	0.36305	(-37.32,38.05)	0.22362	(-22.77,23.21)
p-value for 2-way interaction	0.98669		0.9851		0.98493	
Tricyclics: male	0.44002	(-0.13,1.01)	0.1935	(-0.07,0.46)	0.09514	(-0.06,0.25)
Tricyclics: female	0	(0,0)	0	(0,0)	0	(0,0)
p-value for 2-way interaction	0.99986		0.99981		0.99984	
overall 2-way interaction p-value	1		0.99999		0.99999	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.08775	(-0.01,0.19)	0.12653	(-0.02,0.28)	0.33605	(-0.11,0.78)
Antipsychotics: female	0	(0,0)	0	(0,0)	0	(0,0)
p-value for 2-way interaction	0.99981		0.99982		0.99989	
Mirtazapine: male	0.0604	(-0.04,0.16)	0.08114	(-0.07,0.24)	0.24944	(-0.19,0.69)
Mirtazapine: female	0.20998	(-21.27,21.69)	0.30645	(-30.91,31.53)	0.34095	(-48.2,48.88)
p-value for 2-way interaction	0.98486		0.98478		0.98914	
Tricyclics: male	0.08696	(-0.06,0.24)	0.11767	(-0.11,0.34)	0.28379	(-0.16,0.73)
Tricyclics: female	0	(0,0)	0	(0,0)	0	(0,0)
p-value for 2-way interaction	0.99984		0.99983		0.9999	
overall 2-way interaction p-value	0.99999		0.99999		1	

**Number of Windows**

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Differences in Incident Coronary Artery Bypass Graft (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	-1.317	(-2.4,-0.24)	-0.21936	(-0.33,-0.11)	-0.14663	(-0.22,-0.07)
Antipsychotics: <65	0.71762	(0.34,1.1)	0.39038	(0.19,0.59)	0.24673	(0.12,0.37)
p-value for 2-way interaction	0.00019		0		0	
Mirtazapine: >=65	0.00352	(-1.16,1.17)	-0.0811	(-0.2,0.04)	-0.05597	(-0.14,0.02)
Mirtazapine: <65	0.5527	(0.16,0.95)	0.22795	(0.03,0.42)	0.13262	(0.01,0.26)
p-value for 2-way interaction	0.12588		0.01838		0.02222	
Tricyclics: >=65	-0.1702	(-2.04,1.7)	-0.04309	(-0.26,0.17)	-0.03719	(-0.18,0.1)
Tricyclics: <65	0.41508	(-0.1,0.93)	0.19546	(-0.07,0.46)	0.10589	(-0.06,0.27)
p-value for 2-way interaction	0.35386		0.29121		0.28879	
overall 2-way interaction p-value	0.0029		0.00001		0.00001	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: >=65	-0.14108	(-0.21,-0.07)	-0.2074	(-0.31,-0.11)	-1.19207	(-2.36,-0.03)
Antipsychotics: <65	0.23355	(0.11,0.35)	0.33041	(0.16,0.5)	0.62187	(0.17,1.08)
p-value for 2-way interaction	0		0		0.0026	
Mirtazapine: >=65	-0.05394	(-0.13,0.02)	-0.08186	(-0.19,0.03)	-0.07278	(-1.38,1.23)
Mirtazapine: <65	0.12741	(0.01,0.25)	0.17226	(0,0.34)	0.32566	(-0.1,0.75)
p-value for 2-way interaction	0.0204		0.02109		0.36301	
Tricyclics: >=65	-0.03721	(-0.17,0.1)	-0.05691	(-0.25,0.14)	-0.27715	(-1.57,1.01)
Tricyclics: <65	0.09866	(-0.06,0.26)	0.12664	(-0.1,0.35)	0.37411	(-0.06,0.81)
p-value for 2-way interaction	0.2805		0.29622		0.20771	
overall 2-way interaction p-value	0.00001		0.00001		0.02512	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Coronary Artery Bypass Graft (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.05969	(-3.87,3.99)	0.07397	(-4.56,4.71)	0.05321	(-3.27,3.38)
Antipsychotics: other era	0.3547	(-0.09,0.8)	0.17759	(-0.03,0.39)	0.11035	(-0.03,0.25)
p-value for 2-way interaction	0.9766		0.97541		0.97532	
Mirtazapine: OEF/OIF	0	(0,0)	0	(0,0)	0	(0,0)
Mirtazapine: other era	0.42646	(-0.05,0.9)	0.15256	(-0.07,0.37)	0.086	(-0.06,0.23)
p-value for 2-way interaction	0.99978		0.99983		0.99985	
Tricyclics: OEF/OIF	0.21459	(-12.63,13.06)	0.24883	(-13.99,14.49)	0.18568	(-10.39,10.76)
Tricyclics: other era	0.13336	(-0.5,0.77)	0.10729	(-0.2,0.42)	0.04682	(-0.16,0.25)
p-value for 2-way interaction	0.97402		0.97291		0.97269	
overall 2-way interaction p-value	0.76887		0.79147		0.76483	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.05045	(-3.08,3.18)	0.07446	(-4.54,4.69)	0.0599	(-5.25,5.37)
Antipsychotics: other era	0.10201	(-0.03,0.23)	0.13406	(-0.05,0.32)	0.31909	(-0.2,0.84)
p-value for 2-way interaction	0.9751		0.97507		0.9826	
Mirtazapine: OEF/OIF	0	(0,0)	0	(0,0)	0	(0,0)
Mirtazapine: other era	0.08217	(-0.05,0.22)	0.10133	(-0.09,0.29)	0.28415	(-0.24,0.81)
p-value for 2-way interaction	0.99986		0.99988		0.99986	
Tricyclics: OEF/OIF	0.17345	(-9.63,9.98)	0.25247	(-14.02,14.53)	0.20527	(-16.4,16.81)
Tricyclics: other era	0.04051	(-0.15,0.23)	0.0382	(-0.23,0.3)	0.20311	(-0.31,0.72)
p-value for 2-way interaction	0.97248		0.97245		0.98083	
overall 2-way interaction p-value	0.76599		0.76733		0.73861	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

**Differences in Incident Percutaneous Coronary Intervention (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.47769	(-0.21,1.17)	0.17842	(-0.21,0.57)	0.08882	(-0.25,0.43)
Antipsychotics: female	-0.10194	(-0.95,0.74)	-0.13614	(-0.94,0.67)	-0.12958	(-0.84,0.58)
p-value for 2-way interaction	0.71002		0.67359		0.68505	
Mirtazapine: male	1.43768	(0.67,2.21)	0.43064	(0.01,0.85)	0.21959	(-0.14,0.58)
Mirtazapine: female	1.13838	(-0.11,2.39)	0.90618	(-0.21,2.02)	0.78579	(-0.19,1.76)
p-value for 2-way interaction	0.1967		0.18848		0.16137	
Tricyclics: male	1.94854	(0.85,3.05)	1.03458	(0.42,1.65)	0.63753	(0.11,1.16)
Tricyclics: female	-0.34408	(-1.31,0.62)	-0.38063	(-1.29,0.53)	-0.34765	(-1.16,0.46)
p-value for 2-way interaction	0.3071		0.26064		0.28837	
overall 2-way interaction p-value	0.18109		0.1436		0.13296	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	0.07622	(-0.25,0.4)	0.07981	(-0.27,0.43)	0.2017	(-0.62,1.02)
Antipsychotics: female	-0.12109	(-0.79,0.55)	-0.13179	(-0.84,0.58)	-0.17933	(-1.11,0.75)
p-value for 2-way interaction	0.69105		0.68262		0.6698	
Mirtazapine: male	0.21246	(-0.13,0.56)	0.21869	(-0.15,0.59)	0.47098	(-0.36,1.3)
Mirtazapine: female	0.743	(-0.18,1.67)	0.768	(-0.2,1.73)	0.63006	(-0.59,1.85)
p-value for 2-way interaction	0.16104		0.16507		0.3879	
Tricyclics: male	0.58773	(0.09,1.09)	0.56454	(0.03,1.1)	0.36735	(-0.46,1.2)
Tricyclics: female	-0.32863	(-1.09,0.43)	-0.35735	(-1.15,0.43)	-0.46298	(-1.31,0.39)
p-value for 2-way interaction	0.2889		0.28008		0.25878	
overall 2-way interaction p-value	0.13399		0.1327		0.26159	

**Number of Windows**

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337



**Differences in Incident Percutaneous Coronary Intervention (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.43363	(-1.45,2.32)	-0.21306	(-0.55,0.12)	-0.24527	(-0.54,0.05)
Antipsychotics: <65	0.50586	(-0.16,1.17)	0.25102	(-0.18,0.69)	0.19001	(-0.21,0.59)
p-value for 2-way interaction	0.75199		0.10096		0.06042	
Mirtazapine: >=65	2.04078	(0.08,4)	0.11023	(-0.24,0.46)	0.0177	(-0.29,0.33)
Mirtazapine: <65	1.1679	(0.41,1.92)	0.46513	(-0.01,0.94)	0.26696	(-0.16,0.69)
p-value for 2-way interaction	0.88629		0.62502		0.5784	
Tricyclics: >=65	4.26554	(1.11,7.42)	0.81406	(0.2,1.43)	0.57073	(0.04,1.1)
Tricyclics: <65	0.93146	(-0.07,1.93)	0.45221	(-0.19,1.09)	0.17044	(-0.39,0.73)
p-value for 2-way interaction	0.17697		0.12592		0.12991	
overall 2-way interaction p-value	0.49431		0.06462		0.04023	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.24593	(-0.53,0.04)	-0.25835	(-0.56,0.04)	0.36242	(-1.79,2.51)
Antipsychotics: <65	0.18198	(-0.19,0.56)	0.19127	(-0.2,0.58)	0.13406	(-0.66,0.93)
p-value for 2-way interaction	0.05138		0.0507		0.90093	
Mirtazapine: >=65	0.01303	(-0.28,0.31)	0.00499	(-0.31,0.32)	1.72633	(-0.53,3.99)
Mirtazapine: <65	0.26327	(-0.14,0.67)	0.27225	(-0.15,0.69)	0.22123	(-0.58,1.02)
p-value for 2-way interaction	0.54798		0.51911		0.31043	
Tricyclics: >=65	0.53109	(0.02,1.04)	0.53134	(0,1.06)	1.23275	(-1,3.47)
Tricyclics: <65	0.15276	(-0.38,0.69)	0.09858	(-0.45,0.65)	0.11004	(-0.68,0.9)
p-value for 2-way interaction	0.13838		0.12882		0.42512	
overall 2-way interaction p-value	0.03638		0.03286		0.68237	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Percutaneous Coronary Intervention (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	0.13709	(-0.21,0.48)	0.1853	(-0.23,0.61)	0.17604	(-0.23,0.59)
Antipsychotics: other era	0.17368	(-0.67,1.02)	0.11357	(-0.37,0.59)	0.03476	(-0.43,0.5)
p-value for 2-way interaction	0.47724		0.42937		0.41559	
Mirtazapine: OEF/OIF	0.07582	(-0.3,0.45)	0.09349	(-0.36,0.54)	0.0891	(-0.35,0.53)
Mirtazapine: other era	1.18592	(0.25,2.12)	0.49852	(-0.02,1.02)	0.27297	(-0.22,0.76)
p-value for 2-way interaction	0.93193		0.86327		0.79522	
Tricyclics: OEF/OIF	-0.28072	(-44.38,43.82)	-0.34469	(-52.34,51.65)	-0.34059	(-51.3,50.62)
Tricyclics: other era	1.23211	(-0.04,2.51)	0.87048	(0.13,1.61)	0.50574	(-0.18,1.19)
p-value for 2-way interaction	0.98991		0.98947		0.98944	
overall 2-way interaction p-value	0.90767		0.88539		0.88082	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	0.16907	(-0.22,0.56)	0.17124	(-0.22,0.56)	0.11677	(-0.29,0.52)
Antipsychotics: other era	0.02302	(-0.42,0.46)	0.02236	(-0.41,0.46)	-0.02716	(-0.99,0.94)
p-value for 2-way interaction	0.40906		0.40514		0.57242	
Mirtazapine: OEF/OIF	0.08716	(-0.33,0.51)	0.08801	(-0.33,0.51)	0.03499	(-0.35,0.42)
Mirtazapine: other era	0.26297	(-0.2,0.73)	0.25301	(-0.21,0.71)	0.44747	(-0.54,1.43)
p-value for 2-way interaction	0.7891		0.7851		0.94839	
Tricyclics: OEF/OIF	-0.32372	(-48.79,48.14)	-0.32824	(-48.88,48.23)	-0.29414	(-26.2,25.61)
Tricyclics: other era	0.45699	(-0.2,1.11)	0.37557	(-0.26,1.01)	0.23382	(-0.74,1.21)
p-value for 2-way interaction	0.98946		0.98935		0.9822	
overall 2-way interaction p-value	0.87655		0.87392		0.94126	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

**Differences in Incident Any Cardiovascular Event (per 1,000 patient years) by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	6.1484	(4.74,7.56)	3.06544	(2.26,3.87)	2.19114	(1.44,2.94)
Antipsychotics: female	1.6575	(-0.51,3.82)	1.57493	(-0.69,3.84)	1.4265	(-0.83,3.68)
p-value for 2-way interaction	0.6943		0.69959		0.63285	
Mirtazapine: male	11.0805	(9.49,12.67)	4.28385	(3.43,5.14)	2.55262	(1.77,3.34)
Mirtazapine: female	5.9147	(3.1,8.73)	4.96944	(2.25,7.68)	4.5773	(1.91,7.24)
p-value for 2-way interaction	0.0331		0.03231		0.01676	
Tricyclics: male	9.172	(7,11.34)	5.32873	(4.08,6.58)	2.80277	(1.69,3.91)
Tricyclics: female	0.0776	(-2.23,2.38)	-0.23202	(-2.62,2.15)	-0.27623	(-2.69,2.13)
p-value for 2-way interaction	0.2672		0.16778		0.34624	
overall 2-way interaction p-value	0.0194		0.00996		0.01237	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.98804	(1.29,2.69)	1.81405	(1.18,2.44)	3.39992	(1.7,5.1)
Antipsychotics: female	1.30264	(-0.76,3.37)	1.09599	(-0.71,2.91)	0.9721	(-1.47,3.41)
p-value for 2-way interaction	0.62213		0.66457		0.7925	
Mirtazapine: male	2.40439	(1.67,3.14)	2.13469	(1.48,2.79)	4.18392	(2.46,5.9)
Mirtazapine: female	4.20971	(1.76,6.66)	3.62134	(1.48,5.76)	3.67177	(0.81,6.53)
p-value for 2-way interaction	0.01677		0.01916		0.06954	
Tricyclics: male	2.50101	(1.47,3.53)	1.98387	(1.07,2.9)	1.72844	(0.05,3.41)
Tricyclics: female	-0.28715	(-2.48,1.91)	-0.37995	(-2.28,1.52)	-0.76799	(-2.94,1.4)
p-value for 2-way interaction	0.34387		0.31392		0.35352	
overall 2-way interaction p-value	0.01243		0.01246		0.03297	

**Number of Windows**

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Differences in Incident Any Cardiovascular Event (per 1,000 patient years) by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	17.7625	(13.21,22.32)	1.55151	(0.7,2.4)	0.81792	(0.05,1.59)
Antipsychotics: <65	4.2347	(2.95,5.52)	2.83506	(1.9,3.77)	2.21522	(1.33,3.11)
p-value for 2-way interaction	0.0095		0.66845		0.30348	
Mirtazapine: >=65	21.9791	(17.35,26.6)	2.73831	(1.85,3.62)	1.65023	(0.86,2.44)
Mirtazapine: <65	7.2173	(5.76,8.68)	4.00799	(2.99,5.03)	2.37252	(1.43,3.31)
p-value for 2-way interaction	0.0972		0.77806		0.72102	
Tricyclics: >=65	15.1255	(8.29,21.96)	3.06253	(1.64,4.49)	1.53644	(0.3,2.77)
Tricyclics: <65	6.1445	(4.24,8.05)	4.0118	(2.65,5.38)	1.88783	(0.65,3.12)
p-value for 2-way interaction	0.7701		0.6125		0.63688	
overall 2-way interaction p-value	0.06		0.84188		0.48757	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.68699	(-0.04,1.41)	0.6259	(-0.03,1.28)	7.7199	(2.45,12.99)
Antipsychotics: <65	2.06907	(1.24,2.9)	1.87734	(1.14,2.61)	2.3002	(0.75,3.85)
p-value for 2-way interaction	0.22133		0.20899		0.5127	
Mirtazapine: >=65	1.54061	(0.79,2.29)	1.34033	(0.67,2.01)	10.6059	(5.25,15.97)
Mirtazapine: <65	2.26347	(1.39,3.14)	2.01828	(1.24,2.8)	2.7806	(1.22,4.34)
p-value for 2-way interaction	0.8026		0.88819		0.263	
Tricyclics: >=65	1.33708	(0.18,2.5)	1.0785	(0.04,2.11)	1.948	(-3.17,7.07)
Tricyclics: <65	1.70077	(0.56,2.84)	1.25402	(0.25,2.26)	1.5063	(-0.03,3.04)
p-value for 2-way interaction	0.71255		0.66621		0.6294	
overall 2-way interaction p-value	0.42635		0.42202		0.3746	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Differences in Incident Any Cardiovascular Event (per 1,000 patient years) by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.6363	(-0.12,1.4)	1.43324	(0.01,2.85)	1.48091	(-0.07,3.04)
Antipsychotics: other era	6.06	(4.31,7.81)	3.29436	(2.35,4.24)	2.45527	(1.54,3.37)
p-value for 2-way interaction	0.5464		0.35537		0.30201	
Mirtazapine: OEF/OIF	0.1819	(-0.63,0.99)	0.36131	(-1.11,1.84)	0.34639	(-1.28,1.98)
Mirtazapine: other era	11.181	(9.25,13.11)	4.9105	(3.9,5.92)	3.07439	(2.13,4.02)
p-value for 2-way interaction	0.3276		0.4709		0.68667	
Tricyclics: OEF/OIF	0.3833	(-0.77,1.54)	0.60799	(-1.44,2.66)	0.59274	(-1.66,2.85)
Tricyclics: other era	6.5009	(3.97,9.03)	4.81997	(3.4,6.24)	2.41876	(1.11,3.73)
p-value for 2-way interaction	0.9833		0.75868		0.98552	
overall 2-way interaction p-value	0.5576		0.49535		0.60731	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	1.39442	(-0.05,2.84)	1.21965	(-0.05,2.49)	0.48134	(-0.44,1.4)
Antipsychotics: other era	2.22133	(1.38,3.07)	1.94562	(1.21,2.68)	3.15285	(1.09,5.22)
p-value for 2-way interaction	0.28107		0.29367		0.56119	
Mirtazapine: OEF/OIF	0.34559	(-1.17,1.86)	0.29432	(-1.04,1.63)	-0.02167	(-0.87,0.82)
Mirtazapine: other era	2.88672	(2,3.77)	2.46302	(1.7,3.23)	4.71979	(2.62,6.82)
p-value for 2-way interaction	0.70328		0.69791		0.52184	
Tricyclics: OEF/OIF	0.50936	(-1.57,2.59)	0.35527	(-1.45,2.16)	0.22434	(-0.67,1.12)
Tricyclics: other era	2.12179	(0.91,3.33)	1.53871	(0.51,2.57)	0.92022	(-1.11,2.95)
p-value for 2-way interaction	0.99211		0.98822		0.71728	
overall 2-way interaction p-value	0.5869		0.59923		0.63911	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	-0.01929	(-0.31,0.27)	-0.08245	(-0.35,0.18)	-0.19668	(-0.4,0)
Antipsychotics: female	0.32729	(-0.44,1.09)	0.28836	(-0.71,1.29)	0.171	(-0.55,0.89)
p-value for 2-way interaction	0.39794		0.49424		0.37748	
Mirtazapine: male	0.80431	(0.48,1.13)	0.08244	(-0.2,0.36)	-0.2903	(-0.5,-0.08)
Mirtazapine: female	1.38749	(0.54,2.23)	1.17137	(0.1,2.24)	0.76523	(0,1.53)
p-value for 2-way interaction	0.04185		0.05051		0.01149	
Tricyclics: male	3.4602	(2.98,3.94)	3.07977	(2.65,3.51)	1.46252	(1.15,1.78)
Tricyclics: female	2.14931	(1.2,3.1)	2.35789	(1.15,3.57)	1.54325	(0.68,2.4)
p-value for 2-way interaction	0.75454		0.77165		0.44195	
overall 2-way interaction p-value	0.21888		0.16157		0.09127	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	-0.19619	(-0.4,0)	-0.24954	(-0.5,0.01)	-0.06199	(-0.41,0.29)
Antipsychotics: female	0.17056	(-0.55,0.89)	0.17	(-0.74,1.08)	0.01318	(-0.86,0.89)
p-value for 2-way interaction	0.38113		0.43475		0.91393	
Mirtazapine: male	-0.29375	(-0.51,-0.08)	-0.38255	(-0.65,-0.11)	-0.10572	(-0.45,0.24)
Mirtazapine: female	0.76551	(-0.01,1.54)	0.93341	(-0.04,1.91)	0.47356	(-0.42,1.36)
p-value for 2-way interaction	0.01165		0.01338		0.24871	
Tricyclics: male	1.47606	(1.16,1.79)	1.74686	(1.35,2.15)	1.05021	(0.69,1.41)
Tricyclics: female	1.55937	(0.69,2.43)	1.82563	(0.74,2.91)	1.11967	(0.2,2.04)
p-value for 2-way interaction	0.4406		0.48551		0.31877	
overall 2-way interaction p-value	0.09228		0.10031		0.54907	

**Number of Windows**

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.17536	(-0.64,0.99)	-0.66937	(-1.04,-0.3)	-0.76103	(-1.03,-0.49)
Antipsychotics: <65	0.14154	(-0.15,0.43)	0.00167	(-0.3,0.31)	-0.05335	(-0.29,0.18)
p-value for 2-way interaction	0.93642		0.00159		0	
Mirtazapine: >=65	-0.369	(-1.17,0.43)	-0.72876	(-1.09,-0.36)	-0.87128	(-1.14,-0.61)
Mirtazapine: <65	0.99877	(0.67,1.33)	0.48744	(0.15,0.82)	0.06668	(-0.19,0.32)
p-value for 2-way interaction	0.00015		0		0	
Tricyclics: >=65	3.31179	(2.4,6.3)	1.58999	(0.95,2.23)	0.48486	(0.03,0.94)
Tricyclics: <65	3.09385	(2.64,3.55)	2.95037	(2.48,3.42)	1.43616	(1.08,1.79)
p-value for 2-way interaction	0.13479		0.26312		0.10161	
overall 2-way interaction p-value	0.00065		0.00001		0	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.7595	(-1.03,-0.49)	-0.95399	(-1.29,-0.62)	0.38835	(-0.53,1.31)
Antipsychotics: <65	-0.05484	(-0.29,0.18)	-0.06731	(-0.36,0.23)	-0.13794	(-0.48,0.21)
p-value for 2-way interaction	0		0		0.26847	
Mirtazapine: >=65	-0.87439	(-1.14,-0.61)	-1.10993	(-1.44,-0.78)	-0.47174	(-1.37,0.43)
Mirtazapine: <65	0.06173	(-0.2,0.32)	0.07509	(-0.25,0.4)	0.02879	(-0.32,0.37)
p-value for 2-way interaction	0		0		0.3289	
Tricyclics: >=65	0.4976	(0.04,0.95)	0.55933	(-0.01,1.13)	0.9289	(0,1.86)
Tricyclics: <65	1.45275	(1.1,1.81)	1.66527	(1.23,2.1)	1.09869	(0.74,1.46)
p-value for 2-way interaction	0.10626		0.11386		0.24674	
overall 2-way interaction p-value	0		0		0.08822	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Comparison of New Prescription or Dose Increase of a Diabetes Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.51469	(-0.84,-0.19)	-0.60268	(-1.1,-0.1)	-0.47161	(-0.86,-0.08)
Antipsychotics: other era	-0.36586	(-0.72,-0.01)	-0.11451	(-0.42,0.19)	-0.23215	(-0.47,0.01)
p-value for 2-way interaction	0.01592		0.03979		0.08827	
Mirtazapine: OEF/OIF	0.09473	(-0.29,0.48)	0.25158	(-0.33,0.83)	0.19651	(-0.26,0.65)
Mirtazapine: other era	0.17934	(-0.2,0.56)	0.04122	(-0.28,0.37)	-0.38151	(-0.63,-0.13)
p-value for 2-way interaction	0.83856		0.45831		0.09132	
Tricyclics: OEF/OIF	0.18169	(-0.36,0.72)	0.2311	(-0.58,1.04)	0.07881	(-0.55,0.7)
Tricyclics: other era	2.89196	(2.35,3.44)	3.17675	(2.7,3.65)	1.49381	(1.13,1.86)
p-value for 2-way interaction	0.03197		0.00305		0.04751	
overall 2-way interaction p-value	0.01736		0.00249		0.00587	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	-0.47624	(-0.87,-0.09)	-0.59873	(-1.09,-0.11)	-0.52214	(-0.9,-0.14)
Antipsychotics: other era	-0.23114	(-0.47,0.01)	-0.28031	(-0.57,0.01)	-0.23068	(-0.64,0.18)
p-value for 2-way interaction	0.08528		0.0809		0.02422	
Mirtazapine: OEF/OIF	0.1937	(-0.26,0.65)	0.2371	(-0.33,0.8)	-0.13101	(-0.52,0.26)
Mirtazapine: other era	-0.38574	(-0.64,-0.13)	-0.47576	(-0.78,-0.17)	-0.29731	(-0.71,0.12)
p-value for 2-way interaction	0.09324		0.09384		0.83848	
Tricyclics: OEF/OIF	0.08565	(-0.54,0.72)	0.03809	(-0.74,0.82)	-0.43904	(-0.83,-0.05)
Tricyclics: other era	1.51033	(1.15,1.87)	1.70746	(1.27,2.15)	1.14953	(0.73,1.57)
p-value for 2-way interaction	0.04825		0.04596		0.00027	
overall 2-way interaction p-value	0.00591		0.00544		0.00053	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324



**Comparison of New Prescription or Dose Increase of a Cholesterol Medication by Augmenting Medication Group - Male vs. Female**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	2.03713	(1.62,2.45)	1.82935	(1.44,2.22)	1.74224	(1.36,2.13)
Antipsychotics: female	2.58839	(1.37,3.81)	2.57061	(1.24,3.9)	2.43207	(1.15,3.71)
p-value for 2-way interaction	0.08005		0.14209		0.14319	
Mirtazapine: male	1.58859	(1.14,2.04)	0.57296	(0.16,0.99)	0.41926	(0.01,0.83)
Mirtazapine: female	3.50759	(2.2,4.81)	2.94159	(1.54,4.35)	2.81627	(1.46,4.17)
p-value for 2-way interaction	0.00072		0.00097		0.00059	
Tricyclics: male	4.07443	(3.42,4.73)	3.46343	(2.85,4.08)	3.11965	(2.52,3.72)
Tricyclics: female	3.64394	(2.21,5.08)	3.35014	(1.8,4.9)	3.23902	(1.74,4.74)
p-value for 2-way interaction	0.35429		0.58558		0.40997	
overall 2-way interaction p-value	0.00831		0.00954		0.00727	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	1.7412	(1.36,2.13)	1.74525	(1.35,2.14)	1.72	(1.23,2.21)
Antipsychotics: female	2.43136	(1.15,3.71)	2.42611	(1.12,3.73)	1.64736	(0.27,3.02)
p-value for 2-way interaction	0.14283		0.15116		0.60208	
Mirtazapine: male	0.41996	(0.01,0.83)	0.36666	(-0.05,0.78)	0.55365	(0.07,1.04)
Mirtazapine: female	2.81595	(1.46,4.17)	2.79273	(1.41,4.17)	1.5834	(0.21,2.96)
p-value for 2-way interaction	0.00059		0.00065		0.10669	
Tricyclics: male	3.11655	(2.52,3.72)	3.03423	(2.42,3.65)	1.94057	(1.45,2.43)
Tricyclics: female	3.23514	(1.74,4.73)	3.10854	(1.59,4.63)	1.45072	(0.08,2.83)
p-value for 2-way interaction	0.41028		0.45063		0.96556	
overall 2-way interaction p-value	0.00725		0.00762		0.32416	

**Number of Windows**

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Comparison of New Prescription or Dose Increase of a Cholesterol Medication by Augmenting Medication Group - Age 65 and Older vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	0.99737	(-0.02,2.01)	-0.37809	(-1.02,0.26)	-0.51784	(-1.15,0.11)
Antipsychotics: <65	2.36965	(1.94,2.8)	2.07746	(1.64,2.51)	2.06174	(1.63,2.5)
p-value for 2-way interaction	0.00639		0		0	
Mirtazapine: >=65	-0.28607	(-1.28,0.71)	-0.97396	(-1.6,-0.35)	-1.1352	(-1.75,-0.52)
Mirtazapine: <65	2.13156	(1.66,2.6)	1.12542	(0.65,1.6)	0.9984	(0.53,1.47)
p-value for 2-way interaction	0.00001		0		0	
Tricyclics: >=65	2.16402	(0.54,3.78)	1.26715	(0.21,2.32)	0.89332	(-0.14,1.93)
Tricyclics: <65	3.75956	(3.11,4.4)	3.06542	(2.42,3.71)	2.74305	(2.1,3.39)
p-value for 2-way interaction	0.03862		0.13434		0.08041	
overall 2-way interaction p-value	0.00007		0		0	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	-0.51623	(-1.15,0.12)	-0.5225	(-1.16,0.12)	1.58352	(0.44,2.72)
Antipsychotics: <65	2.06264	(1.63,2.5)	2.05285	(1.61,2.49)	1.74574	(1.24,2.25)
p-value for 2-way interaction	0		0		0.66536	
Mirtazapine: >=65	-1.13566	(-1.75,-0.52)	-1.17246	(-1.8,-0.54)	0.08392	(-1.04,1.21)
Mirtazapine: <65	0.99703	(0.52,1.47)	0.94892	(0.47,1.43)	0.75172	(0.25,1.25)
p-value for 2-way interaction	0		0		0.26126	
Tricyclics: >=65	0.89773	(-0.14,1.93)	0.84648	(-0.2,1.9)	1.6289	(0.48,2.78)
Tricyclics: <65	2.74714	(2.1,3.39)	2.61932	(1.97,3.27)	1.95573	(1.45,2.46)
p-value for 2-way interaction	0.0811		0.0925		0.48587	
overall 2-way interaction p-value	0		0		0.72092	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Comparison of New Prescription or Dose Increase of a Cholesterol Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.54763	(-0.09,1.19)	1.00018	(0.25,1.75)	0.98138	(0.23,1.73)
Antipsychotics: other era	1.84444	(1.36,2.33)	1.89165	(1.46,2.33)	1.84195	(1.41,2.27)
p-value for 2-way interaction	0.11158		0.23473		0.24548	
Mirtazapine: OEF/OIF	0.6549	(-0.08,1.39)	0.88861	(0.03,1.75)	0.87614	(0.03,1.73)
Mirtazapine: other era	0.86679	(0.36,1.38)	0.54228	(0.09,1)	0.39574	(-0.05,0.85)
p-value for 2-way interaction	0.76927		0.34594		0.24136	
Tricyclics: OEF/OIF	1.76641	(0.72,2.81)	1.87203	(0.67,3.08)	1.83861	(0.64,3.04)
Tricyclics: other era	2.83188	(2.12,3.55)	3.09757	(2.45,3.75)	2.75329	(2.11,3.39)
p-value for 2-way interaction	0.996		0.37527		0.57752	
overall 2-way interaction p-value	0.33137		0.2426		0.21812	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.98151	(0.23,1.73)	0.97166	(0.21,1.74)	0.55566	(-0.2,1.31)
Antipsychotics: other era	1.84157	(1.41,2.27)	1.84246	(1.41,2.28)	1.65438	(1.1,2.21)
p-value for 2-way interaction	0.24587		0.23008		0.27687	
Mirtazapine: OEF/OIF	0.87648	(0.03,1.73)	0.86191	(-0.01,1.73)	0.15645	(-0.59,0.91)
Mirtazapine: other era	0.39591	(-0.05,0.85)	0.3491	(-0.11,0.8)	0.4479	(-0.1,1)
p-value for 2-way interaction	0.24113		0.23489		0.77531	
Tricyclics: OEF/OIF	1.83761	(0.64,3.03)	1.75866	(0.54,2.98)	0.71656	(-0.05,1.48)
Tricyclics: other era	2.75238	(2.11,3.39)	2.64464	(2,3.29)	1.78819	(1.23,2.35)
p-value for 2-way interaction	0.57725		0.5675		0.36689	
overall 2-way interaction p-value	0.21817		0.19961		0.66829	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

Comparison of New Prescription or Dose/Potency Increase of a Statin by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.38183	(0.99,1.77)	1.20951	(0.84,1.58)	1.14346	(0.78,1.51)
Antipsychotics: female	1.92019	(0.76,3.08)	1.90417	(0.61,3.19)	1.80892	(0.55,3.06)
p-value for 2-way interaction	0.14336		0.21748		0.2189	
Mirtazapine: male	1.06433	(0.64,1.49)	0.15986	(-0.23,0.55)	0.04833	(-0.34,0.43)
Mirtazapine: female	2.73624	(1.49,3.98)	2.20744	(0.84,3.57)	2.12974	(0.8,3.46)
p-value for 2-way interaction	0.00344		0.00414		0.00288	
Tricyclics: male	2.82483	(2.21,3.44)	2.36703	(1.79,2.94)	2.16445	(1.6,2.73)
Tricyclics: female	2.48702	(1.12,3.85)	2.18487	(0.68,3.69)	2.16555	(0.7,3.63)
p-value for 2-way interaction	0.57815		0.86916		0.70118	
overall 2-way interaction p-value	0.02928		0.02727		0.02384	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: male	1.14228	(0.78,1.51)	1.12643	(0.76,1.5)	1.13394	(0.68,1.59)
Antipsychotics: female	1.80828	(0.55,3.06)	1.79998	(0.53,3.07)	1.1413	(-0.17,2.45)
p-value for 2-way interaction	0.21821		0.21952		0.68859	
Mirtazapine: male	0.04938	(-0.34,0.44)	-0.01129	(-0.4,0.38)	0.14804	(-0.3,0.6)
Mirtazapine: female	2.12965	(0.8,3.46)	2.08953	(0.75,3.43)	1.01088	(-0.3,2.32)
p-value for 2-way interaction	0.00287		0.00304		0.19392	
Tricyclics: male	2.16079	(1.59,2.73)	2.10644	(1.53,2.68)	1.23316	(0.77,1.69)
Tricyclics: female	2.16112	(0.7,3.62)	2.07023	(0.59,3.55)	0.63038	(-0.67,1.93)
p-value for 2-way interaction	0.70171		0.7389		0.67054	
overall 2-way interaction p-value	0.02376		0.02406		0.34524	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

Comparison of New Prescription or Dose/Potency Increase of a Statin by Augmenting Medication Group - Age 65 or Over vs. Under 65

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	0.79384	(-0.17,1.76)	-0.43734	(-1.04,0.17)	-0.53094	(-1.13,0.07)
Antipsychotics: <65	1.64563	(1.24,2.05)	1.39192	(0.98,1.81)	1.37607	(0.96,1.79)
p-value for 2-way interaction	0.0535		0.00004		0.00001	
Mirtazapine: >=65	-0.6317	(-1.58,0.32)	-1.11154	(-1.7,-0.52)	-1.22635	(-1.81,-0.64)
Mirtazapine: <65	1.53839	(1.1,1.98)	0.66056	(0.21,1.11)	0.5632	(0.11,1.01)
p-value for 2-way interaction	0.00002		0		0	
Tricyclics: >=65	1.47092	(-0.07,3.02)	0.83626	(-0.16,1.83)	0.59698	(-0.38,1.58)
Tricyclics: <65	2.62105	(2.02,3.22)	2.04209	(1.43,2.66)	1.85795	(1.24,2.47)
p-value for 2-way interaction	0.09258		0.2706		0.19439	
overall 2-way interaction p-value	0.00033		0		0	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: >=65	-0.53018	(-1.13,0.07)	-0.53788	(-1.14,0.07)	1.27082	(0.18,2.36)
Antipsychotics: <65	1.3764	(0.96,1.79)	1.35113	(0.94,1.77)	1.11198	(0.64,1.58)
p-value for 2-way interaction	0.00001		0.00002		0.95342	
Mirtazapine: >=65	-1.22664	(-1.81,-0.64)	-1.25586	(-1.85,-0.66)	-0.34433	(-1.41,0.73)
Mirtazapine: <65	0.56247	(0.11,1.01)	0.50368	(0.05,0.95)	0.33597	(-0.13,0.8)
p-value for 2-way interaction	0		0		0.23916	
Tricyclics: >=65	0.599	(-0.38,1.58)	0.57269	(-0.42,1.56)	1.14523	(0.05,2.24)
Tricyclics: <65	1.85971	(1.25,2.47)	1.77291	(1.16,2.39)	1.19511	(0.72,1.67)
p-value for 2-way interaction	0.19507		0.21542		0.77523	
overall 2-way interaction p-value	0		0		0.58027	

Number of Windows

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893

**Comparison of New Prescription or Dose/Potency Increase of a Statin by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.31533	(-0.27,0.9)	0.75271	(0.02,1.49)	0.72458	(-0.01,1.45)
Antipsychotics: other era	1.13524	(0.68,1.59)	1.21451	(0.81,1.62)	1.18025	(0.77,1.59)
p-value for 2-way interaction	0.30553		0.59628		0.58616	
Mirtazapine: OEF/OIF	0.3355	(-0.34,1.01)	0.52763	(-0.3,1.36)	0.5131	(-0.32,1.34)
Mirtazapine: other era	0.39711	(-0.09,0.88)	0.1262	(-0.3,0.56)	0.02151	(-0.4,0.45)
p-value for 2-way interaction	0.7799		0.35562		0.2796	
Tricyclics: OEF/OIF	1.64465	(0.68,2.61)	1.84966	(0.68,3.02)	1.85668	(0.69,3.03)
Tricyclics: other era	1.5942	(0.92,2.27)	1.95379	(1.34,2.56)	1.76091	(1.16,2.37)
p-value for 2-way interaction	0.19652		0.68442		0.52131	
overall 2-way interaction p-value	0.28377		0.61245		0.47796	
Medications	Model 3		Model 4		Model 5	
Prazosin (Reference)	Difference	95% CI	Difference	95% CI	Difference	95% CI
Antipsychotics: OEF/OIF	0.72497	(0,1.45)	0.7221	(-0.02,1.47)	0.33409	(-0.36,1.03)
Antipsychotics: other era	1.17935	(0.77,1.58)	1.15946	(0.75,1.57)	1.0116	(0.49,1.54)
p-value for 2-way interaction	0.5879		0.59634		0.51062	
Mirtazapine: OEF/OIF	0.51406	(-0.31,1.34)	0.49735	(-0.35,1.34)	-0.10933	(-0.8,0.58)
Mirtazapine: other era	0.02206	(-0.4,0.45)	-0.03324	(-0.46,0.39)	0.01931	(-0.5,0.54)
p-value for 2-way interaction	0.27892		0.26055		0.75307	
Tricyclics: OEF/OIF	1.85393	(0.68,3.02)	1.83217	(0.64,3.02)	0.92797	(0.22,1.64)
Tricyclics: other era	1.75875	(1.15,2.36)	1.68448	(1.08,2.29)	0.845	(0.32,1.37)
p-value for 2-way interaction	0.52202		0.50833		0.28635	
overall 2-way interaction p-value	0.47852		0.45803		0.35596	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Male vs. Female

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	1.79945	(1.34,2.26)	1.5889	(1.13,2.05)	1.35249	(0.89,1.82)
Antipsychotics: female	2.41798	(0.98,3.85)	2.27604	(0.7,3.85)	2.08038	(0.48,3.68)
p-value for 2-way interaction	0.20473		0.31131		0.31264	
Mirtazapine: male	2.79951	(2.29,3.3)	1.38179	(0.89,1.88)	0.82463	(0.32,1.33)
Mirtazapine: female	4.36751	(2.82,5.91)	3.47364	(1.8,5.15)	3.28784	(1.59,4.99)
p-value for 2-way interaction	0.01193		0.01272		0.00496	
Tricyclics: male	5.88934	(5.16,6.62)	5.35254	(4.63,6.08)	4.53258	(3.8,5.27)
Tricyclics: female	3.75722	(2.06,5.45)	3.17046	(1.33,5.01)	3.16722	(1.3,5.04)
p-value for 2-way interaction	0.2943		0.11647		0.37659	
overall 2-way interaction p-value	0.01063		0.00376		0.00745	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
Prazosin (Reference)						
Antipsychotics: male	1.34107	(0.88,1.81)	1.31082	(0.85,1.77)	1.11519	(0.57,1.66)
Antipsychotics: female	2.08175	(0.49,3.67)	1.89463	(0.33,3.46)	1.54375	(-0.06,3.15)
p-value for 2-way interaction	0.30175		0.38249		0.45348	
Mirtazapine: male	0.83967	(0.34,1.34)	0.76698	(0.27,1.27)	0.79478	(0.25,1.34)
Mirtazapine: female	3.29622	(1.61,4.99)	3.13113	(1.47,4.8)	2.62527	(1.01,4.24)
p-value for 2-way interaction	0.00478		0.00579		0.02142	
Tricyclics: male	4.47874	(3.75,5.21)	4.03085	(3.3,4.76)	3.12537	(2.58,3.67)
Tricyclics: female	3.1014	(1.24,4.96)	2.50604	(0.68,4.33)	2.05805	(0.44,3.67)
p-value for 2-way interaction	0.36955		0.28925		0.58738	
overall 2-way interaction p-value	0.00693		0.00631		0.02422	

Number of Windows

Medications	male	female
Antipsychotics	65363	5537
Mirtazapine	50183	4489
Prazosin	92502	7767
Tricyclics	18647	3337

**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Age 65 and Over vs. Under 65**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	0.93701	(-0.22,2.1)	-0.73991	(-1.67,0.19)	-1.32494	(-2.26,-0.39)
Antipsychotics: <65	2.32693	(1.85,2.8)	1.96942	(1.47,2.47)	1.83193	(1.32,2.34)
p-value for 2-way interaction	0.00855		0		0	
Mirtazapine: >=65	1.07215	(-0.08,2.22)	-0.2691	(-1.19,0.65)	-1.06162	(-1.99,-0.13)
Mirtazapine: <65	3.07989	(2.55,3.61)	1.90274	(1.36,2.45)	1.46188	(0.91,2.02)
p-value for 2-way interaction	0.00025		0.00022		0.00001	
Tricyclics: >=65	5.58992	(3.73,7.45)	4.51744	(2.97,6.06)	3.24908	(1.69,4.8)
Tricyclics: <65	5.21067	(4.49,5.93)	4.45812	(3.71,5.2)	3.85772	(3.1,4.61)
p-value for 2-way interaction	0.75958		0.63763		0.75496	
overall 2-way interaction p-value	0.00118		0		0	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: >=65	-1.3478	(-2.28,-0.41)	-1.32853	(-2.26,-0.4)	0.3814	(-0.92,1.68)
Antipsychotics: <65	1.82976	(1.32,2.33)	1.78745	(1.29,2.29)	1.33101	(0.77,1.89)
p-value for 2-way interaction	0		0		0.1259	
Mirtazapine: >=65	-1.06003	(-1.99,-0.13)	-1.10446	(-2.03,-0.18)	0.13381	(-1.16,1.43)
Mirtazapine: <65	1.48008	(0.93,2.03)	1.40297	(0.85,1.95)	1.11807	(0.56,1.68)
p-value for 2-way interaction	0.00001		0.00001		0.12285	
Tricyclics: >=65	3.17604	(1.63,4.72)	2.83469	(1.3,4.37)	2.91578	(1.6,4.23)
Tricyclics: <65	3.81508	(3.06,4.57)	3.31327	(2.57,4.06)	3.09076	(2.53,3.66)
p-value for 2-way interaction	0.72368		0.81849		0.44066	
overall 2-way interaction p-value	0		0		0.35547	

**Number of Windows**

Medications	>=65	<65
Antipsychotics	10735	60165
Mirtazapine	11073	43599
Prazosin	18071	82198
Tricyclics	3091	18893



**Comparison of New Prescription or Dose Increase of a Blood Pressure Medication by Augmenting Medication Group - Iraq and Afghanistan Era vs. Other Era**

Medications	Unadjusted		Model 1		Model 2	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	0.60818	(-0.14,1.35)	1.39842	(0.48,2.32)	1.21035	(0.27,2.15)
Antipsychotics: other era	1.25276	(0.72,1.78)	1.45412	(0.95,1.96)	1.26223	(0.75,1.77)
p-value for 2-way interaction	0.5696		0.82202		0.87191	
Mirtazapine: OEF/OIF	1.02506	(0.17,1.88)	1.39328	(0.35,2.44)	1.31142	(0.24,2.38)
Mirtazapine: other era	1.82768	(1.26,2.4)	1.35031	(0.81,1.89)	0.76587	(0.22,1.31)
p-value for 2-way interaction	0.64821		0.72946		0.29604	
Tricyclics: OEF/OIF	3.3917	(2.17,4.61)	3.75101	(2.28,5.22)	3.82332	(2.32,5.32)
Tricyclics: other era	3.86972	(3.08,4.66)	4.51281	(3.75,5.27)	3.70519	(2.94,4.47)
p-value for 2-way interaction	0.32348		0.76992		0.56383	
overall 2-way interaction p-value	0.59353		0.96018		0.72992	
Medications	Model 3		Model 4		Model 5	
	Difference	95% CI	Difference	95% CI	Difference	95% CI
<b>Prazosin (Reference)</b>						
Antipsychotics: OEF/OIF	1.22319	(0.29,2.16)	1.10863	(0.18,2.04)	0.20935	(-0.67,1.09)
Antipsychotics: other era	1.24757	(0.74,1.76)	1.24165	(0.73,1.75)	0.86192	(0.25,1.47)
p-value for 2-way interaction	0.83186		0.99821		0.44827	
Mirtazapine: OEF/OIF	1.33691	(0.27,2.4)	1.24554	(0.19,2.3)	0.4429	(-0.43,1.32)
Mirtazapine: other era	0.77762	(0.24,1.32)	0.72085	(0.18,1.26)	0.62889	(0.02,1.24)
p-value for 2-way interaction	0.28209		0.31451		0.97865	
Tricyclics: OEF/OIF	3.75218	(2.26,5.24)	3.22624	(1.75,4.71)	2.23006	(1.33,3.13)
Tricyclics: other era	3.65502	(2.89,4.42)	3.19619	(2.44,3.95)	2.62667	(2.01,3.24)
p-value for 2-way interaction	0.57941		0.67913		0.4358	
overall 2-way interaction p-value	0.72551		0.74767		0.5131	

**Number of Windows**

Medications	OEF/OIF	other era
Antipsychotics	16754	54146
Mirtazapine	11219	43453
Prazosin	28498	71771
Tricyclics	4660	17324

## Myocardial Infarction Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.946	1.043
Antipsychotics: female	0	0
p-value for 2-way interaction	0.949	0.951
Mirtazapine: male	1.213	1.054
Mirtazapine: female	0	0
p-value for 2-way interaction	0.943	0.944
Tricyclics: male	0.974	1.074
Tricyclics: female	0	0
p-value for 2-way interaction	0.942	0.944

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	1.18	1.144
Antipsychotics: <65	0.917	0.995
p-value for 2-way interaction	0.225	0.517
Mirtazapine: >=65	1.518	1.21
Mirtazapine: <65	1.119	0.968
p-value for 2-way interaction	0.114	0.302
Tricyclics: >=65	0.943	1.026
Tricyclics: <65	1.028	1.066
p-value for 2-way interaction	0.765	0.859

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.966	1.016
Antipsychotics: OEF/OIF	1.507	1.685
p-value for 2-way interaction	0.465	0.384
Mirtazapine: other era	1.097	0.975
Mirtazapine: OEF/OIF	2.55	2.482
p-value for 2-way interaction	0.114	0.144
Tricyclics: other era	1.037	1.046
Tricyclics: OEF/OIF	1.252	1.535
p-value for 2-way interaction	0.812	0.504

## Heart Failure Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.762	0.924
Antipsychotics: female	0.493	0.586
p-value for 2-way interaction	0.203	0.212
Mirtazapine: male	1.538	1.264
Mirtazapine: female	3.273	2.929
p-value for 2-way interaction	0.123	0.142
Tricyclics: male	0.943	1.205
Tricyclics: female	1.688	1.754
p-value for 2-way interaction	0.268	0.436

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	0.902	0.923
Antipsychotics: <65	0.78	0.915
p-value for 2-way interaction	0.128	0.929
Mirtazapine: >=65	1.981	1.373
Mirtazapine: <65	1.434	1.22
p-value for 2-way interaction	0.001	0.284
Tricyclics: >=65	1.285	1.382
Tricyclics: <65	0.877	1.11
p-value for 2-way interaction	0.01	0.046

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.783	0.908
Antipsychotics: OEF/OIF	1.172	1.15
p-value for 2-way interaction	0.366	0.58
Mirtazapine: other era	1.455	1.228
Mirtazapine: OEF/OIF	1.694	1.411
p-value for 2-way interaction	0.689	0.753
Tricyclics: other era	1.054	1.223
Tricyclics: OEF/OIF	0.974	0.896
p-value for 2-way interaction	0.889	0.444

## Unstable Angina Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	1.092	1.254
Antipsychotics: female	1.081	1.294
p-value for 2-way interaction	0.986	0.956
Mirtazapine: male	1.283	1.183
Mirtazapine: female	2.245	1.901
p-value for 2-way interaction	0.335	0.462
Tricyclics: male	0.724	0.872
Tricyclics: female	1.607	1.648
p-value for 2-way interaction	0.25	0.302

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	1.064	1.168
Antipsychotics: <65	1.127	1.285
p-value for 2-way interaction	0.838	0.742
Mirtazapine: >=65	1.182	1.087
Mirtazapine: <65	1.367	1.244
p-value for 2-way interaction	0.572	0.635
Tricyclics: >=65	0.593	0.665
Tricyclics: <65	0.845	0.985
p-value for 2-way interaction	0.306	0.129

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	1.124	1.235
Antipsychotics: OEF/OIF	1.674	1.881
p-value for 2-way interaction	0.637	0.598
Mirtazapine: other era	1.258	1.182
Mirtazapine: OEF/OIF	0.85	0.851
p-value for 2-way interaction	0.483	0.604
Tricyclics: other era	0.802	0.882
Tricyclics: OEF/OIF	1.391	1.834
p-value for 2-way interaction	0.618	0.361

## Stroke Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.923	1.072
Antipsychotics: female	0.54	0.596
p-value for 2-way interaction	0.416	0.381
Mirtazapine: male	1.448	1.254
Mirtazapine: female	0.701	0.548
p-value for 2-way interaction	0.246	0.211
Tricyclics: male	0.931	1.048
Tricyclics: female	67769.38	172192.8
p-value for 2-way interaction	0.947	0.956

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	0.897	0.945
Antipsychotics: <65	0.989	1.102
p-value for 2-way interaction	0.711	0.579
Mirtazapine: >=65	1.348	1.052
Mirtazapine: <65	1.5	1.296
p-value for 2-way interaction	0.676	0.463
Tricyclics: >=65	0.885	1.006
Tricyclics: <65	1.094	1.114
p-value for 2-way interaction	0.581	0.716

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.939	1.041
Antipsychotics: OEF/OIF	1.004	1.014
p-value for 2-way interaction	0.941	0.977
Mirtazapine: other era	1.346	1.183
Mirtazapine: OEF/OIF	0.851	0.729
p-value for 2-way interaction	0.522	0.566
Tricyclics: other era	1.077	1.099
Tricyclics: OEF/OIF	0.835	0.654
p-value for 2-way interaction	0.827	0.54

## Coronary Artery Bypass Graft Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.979	1.055
Antipsychotics: female	0	0
p-value for 2-way interaction	0.977	0.977
Mirtazapine: male	1.284	1.224
Mirtazapine: female	1	1
p-value for 2-way interaction	1	1
Tricyclics: male	0.93	0.994
Tricyclics: female	1	1
p-value for 2-way interaction	1	1

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	0.485	0.586
Antipsychotics: <65	1.074	1.149
p-value for 2-way interaction	0.087	0.136
Mirtazapine: >=65	0.374	0.424
Mirtazapine: <65	1.792	1.647
p-value for 2-way interaction	0	0.002
Tricyclics: >=65	0.384	0.448
Tricyclics: <65	1.196	1.189
p-value for 2-way interaction	0.055	0.026

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.983	1.012
Antipsychotics: OEF/OIF	74414.88	71515.29
p-value for 2-way interaction	0.973	0.969
Mirtazapine: other era	1.189	1.165
Mirtazapine: OEF/OIF	74415.02	71515.29
p-value for 2-way interaction	0.958	0.967
Tricyclics: other era	1.071	1.027
Tricyclics: OEF/OIF	0.278	0.292
p-value for 2-way interaction	0.346	0.307

## Percutaneous Coronary Intervention Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.848	0.952
Antipsychotics: female	0.405	0.463
p-value for 2-way interaction	0.3	0.339
Mirtazapine: male	1.077	1.018
Mirtazapine: female	0.842	0.734
p-value for 2-way interaction	0.737	0.69
Tricyclics: male	0.747	0.907
Tricyclics: female	1.807	2.329
p-value for 2-way interaction	0.447	0.406

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	0.859	0.886
Antipsychotics: <65	0.862	0.963
p-value for 2-way interaction	0.988	0.68
Mirtazapine: >=65	1.042	1.055
Mirtazapine: <65	1.103	1.003
p-value for 2-way interaction	0.76	0.811
Tricyclics: >=65	0.751	0.971
Tricyclics: <65	0.825	0.895
p-value for 2-way interaction	0.734	0.695

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.868	0.931
Antipsychotics: OEF/OIF	1.172	1.248
p-value for 2-way interaction	0.635	0.634
Mirtazapine: other era	1.002	0.972
Mirtazapine: OEF/OIF	1.488	1.397
p-value for 2-way interaction	0.45	0.559
Tricyclics: other era	0.819	0.895
Tricyclics: OEF/OIF	18832.76	49826.08
p-value for 2-way interaction	0.919	0.906

## Any Cardiovascular Event Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	0.826	0.968
Antipsychotics: female	0.533	0.628
p-value for 2-way interaction	0.08	0.099
Mirtazapine: male	1.356	1.171
Mirtazapine: female	1.513	1.269
p-value for 2-way interaction	0.695	0.794
Tricyclics: male	0.887	1.079
Tricyclics: female	1.478	1.611
p-value for 2-way interaction	0.157	0.227

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	0.917	0.936
Antipsychotics: <65	0.854	0.973
p-value for 2-way interaction	0.343	0.627
Mirtazapine: >=65	1.601	1.219
Mirtazapine: <65	1.321	1.154
p-value for 2-way interaction	0.01	0.512
Tricyclics: >=65	1.064	1.159
Tricyclics: <65	0.902	1.049
p-value for 2-way interaction	0.141	0.231

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	0.845	0.947
Antipsychotics: OEF/OIF	1.3	1.349
p-value for 2-way interaction	0.153	0.22
Mirtazapine: other era	1.276	1.129
Mirtazapine: OEF/OIF	1.477	1.329
p-value for 2-way interaction	0.543	0.561
Tricyclics: other era	0.986	1.089
Tricyclics: OEF/OIF	1.148	1.153
p-value for 2-way interaction	0.703	0.84



## Mortality Hazard Ratio by Augmenting Medication Group

### Male vs. Female

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: male	1.021	1.141
Antipsychotics: female	1.153	1.349
p-value for 2-way interaction	0.609	0.491
Mirtazapine: male	2.246	1.798
Mirtazapine: female	3.638	3.295
p-value for 2-way interaction	0.095	0.065
Tricyclics: male	1.318	1.308
Tricyclics: female	1.564	1.497
p-value for 2-way interaction	0.558	0.593

### Age 65 and Over vs. Under 65

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: >=65	1.313	1.248
Antipsychotics: <65	1.004	1.089
p-value for 2-way interaction	0.001	0.113
Mirtazapine: >=65	3.462	2.196
Mirtazapine: <65	1.9	1.637
p-value for 2-way interaction	0	0.003
Tricyclics: >=65	1.946	1.63
Tricyclics: <65	1.145	1.15
p-value for 2-way interaction	0	0

### Iraq and Afghanistan Era vs. Other Era

Medication Group	Unadjusted	Propensity Weighted
Prazosin (Reference)	Difference	Difference
Antipsychotics: other era	1.038	1.13
Antipsychotics: OEF/OIF	1.352	1.303
p-value for 2-way interaction	0.105	0.371
Mirtazapine: other era	2.251	1.818
Mirtazapine: OEF/OIF	1.706	1.495
p-value for 2-way interaction	0.042	0.229
Tricyclics: other era	1.432	1.345
Tricyclics: OEF/OIF	1.405	1.072
p-value for 2-way interaction	0.934	0.142